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II 
Abstract 
 
The first part of this dissertation deals with employing the use of multi-component coupling 
reactions (MCC) for the synthesis of large diverse compound libraries.  A review of selected 
literature identified the growing need for more potent and selective HIV/AIDS drugs due to the 
extremely high mutation rate of the HI virus.  We thus chose to test our synthesised compound 
library against the HIV enzyme, reverse transcriptase (RT) in the hopes of identifying a potential 
novel non-nucleoside reverse transcriptase inhibitor (NNRTI).  Two different MCC approaches 
were used in order to give two different classes of compounds; firstly the Groebke-Blackburn 
reaction for the synthesis of imidazo[1,2-a]pyridines and secondly a reaction developed by Poigny 
and co-workers for the synthesis of 3-amino-1-cyano-indolizines.  We were successful in utilizing 
the Groebke-Blackburn to synthesise a variety of imidazo[1,2-a]pyridines in varying yields.  
However, all of the compounds showed poor inhibition of the RT enzyme in the biological assay.  
We thus turned our attention to the synthesis of the 3-amino-1-cyano-indolizines, which proved to 
be very difficult.  It was discovered that this reaction did not proceed to completion and the product 
generally isolated from this MCC reaction was the more stable aldol condensation intermediate.  In 
some of the experiments we were able to isolate mostly small quantities of indolizine compound, 
but when tested against the RT enzyme the results once again were very poor. 
 
A short review in the second section of this dissertation showed the lack of methodology available 
for the synthesis of the dihydrobenzo[b]phenanthridine motif which constitutes the backbone of a 
secondary metabolite known as Jadomycin B.  The major aim of this segment of the project was 
thus to develop methodology to synthesise this biologically important scaffold.  However, our 
methodology failed to yield the desired product as it was not possible to reduce the nitrile 
intermediate to the required amine.  In an attempt to determine whether similar methodology could 
be used for the synthesis of pyranonaphthoquinone containing compounds an unexpected and 
novel reaction was discovered.  It was found that treatment of [2-(1,4-dimethoxynaphthalen-2-
yl)phenyl]methanol with brominating agent NBS results in the synthesis of a naphthopyranone ring 
system known as 12-methoxy-6H-dibenzo[c,h]chromen-6-one.  Following this discovery it was 
attempted to elucidate the mechanism by which NBS performs this novel reaction.  Unfortunately 
we were unable to determine the exact mechanism responsible for this transformation 
conclusively.  The most likely mechanism shows NBS oxidising the benzylic alcohol to an 
aldehyde, which is then converted to an acid bromide facilitating ring closure.  Finally we wished to 
determine if this strategy could be applied in the synthesis of related naphthopyranone ring 
systems, which was shown to be possible with the synthesis of 3-bromo-2-methoxy-6H-
benzo[c]chromen-6-one.    
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Part A 
 
Chapter 1:  Introduction, Literature Review and Aims 
 
Use of Multi-component Coupling Reactions for the Synthesis of Potential HIV Non-
Nucleoside Reverse Transcriptase Inhibitors 
 
Acquired Immune Deficiency Syndrome or AIDS is a disease caused by the Human 
Immunodeficiency Virus (HIV) and is responsible for more then 20 million deaths globally.1, 2  With 
a further 70 million people infected with HIV and no viable cure we are facing one of the worst 
pandemics in our human history.1  Although HIV is a devastating disease to suffer from it has 
further reaching implications in terms of economic, social and political stability.1 For example the 
province of Kwa-Zulu Natal (KZN) in South Africa, one of the world‟s worst afflicted countries, 
shows 26.4% of the working age population to be HIV positive.3  The predictions for KZN show that 
at the current infection rate, two-fifths of the adult population will die of AIDS related illness by 
2025.3  Thurlow et al. predicted that the collective effects of HIV over all economic sectors means 
that the KZN economy will be 43% smaller by 2025.3  Combating the AIDS epidemic is thus of 
grave importance in securing our economic stability as well as addressing the devastating social 
decline which it elicits.1   
 
1.  Brief History of Human Immunodeficiency Virus (HIV) 
 
Along with many discoveries in the science, the discovery of the virus HIV as the cause of AIDS, 
was also one not untouched by luck.2  Human Immunodeficiency Virus (HIV) was first isolated in 
1983 by Dr. Luc Montagnier.2, 4 Had it not been for research into cancer-causing viruses in the 
same time period as the first identified AIDS patients, the knowledge and tools for the discovery of 
the HIV virus may not have existed.2  Many factors including fungi, chemicals and autoimmune 
disease were thought to be the cause of AIDS, but it was the earlier discovery in 1970 by Temin 
and Baltimore which showed human T-cell leukaemia virus types 1 and 2 (HTLV-1 and HTLV2) to 
cause T-cell leukaemia which allowed researchers to eventually discover the cause to be a virus.2, 
5  Animal studies revealed that HLTV not only caused leukaemia and lymphoma, but an AIDS-like 
syndrome.2, 5  This result, as well as the similar epidemiology of HTLV, also transmitted by blood 
and sexual activity, convinced scientists that a virus was the cause of AIDS.2, 5   
 
From 1983-1985 rapid advancements including genome sequencing, understanding of 
pathogenesis, blood tests and development of AZT led to the expectation that AIDS would be 
quickly combated.5  However, by the early 1990s it was clear that if a suitable vaccine was not 
developed HIV would probably become a permanent infection in our species.5  The use of multiple 
drug routines over the last 15 years has significantly extended the period between infection with 
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the virus and the onset of AIDS symptoms, but it is no cure.4, 5  Until a vaccine is discovered the 
production of more potent HIV drugs which can significantly inhibit viral load is vital to slowing the 
mortality rate of this horrific disease.5 
 
2.  Mode of Infection of HIV 
 
            It is widely accepted by scientists that AIDS is caused by the HIV retrovirus.2 A retrovirus is a RNA 
virus containing an enzyme called reverse transcriptase which enables the virus to utilise its single 
strand RNA genome as a template for the production of an intermediate single DNA strand.2, 4, 6  
There are two subtypes of HIV, HIV-1 and HIV-2 which are thought to have originated from two 
different primate species.5  HIV-1 is the more virulent sub-type and more easily transmitted and 
spread, HIV-1 thus accounts for the vast majority of global HIV infections.7  Hence for the purposes 
of this discussion all information on the pathogenesis of HIV will pertain to the HIV-1 sub-type.  
Heterosexual transmission by unprotected sexual intercourse with an infected person is the main 
mode via which one can be infected with the HIV-1 virus and accounts for 80% of all HIV-1 positive 
people.8 Other modes of infection include direct exposure to infected body fluids (blood, semen 
etc.), either by accident or intravenously, and direct mother to child infections.1, 4  
 
Once the HIV-1 virus has entered the host, a protein on the outer envelope of the virus attaches to 
the CD4 receptor protein of the helper T cell, its primary target (Figure 1).4, 6, 9 This interaction 
results in the fusion of the virus envelope with the host cell‟s plasma membrane and allows the 
viral core or capsid containing the nucleic acid and enzymes to enter the T cell cytoplasm.4, 6  Once 
in the cytoplasm, host enzymes remove the capsid releasing the viral RNA and viral enzymes into 
the cell.4  A viral enzyme known as reverse transcriptase now catalyses the synthesis of single 
strand (ss) DNA which is complementary to the viral RNA.4, 6  Host cell DNA polymerase now 
catalyses the synthesis of double stranded (ds) DNA from the complementary ssDNA.4, 6  This 
dsDNA now migrates to the host cell‟s nucleus where the viral enzyme integrase integrates it into 
the host‟s chromosome.4  Once incorporated into the chromosomal DNA of the host cell, the viral 
DNA can use host enzymes to synthesise viral proteins and to transcribe viral RNA.4  This viral 
RNA then leaves the nucleus and initiates the synthesis of viral proteins on host ribosomes.4 The 
viral RNA and new viral proteins are then assembled by host enzymes into new virus particles 
which then exit the cell using host plasma membrane to make the viral envelope.4   
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Figure 1 Schematic of HIV mode of infection and replication9 
 
Since the virus utilises host proteins in its assembly process, normal cellular functioning and 
synthesis of essential proteins are inhibited and the cell eventually dies.4 The newly synthesised 
virus moves off to infect and destroy more host cells, which eventually results in a progressive 
decline in the CD4 T-cell count and greatly inhibits the immune system‟s ability to defend against 
other infectious diseases.4  It is at this point that HIV infected people may develop the disease 
AIDS as their immune systems are no longer able to combat opportunistic diseases caused mainly 
by bacteria, fungi and parasites.4, 10  Diseases such as severe bacterial infections and tuberculosis 
have been identified as the leading causes of death amongst AIDS suffers as these individuals‟ 
severely undermined immune systems are incapable of defending themselves against these 
infections.10 
 
3.  In Search of a Treatment for HIV/AIDS 
 
The response of an individual who is infected with HIV and the progression to AIDS depends on a 
combination of genetic, environmental and health factors and many individuals can live very 
healthy lives for a number of years.10  Science has had some success in prolonging the life span of 
HIV positive people mostly through the development of anti-retroviral drugs.1  However there is 
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unfortunately no cure for HIV/AIDS and new developments in HIV/AIDS research are crucial in 
order to combat this pandemic.1  This section will address the various strategies for combating this 
disease; from the discovery of the first HIV drug, AZT to the current drug therapies used and finally 
new developments in HIV/AIDS research. 
 
3.1  AZT:  The proposed wonder drug 
 
Azidothymidine or AZT 1 (Figure 2) was the first drug approved by the United States Government 
for the treatment of HIV/AIDS.5  AZT was first synthesised in 1964 by Dr. Jerome P. Horwitz for 
use as an anti-cancer agent.11  He wanted to design a novel drug which would prevent the growth 
of cancer cells by preventing replication of the cells.11  A group of compounds called 
dideoxythymidines were synthesised which could mimic DNA nucleosides and act as chain 
terminators in DNA synthesis, thus preventing the growth of cancer cells.11  AZT was among the 
drugs synthesised and screened, but showed no activity and so was quickly forgotten.11  In 1974 
when AZT was revisited by Wolfram Ostertag at the Max Planck Institute who tested it against 
Friend Leukaemia Virus (FLV) and found it to successfully inhibit the virus in mice.11  Burroughs 
Wellcome, a pharmaceutical company in the United States, bought AZT from Ostertag and 
conducted intensive animal tests, but ultimately decided not to develop the drug further as it did not 
seem to have applications for human use.11  AZT was thus shelved away as Burroughs Wellcome 
compound 509US1 and did not make an appearance again until 1984 when pharmaceutical 
companies began screening their compound libraries in the hopes of finding a drug which could be 
used to treat the newly emerging disease, AIDS.11   
 
On 29 October 1984 Dr Janet Rideout selected compound 509US1 for testing against retroviruses 
FLV and Harvey Sarcoma Virus (HaSV).11  AZT showed good activity against these two 
retroviruses and was immediately sent for testing against live HIV at Duke University by Dr. 
Bolognesi who showed the drug to be active against HIV in vivo.11  On 3 July 1985 a furniture 
salesman from Massachusetts named Joseph Rafuse became the first person to be given AZT for 
the treatment of HIV and after six weeks of administration of the drug his T-cell count had 
increased significantly.11  The discovery of AZT and initial positive results of the clinical trial led 
many researchers to the expectation that AIDS would quickly be eradicated; however the rapid 
mutation rate of the HI virus and the subsequent resistance to AZT means that HIV/AIDS still 
remains an alarming problem today.5, 11 
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Figure 2  Representation of AZT5 
 
3.2 Current Treatment Regimens 
 
The reverse transcriptase enzyme of HIV makes a coding error every 3 x 105 bases, this translates 
to almost one mutation in each viral replication cycle.12  These changes in the HIV genome allow 
drug resistant mutant forms of HIV to emerge as they are no longer inhibited by the current drug 
therapies and have hindered efforts to effectively block viral replication.12, 13  AZT, the first drug 
approved for treatment of HIV infection, is on its own no longer able to significantly block the virus 
at clinically meaningful levels and Highly Active Antiretroviral Therapy (HAART) is used today to 
treat HIV.14  HAART or triple therapy is able to radically increase the survival of HIV-infected 
individuals and generally consists of the use of two nucleoside reverse transcriptase inhibitors 
(NRTIs), plus either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease 
inhibitor (PI).14 
 
Due to the essential role that reverse transcriptase plays in virus replication it is thus a major target 
for antiretroviral drugs.15  There are two classes of reverse transcriptase (RT) inhibitors, the 
nucleoside (NRTIs) and non-nucleoside (NNRTIs) reverse transcriptase inhibitors, each affecting 
the RT enzyme in a different location.15  NRTIs are analogs of deoxyribonucleosides which lack the 
hydroxyl group on the 3‟ carbon of the deoxyribose sugar.15  In order for these compounds to have 
antiviral activity they must be metabolically converted by host cell proteins to the triphosphate form, 
which allows it to be mistaken by the virus as a natural nucleotide.15, 16  These phosphorylated 
NRTIs can now function as chain-terminators in the synthesis of single stranded DNA.15  AZT is an 
example of an NRTI, it mimics the nucleoside thymidine but replaces the 3‟-OH group by a 3‟-azide 
(N3) group, thus stopping further inclusion of nucleotides and terminating DNA chain extension.
16  
There are currently eight NRTIs which have been approved for clinical use including 
Azidothymidine 1 (AZT or Retrovir®), dideoxyinosine 2 (ddI or Videx®) and dideoxycytidine 3 (ddC 
or Hivid®) (Figure 3).15, 17  
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Figure 3 Some commercially available NRTIs17 
 
NNRTIs on the other hand are small molecules that are chemically distinct from nucleosides and 
are not dependent on host cell metabolism to be converted to the active form.15 NNRTIs are a 
group of diverse hydrophobic molecules which inhibit the HIV-1 RT reaction through interaction 
with an allosteric site of the enzyme.15, 17  This allosteric site is located on the p66 subunit of the 
HIV-1 RT enzyme, a mere 10Ǻ from the substrate or nucleoside binding site.15, 17  The binding of 
an inhibitor in this allosteric site elicits a change in conformation of the substrate-binding site which 
means that nucleotides can no longer be bound in the active site of the enzyme and DNA 
synthesis cannot occur.17  Four NNRTIs have been approved for clinical use including nevirapine 4 
(Viramune®), delavirdine 5 (Rescriptor®), efavirenz 6 and etravirine 7 (Figure 4) and several more 
have entered into clinical trials and development.15, 17   
 
 
 
Figure 4  Commercially available NNRTIs17 
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The final class of therapeutic agents most commonly used in HAART are the HIV protease 
inhibitors.  HIV protease plays a crucial role in the viral life cycle as it is essential for generating 
mature infectious virus particles by cleavage of peptide bonds of large proteins and polypeptides 
into smaller proteins.18, 19  There are currently nine protease inhibitors approved for clinical use 
including saquinavir 8, ritonavir 9, indinavir 10 and lopinavir 11 (Figure 5).18  The protease 
inhibitors act as competitive peptidomimetic inhibitors by imitating the natural substrate of the HIV 
protease enzyme.18  These mimics contain a non-scissile hydroxyethylene core which prohibits the 
cleavage of the protease inhibitor by the protease enzyme, thus blocking the enzyme site and 
preventing maturation of viral particles.18  
 
 
 
 
 
Figure 5  Some commercially available PIs18 
 
3.3 Recent Developments and Strategies for Treating HIV 
 
Although the use of HAART therapy has greatly prolonged the survival of HIV infected individuals, 
drug resistance due to the rapidly mutating HI virus still remains a huge problem.14  Development 
and testing of more potent RT inhibitors and protease inhibitors remains a wide area of research, 
but due to the rapid rate at which the virus develops resistance to these drugs it is clear that new 
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drug targets need to be identified to efficiently combat the virus.13  A new class of compounds 
known as integrase inhibitors has subsequently been developed.13, 20  These drugs target the viral 
enzyme integrase which is responsible for the insertion of pro-viral DNA into the host-cell‟s 
genome.20, 21   
 
HIV integrase is one of the three viral enzymes essential for viral replication (along with RT and 
protease); this reinforces integrase as an excellent drug target.20, 22  Raltegravir (RAL) 12 (Figure 
6) was approved by the FDA on 12 October 2007 for use in antiretroviral therapy in patients with 
extreme drug resistance and was the first HIV integrase inhibitor to be used as an antiretroviral 
drug.20  The integration of viral DNA into the human genome is a complex process starting with the 
binding of integrase to the viral DNA to form a stable pre-integration complex.20, 22  This pre-
integration complex then migrates from the cytoplasm of the host cell to the nucleus where the viral 
DNA is transferred and integrated into the host DNA.20  RAL functions by blocking the active site in 
the pre-integrated enzyme complex, thus preventing the viral DNA strand from being incorporated 
into the host cell‟s genome.20  HIV integrase inhibitors have just recently been included in the 
antiretroviral regime for treatment of individuals with multi-drug resistant HIV and have shown great 
success in boosting immune recovery in these patients.20  However, this drug class is once again 
not impervious to mutations in the HI virus which render the drugs much less effective and once 
again highlights that the global control of AIDS will require an effective vaccine to stop the spread 
of the HIV virus.4, 20  
 
 
Figure 6  Raltegravir, the first HIV integrase inhibitor20 
 
It has already been widely established that a safe, effective and affordable HIV vaccine is needed 
if we wish to successfully combat AIDS.23  The first HIV vaccine was developed in 1987 and since 
then over 35 different vaccines have been tested in phase I and II clinical trials.23  Only 2 vaccines 
reached phase III trials and a third one is underway, but researchers believe we are still many 
years away from a successful HIV vaccine due to the seemingly insurmountable number of 
challenges scientists face when dealing with this disease.4, 23  Why is it so difficult to develop a 
vaccine?  When one considers the biology of HIV it becomes apparent what the complexities 
associated with an HIV vaccine are.24  Perhaps the biggest hurdle which must be overcome is the 
ability of HIV to persist in the host‟s immune cells by crippling the immune system and avoiding an 
adaptive immune response.24  These problems are further complicated by the rapid mutation of the 
HIV virus which aids in evading the immune response and seriously hampers progress in 
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developing an HIV vaccine.24  The most recent advancement in the field of HIV vaccine 
development was reported by Jin and co-workers who recently submitted a novel polypeptide 
vaccine of HIV T helper epitopes (EP-1043) and a DNA vaccine of HIV CTL epitopes for phase I 
clinical trials.25  The group demonstrated that 64% of their test subjects (non HIV-infected adults) 
had a positive CD4+ T response after two vaccinations.25  Whether the vaccine can be used to 
prevent HIV infection or simply to slow disease progression was not established, but it is hoped 
that upon further study EP-1043, or a modified version of it, could be used as a novel HIV 
vaccine.25 
 
While immunologists and scientists work to develop a successful vaccine and more effective drugs 
to treat HIV infected patients, the most effective solution for stopping the spread of HIV is that of 
education.4 Educating the public on the facts of how HIV is transmitted and empowering women in 
rural communities is the best way of slowing the spread of HIV/AIDS.4  Prevention is better then 
cure and if one can stop the spread of HIV by preaching safe sex, society may well be on its way to 
significantly reducing the number of AIDS patients and eradicating this human tragedy.4  
 
4.  The Use of NNRTIs as Drugs Targeting RT 
 
Whilst we await the elusive HIV vaccine one of the main focuses in HIV treatment is the 
development of more potent drugs which target vital enzymes in the replication cycle of the virus.4  
NNRTIs are such drugs; these drugs target the RT enzyme in HIV preventing the synthesis of viral 
DNA from viral RNA.15  With the advent of HAART therapy the use of NNRTIs has been firmly 
established in the treatment of HIV infection, but due to drug resistance the current NNRTIs are no 
longer as potent.13 Thus the synthesis and development of novel NNRTIs with increased 
resistance selectivity has become the focus of many research groups in the fight against 
HIV/AIDS.13 
 
4.1 The RT Enzyme and Mode of Action of NNRTIs 
 
HIV-1 RT is a heterodimer consisting of p66 and p51 subunits (Figure 7), where the p66 subunit is 
the larger of the two and contains both NRTI and NNRTI binding sites.13, 26  The p66 subunit 
consists of RNA-dependent DNA polymerase (RDDP) and ribonuclease H (RNase H) domains, 
both of which are vital for the process of converting single-stranded RNA into double-stranded 
DNA.13, 15  Reverse transcription is initiated when cellular tRNA is coupled by RDDP to viral RNA at 
the 3‟-end and is then elongated towards the 5‟-end of the viral RNA.15  The resulting product is a 
DNA-RNA hybrid strand which is complimentary to the viral RNA.15  RT RNase H activity is then 
responsible for hydrolysing the ssRNA from the DNA-RNA hybrid resulting in a single strand of 
DNA.15  The single-stranded DNA can now be converted to the double-stranded proviral DNA by 
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the RT enzyme and can then be integrated into the host cell‟s genome using viral enzyme 
intergrase.15   
 
 
 
Figure 7 HIV-1 RT heterodimer showing Nevirapine bound in the allosteric site26 
 
NNRTIs interact with the HIV-1 RT by binding to a site on the p66 subunit called the NNRTI binding 
pocket and is an allosteric site situated 10 Ǻ from the RT polymerase and 60 Ǻ from the RNase H 
active site.13, 15  In contrast to NRTIs, which are competitive inhibitors and actively compete for the 
active site of the polymerase, NNRTIs are non-competitive inhibitors.13  When unliganded and 
NNRTI-bound RT crystal structures are compared it is evident that the NNRTI binding pocket is 
only created by the binding of the inhibitor itself.13  This event is characterised by the movement of 
the side chains of the key amino acids Tyr181 and Tyr188 from a „down‟ position to an „up‟ 
position.13  The importance of these residues for binding of the inhibitor is shown by how 
favourably the virus selects for the mutated enzyme where these two residues are aliphatic so that 
favourable π-stacking interactions with aromatic inhibitors is avoided.13  It is thus obvious that 
design of new NNRTIs should seek to avoid this key interaction in the hopes of significantly 
reducing the rate at which HIV becomes drug resistant.13 
 
In order to design new and effective NNRTIs it is important to understand the mode of inhibition 
and the specific binding actions of the ligands in the enzyme.13, 15  A number of different 
mechanisms have been proposed for NNRTI inhibition of RT.13  Perhaps the simplest explanation 
is that the binding of the NNRTI in the allosteric site of the enzyme reduces the lability of the 
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enzyme and prevents the domain movements which are imperative to the catalytic cycle.13  
Perhaps a more likely suggestion is that on binding of the NNRTI in the allosteric site there is a 
significant and consistent movement of the β2-β3 chains which contain the important amino acids 
Asp110, Asp185 and Asp186.13  It is thus deduced that when these amino acid residues are shifted 
in the active site by the change in conformation of the enzyme, the essential catalytic processes 
cannot occur.13  It is generally accepted that binding of the NNRTI in the allosteric site brings about 
a change in conformation of the active site, preventing the nucleosides from being taken up by the 
enzyme and preventing the key process of synthesising viral DNA.13, 15   
 
4.2 Current NNRTIs and the Mutations Which Confer Resistance 
 
There is unfortunately a wide range of drug resistance mutations described in the literature for 
NNRTIs and this highlights the problem with the current NNRTIs available for use in HAART 
therapy.13, 17  The Tyr181/Tyr188 mutation which has already been discussed, greatly reduces the 
efficacy of the NNRTI nevirapine.13  This is due to the loss of favourable aromatic stacking between 
the pyridine ring of nevirapine and the aromatic side chains of the Tyr181/Tyr188 residues when 
they mutate to aliphatic residues such as cysteine.13  The same mutation,not surprisingly, only 
confers a small loss in potency with the NNRTI efavirenz as the cyclopropyl group already has less 
effective contacts with the Try181/Try188 residues.13 Perhaps newly designed NNRTIs should 
exploit this mutation and include aliphatic regions which could still efficiently bind with the mutated 
enzyme. 
 
The most widely reported resistance mutation is that of K103N, or the mutation of the lysine 
residue at 103 to an asparagine residue.13  Structural studies indicate that this mutation actually 
blocks the entry of NNRTIs into the allosteric site by producing favourable H-bonding interactions 
which stabilise the closed NNRTI binding site.27  This mutation reduces the activity of many FDA 
approved NNRTIs (nevirapine 4, delavirdine 5 and efavirenz 6).28  Delavirdine‟s activity is the most 
affected as this inhibitor actually forms favourable H-bonding contacts with the Lys103 residue; 
when this mutation occurs these H-bond contacts are removed, disfavouring the bonding of 
delavirdine in the allosteric site.27  Efavirenz once again is the NNRTI which best overcomes this 
mutation and still remains up to 90% effective if this mutation occurs.28 
 
A further mutation which confers moderate resistance to a number of NNRTIs is a mutation at 
position 101 or 138.13  The Lys101 residue does not have direct contact with the binding NNRTI, 
but there is generally a chain of three water molecules which link the inhibitor with the Lys101 
residue.13  The Lys101 residue can form a salt bridge with the Glu138 residue of the p51 subunit 
and a mutation at either of these residues can result in an inversion of charge.13  Once this occurs 
the Lys101, water molecules and inhibitor may no longer have a favourable electrostatic 
interaction, thus destabilising the binding of the inhibitor in the NNRTI binding site.13  Likewise a 
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mutation in the Glu138 residue may result in an unfavourable electrostatic interaction across the 
Lys101 and Glu138 salt bridge; again destabilising the binding of the NNRTI in the allosteric site.13  
There are many more mutations which can result in the resistance of HIV to the current NNRTI 
treatments.13  Understanding the mechanisms by which these mutations confer resistance is 
therefore imperative in designing novel NNRTIs which may be more effective in treating HIV 
infections.13, 17 
 
4.3 Developments in the Design and Synthesis of Novel NNRTIs 
 
There are two schools of thought when it comes to the development of novel NNRTIs.29  The first 
strategy focuses on the understanding of drug resistance mechanisms and development of drugs 
to effectively inhibit the mutant virus.29  The second strategy focuses on targeting highly conserved 
areas in the enzyme where the least mutation has occurred and designing drugs to interact with 
this portion of the enzyme.29  Both schools of thought have met with some success and second 
generation NNRTIs have shown increased ability to bind with mutated HIV-1 RT.29  Although 
numerous new classes of compounds have been identified as potential novel NNRTIs, this section 
aims at highlighting only a few of the current successes in NNRTI design and development in 
combating HIV drug resistance.   
 
One of the current successes in novel NNRTI design is the synthesis and development of second 
generation diaryl ethers as lead compounds.30  Tucker et al. discovered lead compound 13 via high 
throughput screening (HTS), but the disappointing pharmacokinetic results forced the group into a 
different direction.30  Using 13 as a lead compound and comparing it to an already known NNRTI 
14 via a molecular modelling program they were able to identify a novel diphenyl ether 
substructure 15 (Scheme 1) which had good docking results with the NNRTI binding site.30  The 
molecular modelling study showed that the amide carbonyl was imperative in maintaining a critical 
hydrogen bond with the backbone NH of Lysine 103, which is crucial in maintaining good potency 
at the K103N postion.30  The modelling study also indicated that a di-meta substitution pattern on 
the A and B aryl-rings as seen in compound 14 would help optimise interactions with the binding 
site and help to improve the potency of this series of compounds.30  The model also indicated that 
the sulfonamide was situated at the enzyme/water interface and was thus fully solvent exposed, 
indicating the potential for various polar substitutions in this area.30 
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Scheme 1 Design of Novel Diaryl Lead Structures30 
 
The group synthesised a variety of compounds based on the modelling study with an indazole 
compound 16 (Figure 8) showing the best NNRTI activity.30  The key carbonyl H-bonding 
interaction is replaced by the indazole moiety which is capable of forming two H-bonds with amino 
acid residue K103, thus increasing its potency.30  The di-meta substitution on the A aryl-ring once 
again increased the potency of the compound and this is thought to be due to the improved π-π 
stacking of the A-aryl ring and the Y188 residue.30  The chlorine atom on the B aryl-ring fits very 
well into a small lipophillic region behind the V179 residue and once again increases binding 
potency.30  Unfortunately the compound showed low bioavailability and poor solubility, but the 
discovery of this compound has become a prototype for novel NNRTI synthesis and efforts for 
improving its solubility are being investigated.30 
 
 
Figure 830 
 
A further success story in the quest for novel and more potent NNRTIs was published by Lui and 
co-workers whose previous work with triazole 17, tetrazole 18 and 1,2,3-thiadiazole 19 
thioacetanilides (TTAs) (Figure 9) had already exhibited significant anti-HIV-1 activity.31  Based on 
this activity the group thought it worthwhile to synthesise new TTAs based on the SAR studies 
done for previously synthesised TTAs, in a bid to improve the interaction between the inhibitors 
and the RT enzyme and improve the biological activity.31   
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Figure 9 Triazole, Tetrazole and 1,2,3-Thiadiazole Thioacetanilide based NNRTIs31 
 
The previous SAR and molecular modelling studies demonstrated that an increase in the volume of 
the substituted phenyl ring linked with the azole proved beneficial in strengthening the π-π stacking 
between the inhibitor and the Tyr181 and Tyr188 amino acid residues of the RT enzyme.31  The 
group thus opted for a larger 2,4-dibromo substitution on the newly synthesised TTAs.31  It was 
also noted from the SAR studies that the anilide phenyl moiety is located at the protein/solvent 
interface and in several of the newly synthesised TTAs this phenyl ring was replaced with several 
substituted heterocycles to improve the interaction between the inhibitor and solvent front.31  The 
group discovered that of the newly synthesised TTAs the 2,4-dibromo derivative containing a 2-
chloropyridin-3-yl heterocycle 20 (Figure 10) was the most potent potential NNRTI and had an 
activity 7-fold that of Nevirapine and Delaviridine, two commercially available NNRTIs.31  Molecular 
modelling studies of compound 20 showed that the 2,4-dibromophenyl ring fits into the aromatic-
rich binding pocket, surrounded by the aromatic side chains of Tyr188, Phe227 and Trp229 amino 
acid residues.31  The analysis showed that the binding mode of the phenyl ring was parallel to the 
Tyr188 side chain, giving rise to positive π-stacking interactions.31  The inhibitor‟s amide carbonyl 
also forms a key H-bond with the backbone N-H of the Lys103 amino acid residue, also improving 
the binding of the inhibitor in the allosteric site.31  Based on the biological testing results and SAR 
studies, these newly synthesised TTAs could serve as potent NNRTIs in the future and synthesis 
of new TTA derivatives and testing of these compounds is currently being conducted by this 
group.31 
 
 
Figure 1031 
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The positive results displayed by both these groups highlights the importance of such processes as 
HTS, SAR studies and molecular modelling in finding compounds which can act as potent and 
selective NNRTIs.  The successes of these groups in developing the potential NNRTIs shows how 
critical it is to use each and every available resource in drug design.  The following sections will 
highlight the use of another one of these important tools in medicinal chemistry, the use of multi-
component coupling reactions for the synthesis of high throughput screening libraries. 
 
5. Multi-Component Coupling Reactions in Medicinal Chemistry 
 
Drug discovery is a competitive field which requires constant innovation and development due to a 
combination of variable factors which include market, patient and regulatory issues.32  Due to high 
failure rates of drugs in phase II and phase III clinical trials and the limited human resources, drug 
development is a slow and risky process.32  Multi-component coupling chemistry emerged in the 
1990s with the ability to address some of the major issues facing the pharmaceutical companies 
today and has since become important in modern drug discovery.32   
 
5.1 What Are Multi-Component Couplings? 
 
Multi-component coupling reactions (MCCs) are powerful condensation reactions which occur in 
one pot and incorporate portions of three or more starting materials in the final product.33  Perhaps 
the most attractive aspect of MCCs is the ability of these types of reactions to create structurally 
complex or highly substituted molecules in a single chemical step.34  Multi-component 
condensations are atom economical in contrast to classical synthesis which requires multiple steps 
and reagents; MCC only require one step thus significantly reducing the generation of by-
products.34  As well as being an important means of generating structurally diverse molecules in an 
atom economical reaction an ideal multi-component reaction should also possess the ability to be 
modified in order to diversify the products.35  This allows for the creation of large libraries of 
compounds which contain a certain privileged skeleton.35  The new approach in medicinal 
chemistry is a scaffold-based approach whereby hundreds of derivatives of a certain core structure 
are prepared and biologically screened.36  MCC allows medicinal chemists to create these large 
screening libraries either in one pot, by varying side chains on starting materials, or by way of post-
MCC modifications.36  It is the use of MCC in the almost effortless creation of these compound 
libraries which have cemented the use of MCC in medicinal chemistry.33  There are numerous 
examples of MCCs in the literature and this section aims to demonstrate the elegance and 
efficiency of a few well known MCCs. 
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5.2 Specific Examples of MCCs 
 
5.2.1 The Ugi Reaction 
 
Perhaps one of the most famous and widely used MCCs is the Ugi reaction, which is a four 
component reaction of an amine, aldehyde, carboxylic acid and isocyanide to afford a peptide-like 
structure (Scheme 2).37  The Ugi reaction is generally initiated by the condensation of the amine 
with the aldehyde to form the intermediate imine, which subsequently reacts with the carboxylic 
acid and isocyanide to give the desired product.37  Many researchers have focused on the Ugi 
reaction to prepare libraries of α-aminoacylamides, but recently the ability of these products to be 
modified post-condensation has become a key focus.38, 39  These post-condensation modifications 
and cyclisations can be used to produce numerous pharmacologically important scaffolds by 
careful selection of the key Ugi-components.39 
 
 
Scheme 2 Mechanism of Ugi 4-Component Coupling Reaction37 
 
The use of the classical Ugi reaction, followed by a post-condensation cyclisation via nucleophilic 
aromatic substitution (SNAr), leading to the novel and versatile two step synthesis of imidazo and 
pyrazolo[1,5-a]quinoxalines was demonstrated by Spatz and co-workers.37  Imidazoquinoxalines 
are an important class of biological heterocycles which are found extensively in pharmaceutical 
agents.37  They have been used as templates for GABA/benzodiazepine receptor 
agonists/antagonists and cAMP and cGMP phosphodiesterase inhibitors in addition to numerous 
other pharmacological applications.40  The first step of the synthesis was the four-component Ugi-
reaction yielding the product 25 as the intermediate for the subsequent cyclisation reaction 
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(Scheme 3).37  The use of 2-fluoroaniline 21 and the heterocyclic carboxylic acid 23, as 
bifunctional starting materials, enabled the nucleophillic aromatic substitution reaction to occur in 
which the nitrogen of the heterocyclic acid component acts as a nucleophile and the fluorine as the 
leaving group to give compounds such as 26.37  The group was also able to demonstrate this 
methodology using a variety of fluoro-substituted amines, aldehydes and isocyanides leading to 
compounds with three points of variable diversity.37 
 
 
Scheme 3 Schematic of 4-oxo-4H-imidazo-[1,5-a]quinoxaline synthesis37 
 
A further example of the Ugi reaction products undergoing post condensation modifications was 
reported by Kalinski et al. who demonstrated the combined use of the Ugi and Heck reactions for 
the synthesis of highly substituted dihydroindoles.39 Their synthesis involved the use of 2-
bromoanilines and acrylic aldehydes as starting materials for the Ugi reaction (Scheme 4).39  The 
acyclic intermediate, Ugi-product 27, was then subjected to an intermolecular Heck-reaction to give 
the final dihydroindole 28.39 
 
 
Scheme 4 Ugi-Heck Synthesis of Substituted Indoles39 
 
5.2.2 MCC based on Transition Metal Catalysis 
 
A recent review showed a transition metal catalysed MCC as the key step in the synthesis of (+)-
frondosin B 30, a marine alkaloid active as an interleukin-8 antagonist.35  The approach utilised a 
Pd-catalysed MCC between a 2-bromomphenol, alkyne and bromoenone to provide the 
intermediated functionalized benzofuran derivative which was successfully cyclised using ring 
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closing metathesis to afford the basic core of frondosin B 29 (Scheme 5).35  The final product 
was obtained in a further six steps with an overall yield of 32%.35   
 
 
 
Scheme 5 Total Synthesis of Frondosin B using Pd-catalysed MCC reaction35 
 
5.2.3 The Strecker reaction 
 
The Strecker reaction, which was discovered in 1850, was the first MCC reaction to be published 
and is of great importance in medicinal chemistry.41  The reaction demonstrates the coupling of an 
amine, carbonyl compound and either hydrogen cyanide or an alkaline metal cyanide to afford α-
amino nitriles (Scheme 6) which are important products en route to the synthesis of α-amino 
acids.41  The Strecker reaction has also been used as an important step in the synthesis of natural 
products as shown by Zhu and co-workers when they demonstrated the use of the asymmetric 
Strecker reaction in the synthesis of D-(R)-4-methoxy-3,5-bisbutyldimethylsiloxy phenylglycine as a 
key intermediate in the synthesis of the antibiotic vancomycin.41, 42   
 
 
 
Scheme 6 Schematic of Strecker Reaction41 
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6.  Multi-Component Couplings for the Development of Imidazo[1,2-a]pyridines 
 
6.1 Groebke-Blackburn Reaction 
 
In 1998, a four-centre, three-component reaction involving 2-aminoazines and 2-aminoazoles to 
form fused imidazoles was reported independently by three different research groups.43  This 
reaction which involves the condensation of a 2-aminoazine or 2-aminoazole with an isocyanide 
and aldehyde, in the presence of catalytic acid (Scheme 7) became known as the Groebke-
Blackburn reaction.44a  The original success of the Groebke-Blackburn reaction being high yielding, 
experimentally simple and the originality of the 3-aminoimidazo[1,2-a]pyridine ring system led to 
further exploration of this unusual transformation.44b  Preliminary studies showed that aldehydes 
(1.2 - 3.0 equiv) and isocyanides (1.2 - 1.5 equiv) are best used in slight excess to the 2-
aminoazine component and that the reactions were not sensitive to either oxygen or moisture.44b  
Further studies highlighted the tolerance of the MCC reaction for structural variations of the three 
components; aldehydes and isocyanides (aromatic, electron-rich and electron-poor, hetero-
aromatic, aliphatic and sterically encumbered) showed little effect on the high yields of the 
reactions.44b  Many hetero-aromatic amidines can be used in the reaction, but the use of electron-
poor amidines tended to slow the reaction down significantly and resulted in many more side-
products.44b  Thus the simple and highly efficient synthesis of imidazo[1,2-a]azines by way of the 
Groebke-Blackburn reaction has led to numerous efforts to develop compound libraries based on 
this drug-like core and further highlights the importance of effective  MCC in medicinal 
chemistry.44a, 45  
 
 
Scheme 7 Schematic of Groebke-Blackburn Reaction43 
 
A probable mechanism (Scheme 8) for the formation of the imidazo[1,2-a]azine core involves a 
non-concerted [4+1] cycloaddition between the protonated Schiff base (which holds both the 
nucleophilic and electrophilic character) and the isocyanide (which behaves as a vinylidene 
carbenoid).43  Under acidic conditions an aldehyde and a primary amine can react to form what is 
known as an iminium ion or Schiff base.46  It is this iminium ion which contains both the 
nucleophilicity and electrophilicty which is essential for the [4+1] cycloaddition of the isocyanide.46  
The final step in the formation of the 3-aminoimidazole is a prototropic shift forming the final 
aromatic product.44a, 44b  
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Scheme 8 Suggested Mechanism of Groebke-Blackburn Reaction44a 
 
 
6.2 Synthesis of Imidazo[1,2-a]pyridines and the Efficacy of MCC 
 
There are a number of synthetic routes for the synthesis of imidazo[1,2-a]pyridines and 
imidazo[1,2-a]pyrimidines (Scheme 9).47  These include:  (i) coupling reactions of 2-aminopyridines 
with α-halocarbonyl compounds; (ii) reaction of 2-chloropyridine with 1,2,3-triazoline and 
subsequent elimination of nitrogen; (iii) cyclizations of 1-(2-alkynyl)-2-aminomethylimidazoles, 
which are obtained from substituted imidazoles via six steps; (iv) reactions of (arylacetyl)imidazoles 
with acetylenedicarboxylic esters; (v) condensation of 2-aminopyridine with glyoxal trimer 
dehydrate in aqueous NaHSO3 and (vi) one-pot condensations of aldehydes, isonitriles and 2-
aminopyridines.47   
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Scheme 9 Various Approaches to the Synthesis of Imidazo[1,2-a]pyrimidine and Imidazo[1,2-
a]pyridine47 
 
Of all the methods which can be employed to synthesise the imidazo[1,2-a]pyridine core, only (i) 
and (vi) allow for diversity in the final products.47  Method (i) is a popular approach for synthesising 
the imidazo[1,2-a]azine core as a variety of substituted 2-aminopyridines and α-halocarbonyl 
compounds are commercially available or can be readily synthesised.47  However, one of the 
biggest drawbacks with this methodology is the inability to form 3-amino monosubstituted 
imidazo[1,2-a]pyridines or imidazo[1,2-a]pyrimidines with this ring closing procedure.47  Hence the 
Groebke-Blackburn MCC reaction is the method of choice for the synthesis of 3-aminoimidazo[1,2-
a]pyri(mi)dine ring systems as it is the only method know to date to allow for significant diversity at 
the 3-position.48 
 
The simplest way in which huge libraries of diverse 3-aminoimidazo[1,2-a]pyri(mi)dine compounds 
can be synthesised is to make use of the variety of commercially available aldehydes, isocyanides 
and substituted 2-aminopyri(mi)dines.43  However, although the diversity of aldehydes is quite 
substantial, there are only a few commercially available isocyanides.43  This problem is easily 
overcome by using an isocyanide with a side chain which can be easily converted to the primary 
amine and further modified at the amino group by, for example acylation or N-arylation.45  Krasavin 
and co-workers demonstrated that t-butyl isocyanide can be used as a convertible isocyanide with 
the tert-butyl group being cleaved in neat TFA under reflux and gave the corresponding 
trifluoroacetamides.49  The latter were then subjected to alkaline hydrolysis to afford the primary 
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amines in excellent yields.49  The subsequent primary amine was then derivatized via Palladium 
catalyzed arylation, acylation, carbamoylation and reductive alkylation.49  In this way the Groebke-
Blackburn multi-component coupling reaction can be used to synthesise large numbers of 
structurally diverse imidazo[1,2-a]azines without being limited by the isocyanide component.49 
 
6.3 Biological Application of Imidazo[1,2-a]pyridines 
 
Imidazo[1,2-a]pyridines and the related imidazo[1,2-a]pyrimidines have received significant 
attention from the pharmaceutical industry owing to their interesting biological applications.48  
These compounds have been known to display bioactivity over a broad range of therapeutic 
classes and have shown antibacterial, antifungal, antiviral and anti-inflammatory properties.48  
There are also several therapeutic agents currently on the market which contain the imidazo[1,2-
a]pyridine core (Figure 11) including alpidem 31 (anxiolytic), zolpidem 32 (hypnotic) and zolimidine 
33 (antiulcer).48 This section aims to illustrate a few of the recent developments in the use of novel 
imidazo[1,2-a]pyridines as biological agents. 
 
 
 
Figure 11 Therapeutic Agents containing the Imidazo[1,2-a]pyridine core48 
 
6.3.1 Anti-viral Applications of Imidazo[1,2-a]pyridines 
 
The human cytomegalovirus (HCMV) is a β-herpes virus which can cause severe illness in 
immuno-compromised people such as AIDS patients or organ transplant recipients.50  The drugs 
which are currently used to treat this disease are Ganciclovir, Foscarnet and Cidofovir, but these 
drugs have many side effects and the drug Ganciclover has been shown to have a toxic effect on 
the bone marrow of patients.50  Gueiffier and co-workers, as part of a study on nitrogen bridgehead 
heterocycles, reported the synthesis and antiviral activity of 7- and 8-methyl-3-benzylthiomethyl-
imidazo[1,2-a]pyridine 34 and 35 (Figure 12) as novel HCMV inhibitors.50, 51  The biological assays 
demonstrated that these compounds had high selectivity for the CMV-infected cells in vivo and 
thus a high selectivity for viral enzymes.51   
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Figure 1251 
 
A further example of the biological applications of imidazo[1,2-a]pyridines was shown by 
Hamdouchi and co-workers, who developed a series of 2-amino-3-substituted-6-[(E)-1-phenyl-2-
(N-methylcarbamoyl)vinyl]imidazo[1,2-a]pyridines 36a-f (Figure 13) which showed excellent 
potential as anti-rhinovirus agents.52  Human rhinoviruses are a group of viruses responsible for 
the common cold, bronchitis, and sinusitis and exacerbate chronic asthma and emphysema.52  A 
wide range of compounds have been shown to exhibit anti-rhinovirus activity, but most compounds 
have been rejected due to problems with toxicity, unfavourable pharmacology and poor 
bioavailability.52  Two synthetic potential rhinovirus benzimidazole inhibitors, enviroxime 37 and 
enviradene 38 (Figure 13) show good in vitro activity.52  However further development of both 
compounds has been discontinued due to their insignificant therapeutic benefit and undesirable 
side effects.52  The newly synthesised imidazo[1,2-a]pyridines showed improved antiviral activity 
and reduced cellular toxicity when compared to enviroxime and enviradene.52  Since the anti-
rhinoviral activity found in this new class of compounds is promising, it is hoped that further 
biological evaluation including bioavailability and broad-spectrum activity will be valuable in finding 
a potential treatment for the common cold.52 
 
 
 
Figure 1352 
 
6.3.2 Anti-Bacterial Applications of Imidazo[1,2-a]pyridines 
 
The type II bacterial topoisomerases DNA gyrase and topoisomerase IV, which are responsible for 
the control of chromosome function, are important drug targets of the quinolone/fluoroquinolone 
class of anti-bacterial agents.53  These therapeutic agents interact with the catalytic subunits of 
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DNA gyrase (GyrA) and topoisomerase IV (ParC).53  The ATPase subunits of these enzymes 
GyrB and ParE have also been identified as targets for small molecule inhibitors; however, the 
anti-bacterial agents used to date have many downfalls including resistance, toxicity and 
permeability, which limited the scope of these drugs.53  East and co-workers identified an 
imidazo[1,2-a]pyridine scaffold to demonstrate anti-bacterial activity through inhibition of the GyrB 
and ParE ATPase subunits.53  The imidazopyridine 39 (Figure 14) was the most active compound 
tested against Gram-positive Staphylococcus aureus ATCC 29213 and Enterococcus faecalis 
ATCC 29212 as well as Gram-negitive E. coli N43 bacterial strains.53  Further SAR studies and 
investigations into the pharmacokinetics and efficacies are being investigated by this group.53 
 
 
Figure 1453 
 
6.3.3 Anti-Parasitic Activity of Imidazo[1,2-a]pyridines 
 
 
 
 
Figure 1554 
 
Coccidiosis is a parasitic disease which is caused by the invasion of the avian intestinal lining by a 
protozoan parasite of the genus Eimeria and is a major cause of mortality in the poultry industry.54  
Over 35 billion chickens are raised worldwide and the major poultry operations administer anti-
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coccidial agents prophylactically; however, increased resistance to current coccidiostats means 
a new range of drugs needs to be developed in order to target novel biochemical pathways.54  A 
recent study indicated that cCMP-dependent protein kinase (PKG) is essential to the survival of the 
parasite and thus represents a good drug target.54  HTS of known kinase inhibitors identified 
imidazo[1,2-a]pyridines as potential PKG inhibitors and broad spectrum anti-coccidial agents.54  
Scribner prepared a variety of 2-aryl-3-(2-aminopyrimidin-4-yl)imidazopyridines with different alkyl 
amine substituents at the 7-postion of the imidazopyridine moiety to test as anti-coccidial agents.54  
The most active compounds 40a, 40b, 41, 42 and 43 (Figure 15) all showed in vivo potency 
against all four species of Eimeria at, or below, 12.5ppm, but due to potential genotoxicity these 
compounds were not developed further.54  The synthesis of less toxic imidazopyridine derivatives 
is currently being continued by the group.54 
 
7.  Multi-Component Couplings for the Synthesis of 3-amino-1-cyano-indolizines 
 
7.1 3-Amino-1-cyano-indolizine by MCC 
 
The synthesis of 3-amino-1-cyano-indolizines by using a MCC was first reported by Poigny and co-
workers as part of an effort to synthesise small molecule inhibitors which could inhibit protein-
protein binding in an attempt to develop a novel prostate cancer treatment.34  As part of the study, 
the group screened approximately 20 000 small molecules of which 11 800 were purchased and 
8160 were synthesised in-house using exclusively different multi-component coupling reactions.34  
Of all the molecules screened, only three different MCC-based scaffolds showed any activity in the 
biological screening and among those scaffolds the 3-amino-1-cyano-indolizines were the most 
potent antagonists.34 The synthesis of 3-amino-1-cyano-indolizines is similar to the Groebke-
Blackburn reaction and involves the condensation of an isocyanide, an aldehyde and cyano-2-
methylene-pyridine in the presence of a catalytic amount of base (Scheme 10) to give the desired 
products in moderately good yields.34   As in the case with the Groebke-Blackburn reaction, by 
making use of the wide variety of commercially available starting materials, both aldehyde and 
isocyanide components could be varied to increase the diversity in the 3-amino-1-cyano-
indolizines.34  In this way large diverse compound libraries of these indolizines can be synthesized 
for high throughput screening against various diseases and pathogens. 
 
 
 
Scheme 10 Schematic of 3-amino-1-cyano-indolizine synthesis34 
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The mechanism of this MCC reaction has not been fully elucidated, but the authors suggest that a 
possible mechanism is through the cheletropic addition of the isocyanide moiety to the 
Knoevenagel-type hetero-diene intermediate (Scheme 11) as in the Groebke-Blackburn 
mechanism.34  The protons which are α- to the nitrile are acidic and can easily be removed by a 
base, thus generating an anion in the α-position.46  The carbonyl carbon of the aldehyde being 
electrophilic then undergoes nucleophilic attack from the α-anion and with subsequent elimination 
of water forms the hetero-diene.46  It is then suggested that a non-concerted [4+1] cycloaddition 
between the hetero-diene and the isocyanide, followed by a prototropic shift to regain aromaticity, 
forms the 3-amino-1-cyano-indolizine scaffold.34 
 
 
 
 
Scheme 11 Proposed Mechanism for the Synthesis of 3-amino-1-cyano-indolizines34 
 
7.2 Synthesis of Indolizines; Why MCC is so efficient 
 
Pyrrolo[1,2-a]pyridine, known as indolizine, is an important scaffold found in natural products and 
has been used as a key motif in the pharmaceutical industry due to the broad spectrum of 
biological activities with which it is associated.55  It is thus not surprising that there are many 
synthetic approaches for the development of this privileged scaffold in the literature.55  Syntheses 
of the indolizine ring system include, as shown in Scheme 12:  (i) the phosphine catalysed 
nucleophilic addition of azoles to allenes,56 (ii) 1,3-dipolar reaction of N-ylides with fluorinated vinyl 
tosylates,57 (iii) 1,3-dipolar cycloaddition of pyridiniums and alkynes,58 (iv) 5-endo-trig 
iodocyclization55 and (v) reaction of α-halo pyridinium salts with β-dicarbonyl species59.   
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Scheme 12 Schematic of key steps in the syntheses of the indolizine scaffold55 - 59 
 
Although many of these syntheses appear to be simple one pot syntheses (ii,iii,v), they do however 
require preparation of the starting materials.  The pyridinium salts and N-ylides need to be 
prepared from the appropriate pyridines and α-halo species (ii,iii,v) and the fluorinated alkenyl 
tosylates need to be prepared from the corresponding fluorinated alcohols (ii), making these 
syntheses less efficient and atom economical than the MCC reaction.57, 58, 59  The diversity of the 
indolizine compounds synthesised by these methods is also limited by the starting materials, as 
although various alkynes (iii) and β-dicarbonyl (v) compounds are commercially available there is 
not a wide variety of highly substituted species found and preparation of these compounds may 
then be necessary.58, 59 The iodocyclization starting material (iv) first needs to be prepared from the 
reaction between the corresponding 2-pyridinyl lithium and α,β-unsaturated aldehyde to give the 
allylic alcohol, which is turn is converted to the allylic acetate, making the synthesis far less 
efficient than the MCC reaction.55  Synthesis (i) is the only true one-pot synthesis, but the diversity 
of the final indolizine compounds is seriously hampered by the lack of functionalized allenes and 
azoles which are commercially available.56   
 
When reviewing the syntheses presented in Scheme 12 it becomes obvious why multi-component 
condensations are amongst the most useful chemical reactions.  The MCC reaction for the 
synthesis of 3-amino-1-cyano-indolizines is not only synthetically efficient, but allows for the 
development of structurally diverse indolizine products.34  The simplest way in which large libraries 
of structurally diverse 3-amino-1-cyano–indolizine compounds can be synthesised is to make use 
of the variety of commercially available aldehydes and isocyanides.34  However, although the 
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diversity of aldehydes is quite substantial, there are only a few commercially available 
isocyanides.43  This problem is easily overcome by using a convertible isocyanide which is 
converted to the primary amine and further modified at the amino group by way of, for example 
acylation or N-arylation45, as is the case with the imidazo[1,2-a]pyridine compounds. 
 
7.3 Biological Applications of Indolizines 
 
It has already been mentioned that the indolizine scaffold is an important one in nature and in the 
pharmaceutical industry.55  This privileged scaffold has been found to have a variety of biological 
activities including anti-inflammatory, antiviral, analgesic, antitumor and cardiovascular activity.60  
Thus indolizines have become important synthetic targets in the development of novel 
pharmaceuticals for the treatment of cancer, cardiovascular disease and HIV infections.60  This 
section will illustrate a few of the biological applications of compounds containing the indolizine 
motif and recent developments in the synthesis of novel indolizines as potential biological agents. 
 
7.3.1 Antibacterial Activity of Indolizines  
 
There are approximately 1.6 million deaths annually worldwide due to tuberculosis (TB).61  Current 
treatments for TB must be taken for a period of 6-9 months and due to the lengthy time period 
many patients stop taking the drugs leading to the growing problem of multi-drug resistant strains 
of TB.61  The increased resistance of the micro-organism against antibacterial compounds calls for 
research and development into producing novel TB agents which are effective against the drug 
resistant TB strains.61  Gundersen et al. began screening indolizine derivatives which had been 
previously studied for their anti-oxidant properties and came across the antimycobacterial 
properties of (±)-1-(hydroxyphenylmethyl)-2,3-diphenylindolizine-7-carbonitrile 44 (Figure 16).61  
The indolizine compound was screened against M. tuberculosis H37Rv and showed excellent 
results in vitro and with continued development may prove to be a potent and selective 
antimycobacterial agent.61 
 
 
 
Figure 1661 
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7.3.2 Cardiovascular Activity of Indolizines 
 
Calcium channel blockers or calcium antagonists have been found to be the most effective 
treatment for ischemic heart disease and hypertension.62, 63  These drugs selectively inhibit Ca2+ 
influx into the heart muscles by blocking the slow inward channels for Ca2+ or inhibit Ca2+ influx into 
vascular smooth muscle causing the muscles to relax.62  There are currently three clinically 
available calcium channel blockers: a 1,4-dihydropyridine, nifedipine 45, a phenylalkylamine, 
verapamil 46 and a benzothiazepine, diltiazem 47 (Figure 17).62  A new class of calcium channel 
blockers has recently been discovered; the 1-[[4-(aminoalkoxyphenyl]sulfonyl] indolizines 48 with 
most compounds being as active as verapamil 46 and diltiazem 47.63  The compound fantoforone 
or SR 33537 49 was discovered to be as potent as nifedipine 45 and has been selected for clinical 
development for the treatment of hypertension.63   
 
 
Figure 1762, 63 
 
7.3.3. Anticancer Activity of Indolizines 
 
Inhibitors of the cytochrome P450 aromatase are therapeutic agents for the treatment of estrogen 
dependent diseases such as breast cancer.64  Several inhibitors of aromatase have been reported 
and are either clinically available or under clinical evaluation; however, many of these inhibitors are 
not as potent as expected in vivo or have terrible side effects.64  Thus the synthesis and 
development of more powerful and specific aromatase inhibitors is of great importance for the 
treatment of breast cancers.64  Molecular modelling studies carried out by Sonnet et al. led to the 
design of a novel hypothetical aromatase inhibitor.64  The group synthesised an array of indolizine 
compounds based on the indolizine pharmacophore and were tested for aromatase inhibition in 
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human placental microsomes.64  The in vitro biological evaluation of these compounds led to the 
identification of two new and potent non-steroidal aromatase inhibitors MR 20494 50 and MR 
20492 51 (Figure 18) which are undergoing clinical development.64 
 
 
Figure 1864 
 
8. Aims of this Section 
 
The selected review in Chapter 1 highlights the growing need for novel NNRTIs with improved 
potency and activity to combat drug resistant forms of the HIV-1 virus.  The review also highlights 
the remarkable ability of MCC reactions to create large libraries of structurally diverse compounds 
in few steps.  This section of the project aims to combine the synthetic efficacy of MCC reactions 
with the mounting need for novel NNRTIs in an effort to identify compounds showing potential anti-
HIV activity.  We thus wish to use MCC reactions to synthesise an imidazo[1,2-a]pyridine and 3-
amino-1-cyano indolizine library which can be tested for activity against the RT enzyme of HIV-1.  
 
 To synthesise a library of imidazo[1,2-a]pyridines via the Groebke-Blackburn reaction (Scheme 
7)43 making use of different commercially available aldehydes, isocyanides and 2-
aminopyridines to diversify the products. 
 
 
Scheme 7 Schematic of Groebke-Blackburn Reaction43 
 
 
 To synthesise a library of 3-amino-1-cyano-indolizines via the multi-component coupling 
approach (Scheme 10)34 making use of the variety of commercially available aldehydes, 
isocyanides and cyano-2-methylene-pyridines. 
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Scheme 10 Schematic of 3-amino-1-cyano-indolizine synthesis34 
 
 Biological testing of the synthetic libraries with a HIV reverse transcriptase kit to identify any 
potential NNRTI activity. 
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Chapter 2:  Results and Discussion  
 
Synthesis of imidazo[1,2-a]pyridines and 3-amino-1-cyano indolizines 
 
1.  Introduction 
 
This chapter concerns the results of the preparation of imidazo[1,2-a] pyridines and 3-amino-1-
cyano-indolizines in accordance with the aims as outlined in Chapter 1. The overview highlighted 
the great need for novel NNRTIs with improved potency against HIV-1 and we thus wished to 
synthesise a variety of compounds which could be tested against HIV-1 RT.  The following 
sections will discuss the use of multi-component coupling reactions in the creation of diverse 
compound libraries which were then tested for reverse transcriptase activity. Important aspects 
such as compound characterisation, synthetic issues, mechanistic detail and finally biological 
testing results will be addressed within this chapter for the synthesised compounds. 
 
2. Synthesis and Attempted Synthesis of imidazo[1,2-a]pyridines 52-62  
 
2.1 The Groebke-Blackburn Reaction 
 
 
 
Scheme 13 Groebke-Blackburn MCC Reaction Reagents and Conditions: K-10 Montmorillonite 
clay, 1,4-dioxane, reflux, 60-90 h  
 
The Groebke-Blackburn three-component coupling reaction is a well documented reaction 
involving the condensation of an aldehyde, an isocyanide and a 2-aminopyridine to afford an 
imidazo[1,2-a]pyridine compound in the presence of a catalytic acid.48  This versatile reaction 
(Scheme 13) was employed in the synthesis of imidazo[1,2-a]pyridines 52-60 (Table 1) and in the 
attempted synthesis of imidazo[1,2-a]pyridines 61 and 62 (Table 1), making use of commercially 
available aldehydes, isocyanides and 2-aminopyridines.  A variety of acid catalysts including 
scandium(III) triflate, ammonium chloride, acetic acid and perchloric acid have been utilised in the 
Groebke-Blackburn reaction48 but ongoing work at the CSIR suggested the use of K-10 
montmorillonite clay as the best promoter for our purposes.  The condensation reactions were 
carried out in 1,4-dioxane and heated at reflux for 60-90 h, after which time the montmorillonite 
clay was removed and the solvent removed in vacuo to afford the imidazo[1,2-a]pyridines as crude 
  
33 
black oils.  These crude products were then purified by column chromatography to afford the 
pure compounds 52-60 in varying yields (Table 1), as well as the aldehyde and 2-aminopyridine 
starting materials.   
 
The mechanism (Scheme 8) of the Groebke-Blackburn reaction is believed to proceed via a non-
concerted [4+1] cycloaddition between the protonated Schiff base and the isocyanide moiety.43 In 
this case under the acidic reaction conditions, brought about by the montmorillonite clay, the 
aldehyde and the primary amine of the 2-aminopyridine moiety condense to form what is knows as 
an iminium ion or Schiff base X.  This iminium ion has both nucleophilic and electrophilic character 
and is a key intermediate allowing the [4+1] cycloaddition to occur with the isocyanide moiety. 43, 46  
The concluding step in the formation of the imidazo[1,2-a]pyridine backbone is a prototropic shift 
which forms the final conjugated product Y.46  Throughout the reaction both the aldehyde and 
isocyanide side chains are conserved, thus by varying the starting aldehydes and isocyanides we 
can confer much diversity to the imidazo[1,2-a]pyridine scaffold.    
 
 
 
Scheme 8 Suggested Mechanism of Groebke-Blackburn Reaction 
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Table 1:  Preparation of imidazo[1,2-a]pyridines 52-62 
 
Entry 
 
Imidazo[1,2-a]pyridine 
 
Yield 
(%) 
 
Entry 
 
Imidazo[1,2-a]pyridine 
 
Yield 
(%) 
 
 
52 
 
 
 
 
   28 
 
 
  53 
 
 
 
 
   31 
 
 
   54 
 
 
 
 
   33 
 
 
  55 
 
 
 
 
   15 
 
 
 
   56 
 
 
 
 
 
   79 
 
 
 
  57 
 
 
 
 
 
  46 
 
 
  58 
 
 
 
 
   37 
 
 
   59 
 
 
 
 
   61 
 
 
   60 
 
 
 
 
   13 
 
 
   61 
 
 
 
   0 
 
 
  62 
 
 
 
   0 
   
 
 
Following the purification of the synthesised imidazo[1,2-a]pyridines by column chromatography, 
compounds 52-60 were characterised by NMR spectroscopy and all integrated for the correct 
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number of aromatic and aliphatic protons and showed the correct number of carbon signals.  
The spectroscopic data of compound 52 compared favourably with that found in the literature.48  A 
characteristic feature of the compounds in the 1H NMR spectrum is the presence of an N-H singlet 
in the region of 3.08 - 2.07 ppm.  An exception to this were compounds 56 and 59 which showed 
the N-H as multiplets at 3.00 ppm and 3.02 ppm respectively, due to overlap with the adjacent 
pentyl CH2 group or cyclohexyl CH group, whilst compound 57 showed the N-H singlet at 5.01 ppm 
due to de-shielding from the aromatic ring causing the signal to move further downfield.   
 
Another key identification aspect was the presence of the amine side chain in the 1H NMR 
spectrum.  Compounds 52, 54, 58, 59 and 60, which contain the cyclohexyl moiety, show a 
multiplet at approximately 2.96 ppm which corresponds to the CH signal adjacent to the NH, as 
well as a large multiplet at approximately 1.89 – 1.05 ppm which integrates for the remainder of the 
protons of the cyclohexyl side chain.  The inclusion of the cyclohexyl ring into these five 
imidazo[1,2-a]pyridines is further substantiated by the 13C NMR spectrum with the presence of the 
deshielded NHCH signal at 56.7 ppm and CH2 signals at 34.1 ppm, 25.7 ppm and 24.8 ppm 
respectively.  Since the cyclohexyl moiety has the ability to rotate freely around the CH-NH single 
bond, two different sets of carbon atoms are equivalent; namely the signals at 34.1 ppm and 24.8 
ppm.  Compounds 53 and 55 which incorporate a t-butyl side chain show the presence of a large 
singlet at approximately 0.98 ppm which integrates for 9 protons and corresponds to the 3 methyl 
groups present in the t-butyl moiety.  The 13C NMR spectra for these compounds show two 
characteristic signals at approximately 55.3 ppm and 30.3 ppm which correspond to the quaternary 
NHC(CH3)3 and the C(CH3)3 carbon atoms respectively.  The n-pentyl side chain of compound 56 
was clearly present as evidenced by the NHCH2 signal at 3.00 ppm, a CH2 at 1.56 ppm, the CH2-
CH2 at 1.45 ppm and the CH3 at 0.90 ppm.  This observation is again mirrored in the 
13C NMR 
spectrum by the presence of signals at 48.1 ppm, 30.3ppm, 29.2 ppm, 22.5 ppm and 14.01 ppm 
which correspond to the five carbon atoms of the n-pentyl side chain.  The inclusion of the side 
chain of compound 57 is verified by the observed singlet at 1.89 ppm, integrating for 6 protons and 
corresponding to the presence of the aromatic methyl groups of the 3,5-xylyl moiety.  The 13C NMR 
spectrum shows the analogous signal at 18.3 ppm corresponding to the aromatic methyl groups.    
 
Further evidence for the synthesis of the desired imidazo[1,2-a]pyridine compounds was obtained 
from the 1H and 13C NMR spectra which verified the incorporation of the aldehyde side chains into 
the products.  The 1H NMR spectra of compounds 52, 53 and 59 all showed a characteristic OCH3 
singlet at approximately 3.86 ppm whilst compounds 54, 55, 56 and 58 show the same 
characteristic OCH3 signal at approximately 3.82 ppm, as well as the aromatic CH3 signal at 
approximately 2.23 ppm.  The 13C NMR spectra for the same compounds displayed the OCH3 
signal at approximately 55.2 ppm and the aromatic CH3 signal at approximately 16.3 ppm.  The 
1H 
NMR spectrum of compound 60 showed a characteristic singlet at 2.89 ppm which integrates for 6 
protons and corresponded to the N(CH3)2 moiety.  The incorporation of this aldehyde side chain is 
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demonstrated by an analogous signal at 40.5 ppm in the 13C NMR spectrum which 
corresponded to the carbon atoms of the N(CH3)2 moiety.  Inclusion of the n-hexyl side chain of 
compound 57 was supported by the presence of the CH2 signals at 2.28 ppm, 1.45 ppm and 1.17 
ppm and a CH3 at 0.72 ppm.  Signals found in the aliphatic region of the 
13C NMR spectrum at 31.5 
ppm, 29.2 ppm, 28.6 ppm, 27.1 ppm, 22.5 ppm and 4.04ppm confirmed the presence of the six 
carbon atoms of the n-hexyl side chain.  The above data provides strong evidence to support that 
the Groebke-Blackburn MCC reaction was successfully employed to synthesise the desired 
imidazo[1,2-a]pyridines.   
 
HRMS provided added evidence for the synthesis of the desired imidazo[1,2-a]pyridines as it 
confirmed the presence of the required molecular ion in all cases.  Compounds 55, 58 and 60 with 
molecular formulae C19H23ON3, C21H23ON3 and C21H26N4 showed molecular ion peaks at 309.1836, 
335.1990 and 334.2152 respectively, which compare favourably to their calculated molecular 
masses of 309.1841, 355.1998 and 334.2152.  The compounds 53, 54, 56 and 57 with molecular 
formulae C18H20N3Br, C21H24ON3Br, C20H24ON3Br and C21H26N3Br all contain a bromine atom, and 
thus displayed two molecular ion peaks corresponding to the two bromine isotopes, 79Br and 81Br.  
Compound 53 exhibited peaks at 373.0788 and 375.0775; compound 54 at 413.1094 and 
415.1082, compound 56 at 401.1071 and 403.110 and compound 57 at 399.1280 and 401.1273, 
which compared favourably with the calculated values.  For compound 59 (C20H22ON3Br) a 
molecular ion peak could not be obtained using EI HRMS; however, the APCI did show both the 
79Br and 81Br M+ peaks.  IR spectroscopy was also employed in the characterisation of these 
compounds and provided a very useful piece of information when determining if the desired 
condensation reactions had occurred.  The IR spectra for compounds 53-60 showed the presence 
of a broad signal at between 3185 cm-1 – 3292 cm-1 which corresponded to the N-H stretch in the 
molecules.  
 
After evaluating all the characterisation data there is strong evidence to suggest that compounds 
52-60 were synthesised and that the Groebke-Blackburn reaction could be applied for the 
development of large libraries of structurally diverse imidazo[1,2-a]pyridines.  However one of the 
major drawbacks of the reaction appears to be the low yields obtained for most of the synthesised 
compounds.  Compounds 61 and 62 decomposed during column chromatography and this is 
probably attributed to the instability of the morpholino side chain on the slightly acidic silica 
medium.  Chromatography remains a serious problem with these types of compounds and may 
account for some of the losses in yield as co-elution of imidazo[1,2-a]pyridines, side products and 
starting materials often occurs.    During the course of the project it was discovered that the best 
method for obtaining pure compounds was by a pre-column to remove as many side products as 
possible, followed by recrystallisation from diethyl ether.   
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However, chromatography alone cannot be blamed for the low yields; perhaps the reaction 
conditions themselves play an integral role in the yields of compounds 52-60.  Many of the 
isocyanides are volatile substances, possibly evaporating during the reaction and thus not allowing 
the [4 +1] addition to occur, resulting in low yields.  Literature48 suggests that shorter reaction times 
may increase some of the yields by reducing the number of side reactions which could occur 
during the long reaction times.  Microwave irradiation is also suggested in the literature48 as a 
means of improving the yields as the solvent may reach higher temperatures, transferring more 
energy to the starting materials.  Optimisation of the reaction conditions could allow the Groebke-
Blackburn reaction to be employed in the synthesis of a number of diverse imidazo[1,2-a]pyridines 
in higher yields, however due to time constraints on the project this was unfortunately not 
attempted.   
 
3.  Synthesis and Attempted Synthesis of 3-Amino-1-cyano indolizines 63-79 
 
3.1 Method A:  Attempted Synthesis of 3-Amino-1-cyano-indolizines 63-70 
 
In accordance with a literature procedure first described by Poigny and co-workers34 we set out to 
synthesise a variety of related compounds, the 3-amino-1-cyano-indolizines which could also be 
tested for activity against HIV-1 reverse transcriptase.  This three-component coupling reaction 
(Scheme 14) is very similar to the Groebke-Blackburn reaction and involves the condensation of 
an isocyanide, an aldehyde and a 2-cyanomethylpyridine in the presence of a catalytic amount of 
base to afford the 3-amino-1-cyano-indolizine compound.  In order to begin building our compound 
library for biological testing we made use of commercially available aldehydes, isocyanides and 2-
cyanomethylpyridine for the reactions. These condensation reactions were carried out at 100˚C in 
1,4-dioxane for a period of 60-90 h, using DBU as the catalytic base.  After this time the solvent 
was removed in vacuo to afford the crude products which were further purified by column 
chromatography and/or recrystalisation. The pure compounds were then characterised by NMR 
spectroscopy, infra red and HRMS and proved to be the corresponding intermediate aldol 
condensation products 63a – 65a, 69a and 70a (Table 2).  A crystal structure determined of 
intermediate aldol condensation compound 64a shows it to be the E-isomer.  Since all the 
intermediate aldol condensation products synthesised throughout were obtained as a single 
gemometric isomer as indicated by NMR spectroscopy, we will assume the geometry of these 
products to be the E-isomer.  This reaction unfortunately failed to synthesise any of the desired 3-
amino-1-cyano-indolizines 63-70 (Table 2) and the possible reason for this will be addressed later 
in this discussion.  
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Scheme 14 3-Amino-1-cyano-indolizine synthesis Reagents and Conditions: 10% DBU, 1,4-
dioxane, 100˚C, 60-90 h 
 
Table 2:  Attempted Preparation of 3-Amino-1-cyano-indolizines 63-70 and the Resultant 
Intermediate Aldol Products 63a-65a, 69a and 70a 
 
Entry 
 
Desired Product 
 
Entry 
 
Actual Product 
 
Yield 
(%) 
 
 
63 
 
 
 
 
63a 
 
 
 
 
28 
 
 
64 
 
 
 
 
64a 
 
 
 
 
 
 
78 
 
 
 
65 
 
 
 
 
 
 
65a 
 
 
 
 
 
51 
 
 
 
66 
 
 
 
 
 
64a 
 
 
 
 
 
59 
 
 
  
 
 
 
 
 
  
39 
 
 
67 
 
 
 
63a 
 
 
 
 
60 
 
 
 
68 
 
 
 
 
 
64a 
 
 
 
 
 
68 
 
 
 
69 
 
 
 
 
 
 
69a 
 
 
 
 
 
43 
 
 
 
 
 
70 
 
 
 
 
 
70a 
 
 
 
 
 
26 
 
 
Compounds 63a-65a, 69a and 70a were all characterised by 1H and 13C NMR spectroscopy which 
clearly indicated that the desired 3-amino-1-cyano indolizine compounds 63-70 had not been 
synthesised.  There was a distinct lack of signals desired from the isocyanide reagent in both the 
1H and 13C NMR spectra and a lack of the characteristic N-H signal in the 1H NMR spectra.  The 1H 
NMR spectra of compounds 63a-65a, 69a and 70a corresponded to the aldol products, with 
integration giving the correct number of protons and the 13C NMR spectra showing the correct 
number of carbon signals.  Another key identifying feature was the presence of a singlet between 
8.33 – 8.80 ppm integrating for a single proton in all the 1H NMR spectra which corresponded to 
the hydrogen of the alkene bond.  This observation was verified by the presence of the 
corresponding alkene carbon signal between 141.8 – 149.9 ppm in the 13C NMR spectra.  A final 
characteristic peak was that of the CN bond which was also present in the 13C NMR spectra of the 
aldol compounds between 117.1 – 119.5 ppm.  Formation of the products could readily be 
explained by an aldol condensation between the carbon atom α- to the nitrile and the aldehyde.  
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This occurs readily because of the acidic nature of the protons α- to the nitrile.  The reaction 
apparently stopped at this point and no subsequent reaction with the isocyanide was observed. 
 
Other key features which could be discerned from the NMR spectra were specific to a synthesised 
aldol compound, i.e. compound 63a which contained a p-methoxy group displays a clear singlet at 
3.86 ppm which integrated for 3 protons in the 1H NMR spectrum.  The corresponding carbon 
signal of the O-CH3 was found at 55.5 ppm.  Compound 65a showed two close singlets at 3.88 
ppm which collectively integrated for 6 protons and corresponded to the two OCH3 groups found 
on the aldehyde side chain. Once again the 13C NMR spectrum mirrored these observations and 
the corresponding carbon signals of the two OCH3 groups were found at 61.75 ppm and 56.21 
ppm.  Compound 69a showed the presence of a singlet at 3.90 ppm and at 2.22 ppm which 
corresponded to the OCH3 and Ar-CH3 respectively, whilst the carbon signals were found at 55.5 
ppm for the OCH3 and at 16.3 ppm for the Ar-CH3.  The 
1H NMR spectrum of compound 70a 
indicated the presence of the N(CH3)2 in the aldol product as a singlet integrating for 6 protons at 
3.02 ppm and the related carbon signal is found at 40.0 ppm.   
 
 
Figure 19:  Ortep Diagram of Compound 64a  
(Showing the 50% probability thermal ellipsoids for all non-hydrogen atoms.) 
 
Conclusive evidence that the desired 3-amino-1-cyano-indolizine compounds had not been 
synthesised was obtained by means of a crystal structure determination of compound 64a (Figure 
19).  The crystallographic data showed that the intermediate aldol product was what we were 
indeed isolating, as no amine side chain from the isocyanide starting material could be observed in 
the product. 
 
HRMS provided additional evidence for the identity of the aldol compounds 63a, 64a, 65a, 69a and 
70a. Compounds 63a, 69a and 70a with molecular formulae C13H12ON2, C16H14ON2 and C16H15N3 
respectively showing the corresponding molecular ion peaks at 236.0924, 250.1081 and 249.1257, 
which corresponded well with the calculated values.  Compound 65a with molecular formula 
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C16H13O2N2Br contains a bromine atom and thus displays two molecular ion peaks, each one 
corresponding to a different bromine isotope; 79Br at 344.0124 and 81Br at 346.0133.  For 
compound 64a an anomaly occurs whereby no molecular ion could be obtained for the molecular 
formula C14H9N2Cl; however a peak at 239.0378 is obtained which corresponds to a molecular 
formula of C14H8N2Cl and depicts the loss of a proton from the molecule.  IR spectroscopy of the 
aldol compounds 63a, 64a, 65a, 69a and 70a was performed and showed the presence of the 
alkene proton between 3168 - 3012cm-1 shifting upfield or downfield depending on what functional 
groups are found on the aromatic ring of the starting aldehyde side chain.  The IR spectra of these 
compounds also show the presence of the –CN nitrile stretch as a weak signal near 2213cm-1.   
 
Subsequent to analysing all the characterisation data and conclusively deciding that compounds 
63a-65a, 69a and 70a were indeed the aldol products, a rationale for the failure of this reaction to 
synthesise the desired 3-amino-1-cyano-indolizine compounds needed to be addressed.  A 
possible reason for the failure of this multi-component coupling reaction to yield the desired 
products can be elucidated from the mechanism of the reaction.  Although a definite reaction 
mechanism has not been fully determined, the proposed mechanism is thought to proceed via the 
cheletropic addition of the isocyanide moiety to the Knoevenagel-type hetero-diene intermediate 
(Scheme 11).34  The first step in the mechanism is proposed to be the removal of the acidic 
protons which are α- to the nitrile by the base, which in this case is DBU.34, 46  The carbonyl carbon 
of the aldehyde moiety then undergoes nucleophillic attack from the α-anion, followed by 
elimination of water to form the Knoevenagel-type hetero-diene intermediate.34, 46  If the reaction 
were to proceed to completion it is at this point that a non-concerted [4+1] cycloaddition between 
the hetero-diene and the isocyanide would occur, followed by a protototropic shift to form the 
desired 3-amino-1-cyano indolizine scaffold.34 
 
 
 
Scheme 11 Proposed Mechanism for the Synthesis of 3-amino-1-cyano indolizines 
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From the mechanistic scheme (Scheme 11) it is clear that our reaction proceeded well to the 
formation of the hetero-diene intermediate, but the non-concerted [4+1] cycloaddition did not occur.  
Upon inspecting the literature it was found that there was one major difference between our 
reaction conditions and those used by Poigny and co-workers.34  The literature procedure utilised 
the solvent n-butanol which is a protic solvent, as opposed to the solvent 1,4-dioxane used in our 
procedure.  It is thought that through hydrogen bonding of the alcohol proton of n-butanol with the 
lone pairs of the nitrile nitrogen, the electron density is more confined to the nitrile.46  This may give 
the the Knoevenagel-type intermediate more of a diene character by preventing the dispersion of 
electron density throughout the conjugated system and thus allowing the [4+1] cycloaddtion to 
occur.  The alkene bond is also perhaps slightly weakened, making it more electrophilic by the 
reduced delocalisation of electrons into the nitrile.  The aldol product formed here is much more 
stable than the corresponding Schiff base product for the Groebke-Blackburn reaction, which 
means that the subsequent reaction with the isocyanide reagent is not as favourable when 
compared to the Groebke-Blackburn reaction.  Thus it was decided that the subsequent attempts 
at the synthesis of 3-amino-1-cyano-indolizines would be carried out in n-butanol and not 1,4-
dioxane.   
 
3.2 Synthesis of Starting Material 2-(6-Chloropyridin-2-yl)acetonitrile 71 and the Synthesis and 
Attempted Synthesis of 3-Amino-1-cyano Indolizines 68, 72-76 
 
3.2.1 Synthesis of 2-(6-Chloropyridin-2-yl)acetonitrile 71 
 
 
 
Scheme 15 Synthesis of 2-(6-Chloropyridin-2-yl)acetonitrile Reagents and Conditions: i) n-BuLi 
(1.4M/hexane), THF, -78˚C, 1 h; ii) 2,6-dichloropyridine, THF, 
-78˚C, 1 h 
 
In addition to the use of n-butanol as a solvent instead of 1,4-dioxane another major difference 
between our procedure and the literature procedure34 was their use of 2-(6-chloropyridin-2-
yl)acetonitrile 71 as opposed to cyano-2-methylpyridine.  Compound 71 is not a commercially 
available starting material and needed to be synthesised from the commercially available 2,6-
dichloropyridine (Scheme 15).  In accordance with a procedure stipulated by Skerlj and co-workers 
CH3CN was added dropwise to a stirring solution of n-BuLi (1.4M/hexane) at -78˚C which resulted 
in a milky white suspension.65  Since the α-hydrogens of the CH3CN are acidic, the n-BuLi 
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abstracts a proton to form the organo-metallic LiCH2CN species.
65  After 1 hour, 2,6-
dichloropyridine was added to the stirring white suspension at which point nucleophilic 
displacement of the chloride occurred to form the (6-chloropyridin-2-yl)acetonitrile 71, marked by a 
change in the colour of the solution from milky white to yellow.46, 65  The reaction mixture was 
quenched with H2O, worked up and the organic solvent removed in vacuo to give a yellow oil, 
which was further purified by column chromatography to afford the desired product, (6-
chloropyridin-2-yl)acetonitrile 71, as a yellow solid in 84% yield.   
 
The compound was characterised by NMR spectroscopy and the spectroscopic data was in 
agreement with that of the literature.65  A key feature of the 1H NMR spectrum was the presence of 
a singlet at 3.94 ppm which corresponded to the α-protons of the cyanomethyl group.  The 13C 
NMR spectrum gave clear signals at 116.29 ppm and 26.13 ppm which corresponded to the CN 
and CH2CN groups respectively. 
 
3.2.2 Method B:  Synthesis and Attempted Synthesis of 3-Amino-1-cyano indolizines 68 and 72-76 
 
 
 
Scheme 16 3-amino-1-cyano-indolizine synthesis Reagents and Conditions: 10% DBU, n-butanol, 
100˚C, 43 h 
 
Following the synthesis of (6-chloropyridin-2-yl)acetonitrile 71, we once again attempted to 
synthesise a variety of 3-amino-1-cyano-indolizine compounds in accordance with the multi-
component coupling procedure stipulated by Poigny and co-workers.34 In an attempt to synthesise 
compounds 68 and 72-76; 2-pyridylacetonitrile or (6-chloropyridin-2-yl)acetonitrile 71, a variable 
aldehyde and an isocyanide were dissolved in n-butanol (Scheme 16).  Catalytic base, DBU was 
added to the solution and the reaction was then stirred at 100˚C for 43 h, after which time the 
solvent was removed in vacuo to afford the crude products.  These crude products were then 
purified by flash chromatography and/or recrystallisation to afford the pure compounds 68, 72, 73 
and 75 (Table 3) in varying yields as well as two aldol products 74a and 76a (Table 3).  It appears 
that changing the solvent from 1,4-dioxane to n-butanol greatly improved the yield of the desired 3-
amino-1-cyano-indolizine compounds; however, some of the reactions still did not proceed to 
completion and once again aldol products 68a, 74a and 76a were isolated. 
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Table 3:  Synthesis and Attempted Synthesis of 3-Amino-1-cyano-indolizine compounds 68 and 
72-76 
 
Entry 
 
3-amino-1-cyano 
indolizine 
 
Yield 
(%) 
 
Entry 
 
Aldol Product 
 
Yield 
(%) 
 
 
68 
 
 
 
 
23 
 
 
68a 
 
 
 
 
42 
 
 
 
72 
 
 
 
 
 
75 
   
 
 
 
73 
 
 
 
 
 
38 
   
 
 
 
 
74 
 
 
 
 
 
 
0 
 
 
 
 
74a 
 
 
 
 
 
 
 
 
13 
 
 
 
75 
 
 
 
 
 
7 
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76 
 
 
 
0 
 
 
76a 
 
 
 
 
8 
 
 
The above compounds were all characterised by NMR spectroscopy, with the exception of 
compound 68 which was unstable in a variety of deuterated solvents and we could thus not obtain 
any useful NMR data for this sample.  A distinct N-H signal is present in compounds 72, 73 and 75 
at 3.36 ppm, 3.56 ppm and 2.89 ppm respectively, and was a good indication that the isocyanide 
reagent had been incorporated into the new compounds.  These compounds showed a definitive 
signal at approximately 2.77 ppm which correlated with NHCH(CH2)5 as well as a group of signals 
at approximately 1.76-0.93 ppm which correlated with the remainder of the cyclohexyl protons.  
These observations were substantiated by the 13C NMR spectra of these compounds which show 
the corresponding carbon signals at approximately 58.5 ppm for NHCH(CH2)5 and 32.8, 25.4 and 
24.6 ppm for the rest of the cyclohexyl carbon atoms. Furthermore, all three compounds displayed 
the C-CN signal between 115.9 ppm and 118.6 ppm in their 13C NMR spectra. The 1H NMR 
spectrum for compound 73 showed a clear singlet at 3.87 ppm which corresponded to the OCH3 
group of the aldehyde side chain, with the corresponding carbon signal found at 55.2 ppm.  
Compounds 72 and 75 show 7-aromatic proton signals in their 1H NMR spectra; which is the 
expected number of signals and confirms the inclusion of the aromatic aldehyde reagent.  The 
NMR spectroscopic data of compounds 72, 73 and 75 was a good indication that the desired 3-
amino-1-cyano-indolizine compounds had been synthesised.   
 
Despite being unable to obtain any viable NMR spectral data for compound 68, a definite 
identification of the product was obtained by means of X-ray crystal determination of the compound 
(Figure 20).  The product was recrystalised from diethyl ether to yield fine yellow crystals from 
which an X-ray crystal structure was obtained.  From the Ortep diagram of compound 68 we see 
that the product has been co-crystallised with the solvent, diethyl ether.  The Ortep diagram also 
indicates very clearly the incorporation of the cyclohexyl isocyanide starting material to afford the 
desired 3-amino-1-cyano-indolizine 68. 
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Figure 20 Ortep Diagram of Compound 68 
(Showing the 50% probability thermal ellipsoids for all non-hydrogen atoms) 
 
 
HRMS was performed on the synthesised 3-amino-1-cyano-indolizine compounds 68, 72, 73 and 
75 and further corroborated that the three component coupling reaction had indeed occurred.  
Compounds 68 and 75 showed molecular ion peaks at 349.1339 and 383.0946 respectively, which 
corresponded to their molecular formulae C21H20N3
35Cl and C21H19N3
35Cl2.  The M+2 peaks 
associated with the heavier chlorine isotope for compounds 68 and 75 were found at 351.1327 and 
387.0918 respectively and correspond to the molecular formulae C21H20N3
37Cl and C21H19N3
37Cl2.  
Compound 72 contains a bromine atom and thus showed two molecular ion peaks; one at 
427.0463 corresponding to molecular formula C21H19N3Cl
79Br and one at 429.0443 with molecular 
formula C21H19N3Cl
81Br.  Chlorine-containing compound 73 displays the same isotopic trend and 
showed two molecular ion peaks at 379.1456 and 381.1444 corresponding to C22H22N3O
35Cl and 
C22H22N3O
37Cl respectively.  IR spectroscopy of the compounds 68, 72, 73 and 75 showed the 
diagnostic N-H stretch as a broad signal between 3293cm-1 - 3373cm-1.  The IR spectra also 
indicated the presence of the CN functional group in the compounds by a signal found at 
approximately 2200cm-1 for all four indolizine products.    
 
Compounds 74a and 76a did not show the distinct N-H signal and this was the first indication that 
the desired 3-amino-1-cyano-indolizine had not been synthesised.  Other evidence to suggest that 
this was the case was that the 1H NMR spectra for both of these compounds did not show the 
correct proton integration and the 13C NMR spectra showed fewer signals than expected from the 
indolizine products.  What is evident in the 1H NMR spectra is the presence of the alkene C-H 
proton for these compounds at approximately 8.58 ppm, which is indicative of the aldol product.   
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Once again HRMS was used to confirm that these molecules were indeed only the aldol 
condensation products.  Compound 76a showed a molecular ion peak at 258.0345, which 
compares favourably to the calculated value of 258.0360 for molecular formula C14H8N2ClF.  The 
aldol product 74a shows two molecular ion peaks each one corresponding to the two different 
bromine isotopes, C14H9N2
79Br and C14H9N2
81Br, and found at 283.9938 and 285.9918.  IR 
spectroscopy of aldol compounds 74a and 76a indicated the C-H stretch of the alkene at 3065cm-1 
and 3016cm-1 respectively and further indicated that these products were in fact the aldol 
condensation products.   
 
It appears that changing the solvent used for the reaction greatly improved the yield of 3-amino-1-
cyano-indolizine from zero, when only aldol product was isolated, to fair yields of the desired 
products.  It is not fully understood why this should be the case, but as explained above the protic 
nature of n-butanol may provide a crucial hydrogen bonding interaction in the reaction.  
 
When inspecting the yields of these varying 3-amino-1-cyano indolizine compounds, it becomes 
clear that the yields of the 5-chloro substituted products were greater than the unsubstituted 
products.  Compounds 72 and 73 had yields of 75% and 38% respectively, whilst compounds 68 
and 75 had yields of only 23% and 7%. We will attempt once again to explain this phenomenon in 
terms of the mechanism (Scheme 11).  The chlorine atom is an electron withdrawing substituent 
and can withdraw electron density from the ortho and para positions by the inductive effect.46 If the 
chlorine substituent were to withdraw electron density from the pyridine ring system it may be 
probable that it could confer further diene-character to the Knoevenagel-type intermediate.46 This 
stabilised hetero-diene may be more favourable in the [4+1] cycloaddition step and allow the 
reaction to go further to completion, resulting in higher yields for the 5-chloro substituted 
compounds.  This inductive effect may also explain why compounds 74a and 76a were isolated as 
aldol compounds, as both lacked the 5-chloro substituent. A more stable hetero-diene intermediate 
may well have been crucial to the success of these two reactions.   
 
The overall yields of these reactions were not very good, with the exception of compound 72.  This 
could be attributed to the fact that the chromatography is difficult, with compounds overlapping with 
starting materials and side products, leading to isolation of only small amounts of pure products.  
However the literature also shows much the same trend in yields and reports very low yields for 
most of the synthesised compounds.34  Thus, despite this reaction allowing for the creation of 
diverse libraries of 3-amino-1-cyano-indolizine compounds, it is not very synthetically efficient.  
Perhaps optimisation of the reaction conditions or the use of a microwave may produce better 
yields, but until then a more classical synthetic approach may be needed if we are to obtain the 
desired products in acceptable yields.      
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3.3 Method C:  Attempted Synthesis of 3-Amino-1-cyano indolizines 64, 77-75 
 
 
 
Scheme 17 Attempted 3-Amino-1-cyano-indolizine Synthesis Reagents and Conditions: variable 
isocyanides, Montmorillonite K-10 clay, 1,4-dioxane, 100˚C, 73 h 
 
Our final effort at synthesising a variety of 3-amino-1-cyano indolizine compounds focused on 
utilising the already synthesised aldol products and attempted to force the [4+1] cycloaddition 
reaction to occur by using acid promotion (Scheme 17).  It was thought that by using an acid 
promoter we could prevent the delocalisation of the nitrile electrons to an even greater extent than 
when using a protic solvent.  It was hoped that this would confer enough electrophilc character to 
the alkene bond and allow for the cycloaddtion reaction to occur more easily, enabling us to isolate 
the desired 3-amino-1-cyano indolizine compounds.  Previously synthesised aldol products 63a, 
64a and 65a (Table 2, pg. 42) were thus dissolved in 1,4-dioxane, which was chosen as it was 
used successfully in the synthesis of the imidazo[1,2-a]pyridine compounds by means of acid 
catalysis.   A variable isocyanide and one mass equivalent of Montmorillonite K-10 clay were 
added to this solution and the reaction was heated at 100˚C for 73 hours.  After this time, the 
reaction was cooled, filtered through celite and the solvent removed in vacuo to afford the crude 
products.  These crude products were purified by flash chromatography and characterised by NMR 
spectroscopy.  Unfortunately none of the desired 3-amino-1-cyano indolizine compounds 64, 77, 
78 and 79 were isolated and the NMR spectroscopy data showed the products to be starting aldol 
compounds 63a-65a (Table 4).  
 
Table 4: Attempted Synthesis of 3-Amino-1-cyano Indolizine Compounds 64, 77-79 from the 
Corresponding Aldol Products 
 
Entry 
 
   Desired Product 
 
Entry 
 
 Corresponding Aldol  
            Product 
 
Yield (%) 
 
 
 
64 
 
 
 
 
 
64a 
 
 
 
 
 
84 
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77 
 
 
64a 
 
 
90 
 
 
 
 
78 
 
 
 
 
 
 
63a 
 
 
 
 
 
 
 
 
78 
 
 
 
 
 
79 
 
 
 
 
 
 
 
65a 
 
 
 
 
 
 
 
 
60 
 
 
From the interpretation of the 1H NMR spectra of the products it was clear that the desired 3-
amino-1-cyano-indolizine compounds 64, 77, 78 and 79 had not been synthesised.  There was no 
evidence in the 1H NMR to suggest that the isocyanide starting material had been included in the 
products, as there were no signals for the amine side chains and no distinct N-H signal.  When 
compared to the 1H NMR spectra of the aldol starting materials it was clear that the isolated 
products were in fact the aldol compounds 63a, 64a and 65a. The loss in yield of the starting 
material was probably due to retention of some of the organic compounds in the montmorillonite 
clay, as well as due to column chromatography.  We could still attempt this reaction in n-butanol to 
determine if the “two-step one-pot” synthesis may still afford the desired indolizine compounds.   
 
Three different methods for the preparation of 3-amino-1-cyano-indolizines are presented in the 
above discussion.  Method A was only able to yield the aldol products formed from the base-
catalysed condensation of cyano-2-methylene-pyridine and aldehyde starting materials.  This 
methodology could have been salvaged had method C shown any success in allowing the non-
concerted [4+1] cycloaddition reaction to occur with the aldol products and an isocyanide under 
acidic conditions.  We might then have been able to synthesise the desired indolizine compounds 
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in a “two-step one-pot” synthesis and potentially avoid the host of side reactions that occur from 
the true multi-component coupling reaction.  Method B showed some success in synthesising the 
required 3-amino-1-cyano indolizines, although the chromatography remains tedious and the yields 
poor.  We could however, utilise this method to create a series of diverse 3-amino-1-cyano 
indolizine compounds, but the literature suggests that the yields would still be very poor.34  It 
appears that despite the limited success of method B in synthesising the indolizine products, it may 
be more efficient to utilise another method to prepare these types of compounds in better yields.   
 
4. Biological Testing Results of Imidazo[1,2-a]pyridines 52–60 and 3-Amino-1-cyano 
Indolizines 68, 73 and 75 
 
The following discussion pertains to the biological testing results of a variety of imidazo[1,2-
a]pyridines and 3-amino-1-cyano indolizines.  These compounds were tested for inhibition of an 
HIV-1 enzyme, reverse transcriptase in the hope of identifying a viable compound which can be 
further developed as a potent and effective NNRTI.  The biological testing was carried out by the 
CSIR Biosciences Pharmacology Group using an HIV reverse transcriptase kit, which is available 
from Roche Pharmaceuticals.  To assess the inhibitory activity of the test compounds they were 
incubated with HIV-1 reverse transcriptase and the residual percentage enzyme activities 
expressed, relative to a control test without inhibitor.  For a full explanation of the inhibitory HIV-1 
reverse transcriptase testing procedure the reader is referred to the experimental section general 
procedures (pg. 134).   
 
4.1 Biological Testing Results of imidazo[1,2-a]pyridines 52–60 as HIV-1 Reverse Transcriptase 
Inhibitors 
 
Imidazo[1,2-a]pyridines 52–60 were dissolved in DMSO to give a concentration of 10mM and later 
diluted to 50µM for the assay.  They were then tested for inhibitory activity against HIV-1 reverse 
transcriptase, using a nevirapine reference standard and a positive control containing only reverse 
transcriptase enzyme with no inhibitor.  The control showed 100% remaining enzyme activity and 
Nevirapine showed 0.2% remaining enzyme activity, demonstrating that it is an excellent inhibtor of 
HIV-1 reverse transcriptase.  The nine imidazo[1,2-a]pyridines which we sent for evaluation 
showed extremely poor inhibition of the reverse transcriptase enzyme and showed residual 
enzyme activities of > 80% (Graph 1) (Table 5).  In order to be considered a promising inhibitor 
the compounds need to show at least 80% suppression of RT enzyme activity, which was not 
achieved by any of our tested imidazo[1,2-a]pyridines.  In conclusion, this set of compounds can 
be abandoned as potential HIV-1 reverse transcriptase inhibitors.  However, the possibility still 
remains that these compounds may show promising biological applications when tested for anti-
tumour, anti-bacterial and anti-malarial activities, which are possibilities suggested by the multitude 
of variable biological applications presented in Chapter 1.   
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Table 5:  Percentage Residual Enzyme Activity for Imidazo[1,2-a]pyridines 52-60 
 
Compound 
 
% Enzyme Activity 
Control 100.0 
Nevirapine 0.2 
52 84.4 
53 86.1 
54 87.9 
55 96.4 
56 91.2 
57 84.0 
58 91.6 
59 94.3 
60 92.5 
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Graph 1:  Biological Test Results of the Inhibitory Activity of Imidazo[1,2-a]pyridines against HIV-1 
Reverse Transcriptase 
 
4.2 Biological Testing Results of 3-Amino-1-cyano Indolizines 68, 73 and 75 as HIV-1 Reverse 
Transcriptase Inhibitors 
 
3-Amino-1-cyano-indolizines 68, 73 and 75 and aldol compound 76a were dissolved in DMSO to 
give a concentration of 10mM and tested in the same way as the imidazo[1,2-a]pyridines at a final 
concentration of 50μM of inhibitor.  Once again these compounds showed poor inhibition of the 
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HIV-1 reverse transcriptase enzyme with compounds 73, 75 and 76a showing >70% residual 
enzyme activity and compound 68 showing 69.4% residual enzyme activity (Graph 2) (Table 6).  
Although these results are slightly better then the results of the imidazo[1,2-a]pyridines, they are 
nowhere near the percentage needed to be considered promising inhibitors.  It is obvious that 
these compounds cannot be considered for development as novel and potent NNRTIs, but once 
again may show other interesting biological applications in the anti-tumor, cardiovascular and anti-
bacterial class of inhibitors.   
 
Table 6:  Percentage Residual Enzyme Activity for 3-Amino-1-cyano Indolizines 68, 73 and 75 and 
Aldol Compound 76a 
 
Compound 
 
% Enzyme Activity 
Control 100.0 
Nevirapine 0.5 
68 69.4 
73 71.8 
75 75.8 
76a 77.1 
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Graph 2:  Biological Test Results of the Inhibitory Activity of 3-Amino-1-cyano-Indolizines against 
HIV-1 Reverse Transcriptase 
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Chapter 3:  Conclusions and Future Work 
 
Synthesis of imidazo[1,2-a]pyridines and 3-amino-1-cyano Indolizines 
 
1.  Conclusions and Future Work 
 
Chapter 1 briefly introduced a number of increasingly drug-resistant forms of the HIV-1 due to the 
virus‟ extremely high mutation rate.  These mutations have led to a great need for novel HIV-1 
inhibitors with improved potency against the virus.  The main aim of this section of the project was 
to use the highly efficient synthetic methods of MCC reactions to develop a small molecule library.  
This collection of compounds could then be tested against HIV-1 reverse transcriptase in the 
hopes it would uncover a potentially novel NNRTI.   
 
1.1 Synthesis of Imidazo[1,2-a]pyridines 
 
The first aim of this project was the use of the well known Groebke-Blackburn three-component 
coupling reaction (Scheme 13, pg 32) in the synthesis of a library of imidazo[1,2-a]pyridines.43   
We chose this reaction as it can be successfully employed with a variety of different aldehydes and 
isocyanides and we could thus create a structurally diverse compound library.  The Groebke-
Blackburn reaction was successfully used for the synthesis of imidazo[1,2-a]pyridines 52-60, which 
were isolated in various yields ranging from fair to good.  This three-component coupling reaction 
was also utilized in the attempted synthesis of imidazo[1,2-a]pyridines 61 and 62 which we suspect 
were probably synthesised, but decomposed during column chromatography.   
 
As we were able to synthesise a small imidazo[1,2-a]pyridine library we could conclude that the 
Groebke-Blackburn reaction is an efficient means of developing a structurally diverse library of 
these types of compounds.  However, one of the major drawbacks with this reaction were the low 
yields for some of the isolated compounds.  Many factors may be responsible for the low yields 
and we cannot identify one factor as the main cause.  This reaction undergoes many side 
reactions, which in turn makes the chromatography of these compounds extremely tedious and 
difficult.  Many of the products were isolated as mixed fractions with a side-product or starting 
material and so may have to be re-columned or recrystallised; leading to losses in yield.  The 
isocyanide starting materials were often volatile liquids and were prone to evaporation before and 
during the reaction.  This means that the MCC reactions could not proceed to completion and the 
yields will inevitably be lower.   
 
Literature suggests that shorter reaction times may increase some of the yields of the isolated 
products by reducing the number of side reactions which can occur during the longer reaction 
times.48  For future experiments it is also notable that microwave irradiation can be used as a 
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means of doing these experiments on a shorter time scale and with improved yields.48  
Microwave experiments are usually completed within 1 hour as opposed to our reaction time of 60-
90 hours.48   
 
1.2 Synthesis of 3-Amino-1-cyano-indolizines 
 
Our second major aim was to synthesise a library of 3-amino-1-cyano-indolizine compounds also 
using a multi-component coupling approach.  We utilised a method first described by Poigny et al. 
which made use of an aldehyde, isocyanide and cyano-2-methylpyridine for synthesising a variety 
indolizine compounds.34  Over the course of the project we made use of thee different variations of 
this multi-component coupling reaction and only one method had marginal success in synthesising 
the desired 3-amino-1-cyano indolizine compounds.   
 
The first method which we employed for the synthesis of a variety of 3-amino-1-cyano-indolizine 
compounds utilised an isocyanide, an aldehyde and 2-cyanomethylpyridine in 1,4-dioxane in the 
presence of catalytic base DBU (Scheme 14, pg 38).  We were unable to isolate any of the 
desired indolizine compounds with this method and instead only isolated intermediate aldol 
condensation products 63a, 64a, 65a, 69a and 70a.  It was thought that the use of 1,4-dioxane as 
a solvent, and not n-butanol as described in the literature,34 was responsible for the failure of this 
method to isolate any of the desired indolizine compounds.  The use of n-butanol may provide a 
key hydrogen-bonding interaction with the intermediate Knoevenagel-type diene, which prevents 
the dispersion of electron density throughout the conjugated system and allows the [4+1] 
cycloaddtion to occur.  It is for this reason that the subsequent attempt at the synthesis of 3-amino-
1-cyano indolizines was carried out using n-butanol as a solvent.    
 
Our second attempt at synthesising a variety of 3-amino-1-cyano-indolizine compounds utilised an 
aldehyde, an isocyanide and either 2-cyanomethylpyridine or (6-chloropyridin-2-yl)acetonitrile in n-
butanol in the presence of catalytic base (Scheme 16, pg 43).  This time the reaction did afford 
some of the desired indolizine compounds 68, 72, 73 and 75, but once again intermediate aldol 
product 74a and 76a were also isolated.  It appears that changing the solvent from 1,4-dioxane to 
n-butanol greatly improves the ability of the multi-component reaction to yield the desired indolizine 
compounds, although some of the reactions still do not proceed to completion.  Once again in the 
cases where we did isolate the desired indolizine products the yields are poor (7%-32%), with 
exception of compound 72.  This may be due to the chromatography of these compounds being 
extremely difficult, with compounds overlapping with starting material and by products leading to 
minimal isolation of pure products.  The literature reports much the same trend and shows very low 
yields for most of their synthesised compounds.  It can be concluded that despite this reaction in 
some cases allows for the synthesis of structurally diverse 3-amino-1-cyano-indolizine products, it 
  
55 
is not a synthetically useful reaction.  We may have to use longer and more classical synthetic 
methods for the creation of these types of compounds in the future. 
 
Our final effort at synthesising a variety of 3-amino-1-cyano-indolizine compounds focused on 
using the already synthesised intermediate aldol products and attempting to drive the [4+1] 
cycloaddtion forward using acid promotion and an isocyanide (Scheme 17, pg 45).  The rationale 
was that by using an acid promoter we could prevent the delocalisation of the nitrile electrons more 
efficiently than if we used only a protic solvent.  Unfortunately this reaction did not yield any of the 
desired indolizine compounds and only the starting aldol compounds 63a, 64a and 65a were 
isolated from the reaction.  This was a very disappointing result as it was hoped that should this 
methodology have any success in isolating 3-amino-1-cyano-indolizines, we could then develop a 
„two-step one-pot‟ synthesis.  This synthesis would potentially avoid the host of side reactions that 
occur during the multi-component reaction and perhaps improve yields of the desired indolizines. 
 
In conclusion, none of the methods presented above show any real synthetic value for preparing 3-
amino-1-cyano-indolizines efficiently and in good yields.  Despite the very limited success of the 
second method (Scheme 16) it is definitely advisable to attempt to synthesise these types of 
compounds following some better methodology in the future.   
 
1.3 Biological Testing Results 
 
The final aim for this section of the project was the biological testing of the imidazo[1,2-a]pyridine 
and 3-amino-1-cyano indolizine libraries against HIV reverse transcriptase.  We wished to 
determine if any of our synthesised compounds showed any potential NNRTI activity in the hope of 
determining a viable compound which can be further developed as a novel HIV drug.  
Unfortunately all nine of the imidazo[1,2-a]pyridines which were sent for biological testing showed 
extremely poor inhibition of the reverse transcriptase enzyme and showed residual enzyme 
activities of >80%.  This set of imidazo[1,2-a]pyridines can thus be abandoned as potential 
NNRTIs, but these compounds should still be tested as anti-tumor, anti-bacterial and anti-malarial 
agents as they may still demonstrate interesting biological applications.  Synthesised 3-amino-1-
cyano-indolizines 68, 73 and 75, as well as intermediate aldol product 76a were also sent for 
biological testing.  Once again these compounds also demonstrated poor inhibition of the HIV-1 
reverse transcriptase enzyme and showed >70% remaining enzyme activity (Graph 3).  These 
compounds thus cannot be considered for use as NNRTIs, but once again should also be tested 
for anti-tumor, anti-bacterial and anti-malarial applications.  One further aspect that could be 
investigated with these 3-amino-1-cyano-indolizine compounds would be whether removal of the 
nitrile functional group would improve the efficacy of these compounds as NNRTIs.  It is thought 
that cleaving the nitrile group will change a key substrate-enzyme interaction i.e. a hydrogen 
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acceptor will be replaced with a π-π stacking interaction.  It will be interesting to note if this post 
synthetic modification would provide more promising biological testing results. 
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Part B 
 
Chapter 4:  Introduction, Literature Review and Aims 
 
Development of Methodology for the Synthesis of Benzo-fused Heteroaromatic 
Naphthoquinone and Naphthopyranone Ring Systems using Palladium Mediated 
Suzuki-Miyaura Coupling as a Key Step 
 
 
Aromatic polyketides which feature both the benzo-fused naphthoquinone and nahpthopyranone 
structural motifs represent one of the largest families of secondary metabolites found in nature and 
are of considerable interest due to their biological activities and structural intricacies.66, 67  These 
compounds have a wide range of biological applications including antibacterial, antitumor, antiviral 
and enzyme inhibitory activities and have thus become a very important class of therapeutic 
agents.66, 67 These aromatic polyketides are thus popular synthetic targets due to their extensive 
pharmaceutical applications.66, 67  However due to the challenging synthetic nature of these motifs, 
syntheses tend to be long, laborious and inefficient and often result in low yields.68  Thus, as part of 
our research program, a methodology study was undertaken to develop a new, synthetically 
efficient and reliable method for the synthesis of these two structural motifs using Suzuki coupling 
as a key step in building these important scaffolds.   
 
1.  Palladium Mediated Suzuki-Miyaura Cross-Coupling Reaction 
 
In 1979 Miyaura, Yamada and Suzuki laid the ground work for what has become one of the most 
important and useful methods for the construction of carbon-carbon bonds in organic chemistry.69a   
Their original coupling reactions reported the use of alkenyl boronates with alkenyl bromides; 
however, the immense amount of research which has been conducted over the past 30 years has 
led to vast improvements in what is now known as the Suzuki-Miyaura cross-coupling reaction.69a  
These improvements have led to the use of a variety of starting substrates, room temperature 
reactions, low catalyst loadings and the ability to work with sterically hindered substrates.69b  The 
immeasurable applications of the Suzuki-Miyaura cross coupling reaction in the synthesis of 
carbon-carbon bonds in pharmaceuticals, fine chemicals and industrials has firmly cemented it as 
one of the most important reactions in modern organic chemistry.69b  
 
1.1 Suzuki-Miyaura Cross-Coupling Reaction 
 
The Suzuki-Miyaura cross-coupling reaction is a powerful transformation which allows the coupling 
of alkenyl- or aryl-boronic acids with an alkenyl- or aryl-halide catalyzed by a palladium(0) complex 
in the presence of a base to form C-C bonds (Scheme 18).70  The key advantages of the Suzuki 
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coupling reactions are the use of mild reaction conditions and the commercially availability of the 
diverse boronic acids which are environmentally safer than many of the other organometallic 
reagents.71  The reaction relies on a palladium catalyst such as Pd(PPh3)4 known as tetrakis (the 
most commonly used catalyst), which can be prepared beforehand or in situ to bring about C-C 
bond formation.71  One of the major drawbacks of the Suzuki reaction is that all oxygen must be 
excluded from the system to prevent the oxidation of the palladium(0) species, which is key to the 
cross coupling reaction mechanism.71  As mentioned before, developments over the last 30 years 
have allowed a large variety of substrates to be utilised in the Suzuki coupling reaction.69  
Potassium trifluoroborates, organoboranes and boronate esters may be used in place of boronic 
acids and pseudo-halides such as triflates may also be used as coupling partners, but are 
generally more expensive to prepare or purchase.69, 71   
 
 
 
Scheme 18 Schematic of Suzuki-Miyaura Cross Coupling Reaction for the Formation of the Bi-aryl 
Axis70 
 
The mechanism of the Suzuki-Miyaura cross coupling reaction is best explained by a catalytic 
cycle involving three key steps involving the transition metal, palladium (Scheme 19).72  The first 
step of the mechanism involves the oxidative addition of the carbon electrophile 81 to the 
zerovalent palladium species 80 to form the organo-palladium species 82, which on reaction with 
the base gives key intermediate 83.72 This highlights one of the very important functions of the 
base in the Suzuki reaction in „mopping up‟ the halide ion preventing the reverse reaction.73  The 
second key step is a transmetallation of the nucleophilic carbon from the boronate complex 85 to 
the organo-palladium species 83 to form intermediate 87.72 A second important function of the 
base is highlighted by this transmetallation step.  As the organic groups of the organoboron 
compounds 84 are weakly nucleophilic, the coordination of the negatively charged base to the 
boron atom 85 is used as an efficient way of improving the nucleophilicity of the organic group to 
be transferred.73  The final step in the catalytic cycle is the reductive elimination of the desired 
cross-coupling product 88 and the regeneration of the palladium(0) catalyst 80.72  
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Scheme 19 Catalytic Cycle of Suzuki-Miyaura Cross-Coupling Reaction72 
 
1.2 Suzuki-Miyaura Cross-Coupling:  The Wits Approach 
 
1.2.1 The Synthesis of Angularly Fused Polyaromatic Compounds 
 
The Suzuki-Miyaura cross-coupling reaction has been used extensively in our labs, mainly for the 
construction of a biaryl axis.  The first example is the use of the Suzuki-Miyaura cross coupling 
reaction as a key step in the synthesis of Polycyclic Aromatic Hydrocarbons (PAHs).74 This large 
class of compounds is primarily recognised for their carcinogenic activities, but recently these 
compounds have been investigated for other reasons and have found a niche as large ligands in 
transition metal catalysis.  The synthesis of benzo[a]anthracene-7,12-dione 89 (Scheme 20) in an 
82% yield is amongst one of the PAHs synthesised by de Koning and co-workers using Suzuki-
Miyaura coupling as a key step in building these large scaffolds.74   
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Scheme 20 The Synthesis of Benzo[a]anthracene-7,10-dione  Reagents, Conditions and Yields (i) 
10% mol Pd(PPh3)4, 2M aq. Na2CO3, DME/EtOH, 100%; (ii) CAN, H2O/MeCN, 87%; (iii) KOBu
t, 
DMF, 80oC, hv, 82%.74 
 
1.2.2 The Synthesis of Benzo[a]carbazoles 
 
Benzo- or pyrido-fused carbazoles are also of great interest to synthetic chemists as these 
systems are often found as scaffolds of biologically active products and are being developed as 
potential antitumor agents.75 The same methodology as illustrated in Scheme 20 could also be 
adopted for the synthesis of these potentially bioactive carbazole molecules.75  N-Methyl 2-
bromoindole-3-carbaldehyde underwent Suzuki-Miyaura cross-coupling with boronic acids in the 
presence of palladium(0) (Scheme 21).75  Treatment of these coupled products with potassium-t-
butoxide in the  presence of light afforded the same ring-closure as previously seen in the PAH 
systems, but instead formed the benzo[a]carbazole compound 90.75 
 
 
 
Scheme 21 The synthesis of Benzo[a]carbazoles Reagents, Conditions and Yields (i) 10% mol 
Pd(PPh3)4, 2M aq. Na2CO3, DME/EtOH, 93%; (ii) KOBu
t, DMF, 80oC, hv, 78%.75 
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2.  The Naphthoquinone Derivatives 
 
As mentioned earlier, the naphthoquinone motif is a very important one as it is found in a vast 
number of secondary metabolites and constitutes a chief class of therapeutic agents.66  Whilst 
these naphthoquinone-containing compounds show a wide range of biological activities from 
antiviral to anti-inflammatory agents, their use as antitumor and antibiotic agents is the most 
common.76  The reason for the potency of compounds containing this motif against bacteria and 
tumours is to do with the chemical properties of the quinone itself.76  In a system such as that 
found for rapidly dividing cells and bacteria, oxygen is being rapidly used up, creating an oxygen 
deficient or reductive area in the body.76  The ability of the quinone to be reduced to the 
hydroquinone in vivo allows it to act as a bisalkylating agent attacking the rapidly dividing cells 
responsible for the reductive system.76  This means that quinones are potent and selective 
pharmaceutical agents for the treatment of cancers and bacterial infections.76  This highlights the 
need for development of novel methodology for the efficient synthesis of quinone-containing 
compounds which could be used as potential bioactive compounds.  The following section aims to 
demonstrate the vast biological applications of naphthoquinones as therapeutic agents and also 
the synthetic strategies employed for the creation of this extremely important privileged scaffold.  
 
2.1 Biological Applications and Synthetic Strategies for Pyranonaphthoquinones 
 
Pyranonaphthoquinones display the characteristic biological activities expected of the 
naphthoquinone substructure.76  For example, nanaomycin A 91, francolin 92, kalafungin 93 and 
medermycin 94 (Figure 21) have been shown to be extremely active against many strains of the 
Gram-positive bacterial species of Staphylococcus and Bacillus as well as being active against 
fungi and mycoplasms.76, 77  Many synthetic routes to these pyranonaphthoquinones have been 
reported76 and this section will illustrate a number of the methodologies employed to synthesise 
these natural product antibiotics. 
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Figure 21 Some Bioactive Pyranonaphthoquinones76 
 
2.1.1 Synthesis of Pyranonaphthoquinone Motif by Furonaphthofuran Annulation-Oxidative 
Rearrangement 
 
The pyranonaphthoquinone antibiotic medermycin 94 was isolated from Streptomyces 
tanashiensis and was found to be active against gram positive organisms, antibiotic resistant cell 
lines of L5178Y lymphoblastoma and Ehrlich carcinoma in mice and human leukaemia K562 
cells.78  However, despite the obvious biological application of this molecule only one total 
synthesis of it has been reported to date.78  Brimble and Brenstrum designed a synthetic strategy 
for the synthesis of the 2-deoxyglycosyl analogue of medermycin 95, which is flexible at the point 
of introduction of the C-glycoside so that a range of medermycin derivatives can be synthesised 
(Scheme 17).78  The group successfully synthesised the 2-deoxyglycosyl analogue of medermycin 
95 using a furonaphthofuran annulation-oxidative rearrangement strategy (Scheme 17) to form the 
pyranonaphthoquinone ring system.77, 78  This strategy involves the conversion of one tri-cyclic 
system into another tri-cyclic system.77, 78, 79  The reaction proceeds via an uncatalysed 1,4-addition 
of 2-trimethylsiloxyfuran 96 to the C-glycoside linked 2-acetyl-1,4-naphthoquinone 97 and gives the 
furo[3,2-b]naphtho[2,1-d]furan 98, which then undergoes oxidative rearrangement with cerium(IV) 
ammonium nitrate to give the desired furo[3,2-b]naphtho[1,3-d]pyran 99.77, 78, 79  The final step is 
the reduction of the hemiacetal 99 to the cyclic ether 95 which is prepared using triethylsilane in 
trifluoroacetic acid.79   
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Scheme 17 The Synthesis of Medermycin Derivative Reagents and conditions: (i) MeCN; (ii) CAN, 
H2O, room temp; (iii) Et3SiH, CF3CO2H, -78
oC to room temp.77, 78, 79 
 
2.1.2 Synthesis of Pyranonaphthoquinone Motif by Intramolecular Michael Addition 
 
The pyranonaphthoquinones nanaomycin A 91 and francolin 92 show characteristic biological 
activities and are active against Gram-positive bacteria, fungi and mycoplasms.76  It is due to their 
wide range of biological activities that many synthetic routes have been reported for the synthesis 
of these pyranonaphthoquinone containing compounds.76  Uno also established an efficient 
synthetic strategy which led to the total synthesis of four natural products containing the 
pyranonaphthoquinone motif: eleutherin 100, isoeleutherin 101, nanaomycin A 91 and 
deoxyfrenolicin 102 (Figure 22).76 
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Figure 22 Natural Products containing the Pyranonaphthoquinone motif76 
 
This retrosynthetic route (Scheme 23) shows that the construction of the pyran ring system could 
be achieved by intramolecular Michael addition or etherification.76  The required carbon chains for 
the ring closure are prepared from the reaction of alkanoylnaphthoquinones with simple or modified 
allylmetals.76  The group also demonstrated that the tin allyl reagents gave the best yields (nearly 
100%) for the intramolecular Michael addition precursors.76   
 
 
 
 
Scheme 23 Retrosynthetic Strategy for Synthesis of Pyranonaphthoquinone-containing Products76 
 
2.1.3 Synthesis of Pyranonaphthoquinone motif by Photoannulation Reaction 
 
The final synthetic approach to be highlighted in this review is employed in the synthesis of 
pyranonaphthoquinone 105b which is an analogue of naphthgeranine E 105c, a member of a 
family of bioactive naturally-occurring naphthoquinones found in Streptococcus violaceus.80  This is 
the first and only reported synthesis in the literature where a direct analogue of the naphthgeranine 
family of natural products has been synthesised.80  The key steps of this synthetic strategy are the 
thermally induced ring expansion of the 4-arylcyclobutenone 103 to the 2-aryl-3-isopropoxy-1,4-
naphthoquinone 104 and the subsequent photoannulation reaction of the quinone 104 for the 
construction of the pyranonaphthoquinone nucleus 105a and its regioisomer 105 (Scheme 24), in 
an 82% yield as a 1:1 mixture.80   
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Scheme 24 Synthesis of Naphthgeranine E Derivatives, Reagents and conditions:  i) LiC6H3-4-
OTIPS-3CH2OTIPS, THF, -78
oC; ii) TFAA; iii) LiC6H3-2,4-(OCH3)2, -78
oC, THF;  iv) p-xylene, 
138oC; v) Ag2O, K2CO3; vi) hv, DDQ, benzene.
80 
 
2.2 Biological Applications and Synthetic Strategies for Kinamycin Antibiotics 
 
The kinamycin antibiotics were first isolated from Streptomyces murayamaensis and were 
originally characterised by Omura and co-workers as being benzo[b]carbazole cyanamides 106 
(Figure 23).81  This group of compounds have been shown to possess activity against Gram-
positive and Gram-negative bacteria, Ehrlich ascites carcinoma and sarcoma-180.81  Subsequently 
four additional biologically active metabolites have been isolated from the same organism; 
kinamycin E 107, kinamycin F 108, prekinamycin 109 and ketoanhydrokinamycin 110 (Figure 
23).82  Recently, 3-O-isobutyrylkinamycin 111 and 4-deacetyl-4-O-isobutyrylkinamycin 112 (Figure 
23) were isolated from a Saccharothrix species.82  These compounds show activity against Gram-
positive bacteria, L1210 leukemia, IMC carcinoma, LX-1 human lung carcinoma and SC-6 human 
stomach carcinoma.82 
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Figure 23 Kinamycin Antibiotics82 
 
2.2.1 Synthesis of Benzo[b]carbazoloquinones by Coupling of Organostannanes with 
Bromoquinones 
 
Echavarren et al. set out to synthesise prekinamycin 109 relying on the coupling of 2-
bromonapthoquinone with stannanes, in the presence of palladium or copper catalyst as a key 
step.83  The coupling of the naphthoquinone 114 with arylstannane 115 with Pd(PPh3)4 and CuBr 
(5 mol% each) as the catalysts, gave the desired coupled product 116 in excellent yield (scheme 
25).83  Hydroxylation of 116 afforded 117 in a quantitative yield and removal of the BOC protecting 
group by heating at reflux in H2SO4 resulted in ring-closure and gave a 1:1 ratio of products 118 
and 119 in an overall yield of 80%.83  The desired regioisomer 119 was finally N-cyanated with 
excess BrCN in the presence of Et3N and DMAP to give product 120 in a quantitative yield.
83  
Finally demethylation of 120 with BBr3 gave the desired prekinamycin 109 in a yield of 90%.
83  
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Scheme 25 Synthesis of Prekinamycin Reagents and Conditions: i) 5 mol% Pd(PPh3)4, 5 mol% 
CuBr,1,4-dioxane, reflux (90%); ii) TFA, TFAA, aq. THF, 23oC (100%); iii) MeOH, cat. H2SO4, reflux 
(80%) iv) excess BrCN, Et3N, DMAP, CH2Cl2, 23
oC (100%); v) BBr3 (90%)
83 
 
2.3 Biological Applications and Synthetic Strategies for Jadomycin Antibiotics 
 
The final class of naphthoquinone-containing compounds with interesting biological activities are 
the jadomycin antibiotics.  The jadomycins are a unique family of angucycline-derived antibiotics 
because of their pentacyclic 8H-benz[b]oxazolo[3,2-f] phenanthridine backbone and is distinctive to 
the jadomycin antibiotics.84  The jadomycins are active against both Gram-positive and Gram–
negative bacteria and yeast.66, 84  Jadomycin B 121 (Figure 24) is the principal product produced 
when Streptomyces venezuelae ISP5230 is fermented under stress conditions, such as heat 
shock, ethanol treatment or phage infection.  Although the biosynthetic pathway for the synthesis 
of jadomycin B 121 has not been fully elucidated, some of the important steps in the synthesis are 
known.84  The key step of the jadomycin biosynthesis is the oxidative opening of the 5,6-bond of an 
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angucyclinone intermediate and the subsequent incorporation of the isoleucine amino acid from 
which the nitrogen heteroatom is derived.84  It is not known if the incorporation of this amino acid is 
catalyzed by an enzyme and to date no responsible enzyme candidate has been identified in the 
jadomycin gene cluster.84 By replacing isoleucine in the jadomycin B production medium with other 
amino acids, eleven new jadomycin derivatives have been generated.66   
 
Jadomycin B 121 and five of its derivatives; jadomycins A 122, F 123, V 124, S 125 and T 126 
(Figure 24), which incorporate alanine, phenylalanine, valine, serine and threonine, were tested 
against four different cancer cell lines (HepG2, IM-9, IM-9/Bcl-2 and H460).66  It was found that 
jadomycin S 125 was most potent against HepG2, IM-9 and IM-9/Bcl-2, whilst jadomycin F 123 
was most potent against H460, as these derivatives caused the most apoptosis in the specific 
cancer cell line.66  The jadomycins are known to elicit a wide range of antibacterial activities, but 
now their antitumor activities are of interest.66  The fact that various amino acids with varying side 
chains can be incorporated into the jadomycin skeleton makes these compounds of further value, 
as jadomycin thus offers an ideal scaffold to exploit for novel bioactive compounds.66 
 
 
 
 
Figure 24 Structures of Jadomycin Derivatives66 
 
2.3.1 Synthesis of Phenanthroviridin aglycon  
 
There are no reported syntheses of the dihydrobenzo[b]phenanthridine motif as found in the 
skeleton on jadomycin.  There is however a reported synthesis of a very closely related compound, 
phenanthroviridin aglycon 128, which is a natural product isolated from Streptomyces 
virdiochromogenes DSM 397.82  The product was synthesised by Gould and co-workers as part of 
a study on the synthesis of kinamycin antibiotics which are discussed above.82  The group was 
able to prepare the phenanthroviridin compound from a (bromoaryl)naphthamide compound 127 
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(Scheme 26), which was a key intermediate in their synthesis of prekinamycin.82  The desired 
phenanthroviridin aglycon 128  was then obtained in good yield by way of a sequence of metal-
halogen exchange, formylation, Hofmann rearrangement, cyclisation, deprotection and oxidation to 
1,4-quinone (Scheme 26).82  
 
 
 
 
Scheme 26 Synthesis of Phenanthroviridin Aglycon Reagents and Conditions: i) 2.5 equiv t-BuLi, -
890C; ii) DMF; iii) NaOMe/Br2 (-54
oC – 55oC); iv) H2O/reflux (NaOH); v) BBr3/CH2Cl2.
82
  
 
3.  The Naphthopyranone Derivatives 
 
Another group of aromatic polyketides which are of considerable interest are compounds 
containing the oxygenated benzonaphthopyranone motif.67 They are of interest not only because 
they display a variety of biological activities, but are also structurally intricate and thus of 
significance to synthetic chemists.67  Chartreusin 129, chrymutasin A 130, arnottin 1 131, 
hayumicinone 132 and gilvocarcin V 133 (Figure 25) are a few selected aromatic polyketide 
antibiotics which share a benzonaphthopyranone moiety and demonstrate a variety of antibiotic 
and antitumor activities.67  Despite their obvious biological importance there are very few reported 
syntheses of these types of systems, mainly due to their challenging structural features as 
demonstrated by the chartreusin and chrymutasin compounds.67, 85  This section will further 
highlight the biological relevance of these polyketide antibiotics as well as elucidate some of the 
synthetic strategies employed for the synthesis of the benzonaphthopyranone motif. 
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Figure 25 Structures of Benzonaphthopyranone Antibiotics67 
 
3.1 Biological Applications and Synthetic Approaches to the Chartreusin Antibiotics 
 
Chartreusin 129 is the most studied member of the benzonaphthopyranone antibiotics and was 
first isolated in 1953 from the culture broth and mycelial cake of Streptomyces chartreuses, and 
fully characterised in 1964.67  The compound was first investigated because of its antibacterial 
activity, but further studies revealed chartreusin 129 to have significant chemotherapeutic activity 
against several mouse cancers in vivo.86  Chartreusin 129 shows excellent activity against tumour 
cell lines such as murine P388, L1210 leukemia and B16 melanoma; however the development of 
chartreusin 129 as a pharmaceutical has been hampered due to its unfavourable 
pharmacokinetics.86  The compound has very slow gastrointestinal absorption, poor water solubility 
and rapid biliary excretion, which limits its ability to be an effective anticancer drug.86   
 
Due to the excellent antitumor activity shown in vitro by chartreusin much attention has been 
directed at addressing these poor pharmacokinetic shortcomings and both natural and 
semisynthetic chartreusin analogues have been identified with improved in vivo properties.86  A 
natural derivative of chartreusin 129, elsamicin A 134 (Figure 26) which is produced by an 
unidentified actinomycete strain has improved water solubility due to the amino sugar moiety.86  A 
semisynthetic derivative of chartreusin, IST-622 135 has also been identified as a pro-drug with 
greatly improved pharmacokinetic properties.86  Currently both elsamicin A 134 and IST-622 135 
are undergoing phase II clinical trials for breast cancer in Japan.86 
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Figure 26 Structures of Antitumor Agents; Chartreusin 129, Elsamicin A 134 and IST-622 13586 
 
3.1.1 Synthesis of Benzonaphthopyranones by Hauser-Kraus Annulation 
 
There is only one reported synthesis for the production of the benzonaphthopyranone motif as 
found in the chartreusin antibiotic.  Work done by Mal et al. showed the use of Hauser-Kraus 
annulation for the synthesis of the chartarin 136b (Scheme 27), which is the analogue of 
chartreusin 129 without the sugar moiety.67  For the total synthesis of chartarin, the required 
coumarin 139 was prepared in three steps from the aminotoluate 137.67  The crucial annulation of 
coumarin 139 with cyanophthalide 140 was performed to give 136a in an 86% yield.67  The use of 
HBr promoted the demethylation of 136a to give chartarin 136b in an 81% yield.67  The group was 
also able to extend the methodology to the synthesis of the benzonaphthopyranone cores as found 
in chrymutasins and hayumicins, and later to the gilvocarcin antibiotics.67 
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Scheme 27 Synthesis of chartarin Reagents and Conditions: i) 5.4 vol% H2SO4, NaNO2, 0
oC – 
reflux (66%); ii) (CH2)6N4, PPA, reflux (30%); iii) Ph3P=CHCOOEt, Et2NPh, reflux (95%); iv) LiOt-
Bu, -60oC – rt (86%); v) HBr, AcOH, reflux (81%).67 
 
3.2 Biological Applications and Synthetic Approaches to the Gilvocarcin Antibiotics 
 
Gilvocarcin V 133, defucogilvocarcin V 141, and its methyl 142 and ethyl 143 derivatives (Figure 
27), represent an important group of benzonaphthopyranone natural products which have been 
isolated from various strains of Streptomyces, and in addition show significant antibacterial and 
antitumor activity.85  Gilvocarcin V is the most widely used compound and shows excellent 
antitumor activity and extremely low toxicity.87 
 
Figure 27 Structure of Gilvocarcin Antibiotics87 
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3.2.1 Cross Coupling Strategies for the Synthesis of Gilvocarcin Antibiotics 
 
Snieckus and co-workers reported the total synthesis of defucogilvocarcin V 141, and its methyl 
142 and ethyl 143 derivatives (Figure 27), in a continued attempt to demonstrate the synthetic 
advantages of transition metal-catalysed cross-coupling reactions.85  This section will demonstrate 
the synthetic strategy employed for the production of the defucogilvocarcin V analogue 141.  To 
initiate the synthesis an iodinated trioxygenated naphthalene species 144 (Scheme 28) was cross-
coupled with the arylboronic acid 145 in a Pd(0)-catalysed Suzuki-Miyaura reaction to give the 
biaryl compound 146 in excellent yield.85  Compound 146 then underwent an anionic Fries 
rearrangement under standard conditions of treatment with LDA, followed by an acid workup, to 
give the tetracyclic lactone 147 in a modest yield.85  Stille coupling  with vinyltributyltin converted 
compound 147 to the desired vinyl analogue 148 in a 69% yield and selective deprotection of the 
isopropyl ether with BCl3 gave the final product, defucogilvocarcin V 141 in an overall yield of 
14%.85 
 
 
 
Scheme 28 Synthesis of Defucogilvocarcin V Reagents and Conditions:  i) i. 3 equiv LDA, THF, 
reflux, 1hr; ii. HOAc, reflux, 10min; ii) 2mol % Pd2(dba)3, LiCl, (2-furyl)3P, NMP, rt/5hr; iii) BCl3, 
CH2Cl2, 0
oC, 10 min.85 
 
3.2.2 Palladium-Catalysed Ring Closure for the Synthesis of Gilvocarcin Antibiotics 
 
As part of a study on the use of palladium-catalysed intramolecular ring-closures as an approach to 
benzo[b]fluorenes, Qabaja and Jones published the synthesis of a benzonaphthopyranone closely 
related to the methyl derivative of defucogilvocarcin 142.88  The group synthesised this compound 
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as an intermediate in the synthesis of a WS-5995C antibiotic which is isolated from a bacterium 
Steptomyces acidizcabies and also shows excellent antitumor activity.88  Unfortunately their 
proposed synthesis never gave the desired WS-5995C antibiotic, but it did provide an efficient 
synthetic strategy for the production of gilvocarcin antibiotics.88  The synthesis of the 
benzonaphthopyranone proceeded by way of the reaction of the hydroquinone 149 with the acyl 
chloride 150 (Scheme 24), to give the resulting ester 151 in a 71% yield.88  The ester product 151 
was first methylated and then subjected to Pd-catalysed intramolecular ring-closure to give the 
benzonaphthopyranone product 152 in a 75% yield.88 
 
 
 
Scheme 29 Synthesis of Benzonaphthopyranone Motif Reagents and Conditions: i) DMAP, i-
Pr2NEt, THF; ii) Me2SO4, K2CO3, acetone; iii) PdCl2(PPh3)2, NaOAc, DMA.
88 
  
4. Aims of this Section 
 
From the above selected review we can see the biological relevance and applications of 
naphthoquinone and naphthopyranone containing antibiotics.  The overview also highlights the 
limited methodology for the synthesis of some of these types of structures, particularly the 
dihydrobenzo[b]phenanthridine motif as found in the jadomycin antibiotics.  The main aim of this 
section is the development of methodology for the synthesis of this dihydrobenzo[b]phenanthridine 
motif.  We then hope to expand this methodology for the synthesis of related naphthoquinone-
containing compounds and other natural products containing these important scaffolds. 
 
 To develop methodology for the synthesis of the benzo-fused naphthoquinone motif as 
found in jadomycin antibiotics. 
 
The main aim of this section is the use of the Suzuki-Miyaura cross-coupling reaction to create the 
biaryl axis needed for the development of methodology for the synthesis of the 
dihydrobenzo[b]phenanthridine 153 motif and the dihydrobenzo[c,g]chromene motif 154 (Scheme 
30).  The starting point of the synthesis is the protection of the 1,4-naphthoquinone, followed by 
bromination at the ortho-postion, and then the Pd(0)-catalysed Suzuki-Miyaura cross-coupling 
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reaction with the relevant boronic acid to create the required biaryl product (Scheme 30).  
Reduction of nitrile or aldehyde, oxidation back to the quinone and intra-molecular Michael addition 
are then hoped to create the desired benzo-fused naphthoquinone-containing products.  Once the 
methodology has been successfully employed for the synthesis of the desired naphthoquinones, 
we wish to extend it to more complex starting materials in the hope that we develop a general 
procedure for the synthesis of a variety of naphthoquinone-containing products. 
 
 
 
 
Scheme 30 Proposed Synthesis of the Naphthoquinone Motif 
 
 To develop reproducible methodology for the synthesis of the naphthopyranone motif as 
found in the gilvocarcin antibiotics. 
 
It was discovered during the course of this project that NBS could perform an interesting and 
unexpected ring-closing reaction on one of the substrates required for the synthesis of the 
dihyrobenzo[c,g]chromene motif 154 (Scheme 30).  This unforeseen result led to the synthesis of 
12-methoxy-6H-dibenzo[c,h]chromen-6-one 155 (Scheme 31), which is the scaffold found in a 
range of biologically important naphthopyranone antibiotics known as the gilvocarcin antibiotics 
(Figure 27).  With this unpredicted product in hand we wished to determine if this reaction could be 
reproduced and extended to related naphthopyranone scaffolds. We also aimed to elucidate the 
mechanism by which NBS performs this ring-closing transformation.   
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Scheme 31 Synthesis of 12-Methoxy-6H-dibenzo[c,h]chromen-6-one 
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Chapter 5: Results and Discussion  
 
Synthesis of Benzo-fused Hetero-aromatic Naphthoquinone and Naphthopyranone Ring 
Systems 
 
1.  Introduction 
 
The following discussion will address matters in the synthesis of the 
dihydrobenzo[b]phenanthridine motif 153 which constitutes the backbone of an important 
secondary metabolite, jadomycin B 121.  To date no known syntheses of this scaffold have been 
reported, which made this motif an extremely valuable target for this project.  Jadomycin B 121 and 
its derivatives show a remarkable capacity for biological applications and are known to be active 
against both Gram-positive and Gram–negative bacteria, with their antitumor activities recently 
becoming of great interest.66, 84 This discussion will address the results in accordance with the 
attempts at the synthesis of this important scaffold, as well as characterisation of the synthesised 
compounds.  In addition we will also examine the results of the attempts to extend the synthetic 
methodology to other systems in order to form a range of related benzo-fused hetero-aromatic 
naphthoquinone products.  Finally, this section will introduce an extremely interesting novel result 
which unexpectedly occurred during the course of what we believed would be a standard aromatic 
bromination reaction.  The product from this reaction culminated in the introduction of the second 
major aim of this project; the synthesis of 12-methoxy-6H-dibenzo[c,h]chromen-6-one 155 and 
other related naphthopyranone ring systems.  
 
2.  Attempted Synthesis of 5,6-Dihydrobenzo[b]phenanthridine-7,12-dione 153 and 5,6-
Dihydrophenanthridine-1,4-dione 161 
 
2.1 Attempted Synthesis of 5,6-Dihydrobenzo[b]phenanthridine-7,12-dione 153 
 
The synthesis presented below (Scheme 32) details how we hope to achieve the synthesis of 
compound 153, the motif of jadomycin B 121.  Starting from commercially available 1,4-
naphthoquinone we wished to protect the staring material as 1,4-dimethoxynaphthalene and 
subsequently mono-brominate in the ortho-position using known literature procedures.89, 90  By 
converting the brominated product to the corresponding boronic acid and coupling it with a relevant 
aryl-halide we hoped to create a biaryl axis from which we can develop the methodology for the 
synthesis of 153.  A simple method of achieving this desired biaryl axis is to invoke the use of 
Suzuki-Miyaura cross-coupling which is a palladium(0)-catalyzed coupling reaction forming C-C 
bonds.70  The ensuing reduction of the nitrile to the amine and oxidation of the naphthalene motif to 
the naphthoquinone will hopefully create conditions for an intra-molecular Michael addition to occur 
resulting in the synthesis of 5,6-dihydrobenzo[b]phenanthridine-7,12-dione 153.   
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Scheme 32 Proposed Synthetic Stratergy for the Synthesis of 5,6-Dihydrobenzo[b] 
phenanthridine-7,12-dione 153 
 
2.1.1 Synthesis of 1,4-Dimethoxynaphthalene 156 
 
 
Scheme 33 Synthesis of 1,4-Dimethoxynaphthalene 156 Reagents and Conditions; i) Na2S2O4, 
diethyl ether, H2O, rt, 1 h ii) K2CO3, dimethyl sulphate, acetone, reflux, 22 h 
 
The first major aim of this project was the use of Suzuki-Miyaura cross-coupling to create the biaryl 
axis needed for the development of methodology for the synthesis of the 
dihydrobenzo[b]phenanthridine motif 153 (Scheme 32).  The starting point of the synthesis was the 
protection of commercially available 1,4-naphthoquinone as the analogous ether, 1,4-
dimethoxynaphthalene 156 (Scheme 33). To achieve this, 1,4-naphthoquinone and the reducing 
agent Na2S2O4 were dissolved in diethyl ether and H2O, and shaken together vigorously in a 
separating funnel for 1 hour.  The Na2S2O4 reduces the 1,4-naphthoquinone to the 1,4-
dihydroquinone, which is unstable to oxygen and so used directly in the following step without 
characterisation.  The intermediate 1,4-dihydroquinone was quickly dissolved in acetone and 
K2CO3 and dimethyl sulfate were added to the solution, and the reaction was heated at reflux for 
22 hours.  The K2CO3 base removes the protons of the 1,4-dihydroquinone and allows the 
methylating agent, dimethyl sulfate, to deliver the desired methyl groups.  Subsequent to a work-
up, the crude brown oily product was purified by column chromatography to yield the desired 1,4-
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dimethoxynaphthalene 156 as an off-white solid in a 79% yield.  The losses in yield are most 
probable due to the poor quality of the starting 1,4-naphthoquinone and purification of the starting 
material may have resulted in higher yields.       
 
The product was characterised by 1H and 13C NMR spectroscopy and the spectroscopic data was 
in agreement with that of the reported values in the literature.89 A key identifying feature was the 
presence of a singlet at 3.93 ppm in the 1H NMR spectrum which integrated for 6 protons and was 
a result of the two OCH3 groups. The corresponding carbon signal was found in the 
13C NMR 
spectrum at 55.7 ppm.  
 
2.1.2 Synthesis of 2-Bromo-1,4-dimethoxynaphthalene 157 
 
 
 
Scheme 34 Synthesis of 2-Bromo-1,4-dimethoxynaphthalene 157 Reagents and Conditions; NBS, 
CH2Cl2, rt, 21 h 
 
Having successfully synthesised compound 156, the following step in the synthesis was the mono-
bromination of the compound in a position ortho to the methoxy group (Scheme 34).  This was 
achieved by dissolving 1,4-dimethoxynaphthalene 156 in CH2Cl2 and reacting it with 1 equivalent 
of NBS at room temperature for 21 hours.  The resultant solution was subjected to a work-up 
procedure and purified by column chromatography to yield the desired 2-bromo-1,4-
dimethoxynaphthalene 157 as a white solid in a 65% yield.  Although the yield of this reaction is 
not very high, the mild reaction conditions and the ease with which the bromination is achieved, 
makes this method highly favourable compared to other bromination strategies.   
 
The spectroscopic data of compound 157 were in agreement with that of Bloomer and Zheng.90  
The 1H NMR spectrum of compound 156 showed a distinct singlet at 6.66 ppm which integrated for 
2 protons and corresponded to hydrogen atoms H2 and H3 which are both ortho to the methoxy 
groups.  However, the 1H NMR spectrum of compound 157 showed the presence of only one of 
these protons, H3, as a clear singlet at 6.88 ppm was found which only integrated for 1 proton.  The 
absence of this second proton signal confirms that the mono-bromination in the ortho-position was 
successful.  Another clear indication that the bromination reaction had occurred was that both the 
1H and 13C NMR spectra of compound 157 showed a marked increase in the number of signals 
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found.  This relates to the fact that the newly synthesised compound 157 is no longer 
symmetrical, unlike its parent compound 1,4-dimethoxynaphthalene 156.  The 1H NMR spectrum 
of 156 showed both OCH3 groups as a singlet at 3.93 ppm due to the symmetrical nature of the 
molecule, but the 1H spectrum of compound 157 shows two distinct OCH3 signals at 3.96 and 3.95 
ppm, respectively.     
 
2.1.3 Synthesis of 1,4-Dimethoxynaphthalen-2-yl boronic acid 158 
 
 
Scheme 35 Synthesis of 1,4-dimethoxynaphthalen-2-yl boronic acid 158 Reagents and 
Conditions; i) n-BuLi, THF, -78˚C, 40 min ii) trimethyl borate, THF, -78˚C, 1 h 
 
Before the Suzuki-Miyaura cross-coupling reaction could be achieved, we needed to synthesise 
the corresponding boronic acid of 2-bromo-1,4-dimethoxynaphthalene 157.  The synthesis of 1,4-
dimethoxynaphthalen-2-yl boronic acid 158 (Scheme 35) was accomplished by dissolving 
compound 157 in dry THF in a two-necked flask and thoroughly degassing the solution with N2 
gas.  The reaction solution was then cooled to -78˚C using a liquid N2 and acetone bath.  Three 
equivalents of n-BuLi were added slowly to the reaction mixture and the solution was left stirring for 
a further 40 minutes at -78˚C, before the addition of three equivalents of trimethyl borate.  The 
solution was stirred for a further 1 h at -78oC and then quenched with 10% HCl solution.  The 
organic extracts were collected and the solvent removed in vacuo to give a clear oil, which upon 
the addition of acetone afforded the desired boronic acid 158 as a white solid in a yield of 76%.  
The boronic acid product 158 was not characterised as it is unstable, and insoluble in a variety of 
deuterated solvents and was thus used directly in the following synthetic step. 
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2.1.4 Synthesis of 2-(1,4-Dimethoxynaphthalen-2-yl)benzonitrile 159 
 
 
 
Scheme 36 Synthesis of 2-(1,4-Dimethoxynaphthalen-2-yl)benzonitrile 159 Reagents and 
Conditions; Pd(PPh3)4, 2M aq. Na2CO3, DME, EtOH, reflux, 23 h 
 
Having 1,4-dimethoxynaphthalen-2-yl boronic acid 158 in hand we could now build the biaryl axis 
required for the synthesis of dihydrobenzo[b]phenanthridine motif 153 (Scheme 32).  This was 
done by using the palladium mediated Suzuki-Miyaura cross-coupling reaction which will couple 
the synthesised boronic acid 158 with commercially available 2-bromobenzonitrile (Scheme 36).  
15% of tetrakis [Pd(PPh3)4], which is the catalyst used for the Suzuki-Miyaura cross-coupling 
reaction, was placed in a 3-neck round bottom flask.  The catalyst is very sensitive to oxygen and 
so the reaction mixture must first be evacuated of all oxygen and then carried out under an inert N2 
atmosphere. Next the 1,4-dimethoxynaphthalen-2-yl boronic acid 158 and 2-bromobenzonitrile 
were dissolved in DME and EtOH, degassed and added to the Pd(PPh3)4 in the reaction vessel via 
a dropping funnel.  Finally an aqueous 2M Na2CO3 solution was also degassed and added to the 
reaction vessel via a dropping funnel and the resultant solution was then heated at reflux for 23 
hours.  The reaction was then quenched with H2O, the organic extracts collected and the solvent 
removed in vacuo to afford a pale residue.  The crude product was finally purified by column 
chromatography to give the desired Suzuki product, 2-(1,4-dimethoxynaphthalen-2-yl)benzonitrile 
159 as a white solid in a 50% yield.  
 
 
 
Scheme 37 Synthesis of 2-(1,4-Dimethoxynaphthalen-2-yl)benzonitrile 159 Reagents and 
Conditions; i) Pd(PPh3)4, 2M aq. Na2CO3, DME, EtOH, reflux, 19 h ii) Pd(PPh3)4, K3PO4, DMF, 
reflux, 47 h 
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The 50% yield of compound 159 from the Suzuki reaction was disappointing and could have been 
due to impure boronic acid 158.  Since compound 158 was not characterised by NMR 
spectroscopy we had no way of knowing what the ratio of starting material to product was or how 
pure the boronic acid actually was.  This may have led to the low yields as there may have been 
insufficient boronic acid 158 in the reaction mixture to allow the reaction to go to completion.  With 
this in mind, we decided that we would couple commercially available 2-cyanophenylboronic acid 
with previously synthesised 2-bromo-1,4-dimethoxynaphthalene 157 (Scheme 37) in the hopes of 
improving the yields.  This would also have the added benefit of reducing the number of synthetic 
steps required for the synthesis of target molecule dihydrobenzo[b]phenanthridine 153.  The 
reaction procedure for the Suzuki-Miyaura cross-coupling of 2-cyanophenylboronic acid with 2-
bromo-1,4-dimethoxy naphthalene 157, used the same reaction conditions as previously discussed 
(Scheme 36), in spite of the coupling partners being exchanged (Scheme 37).   After 19 hours of 
heating at reflux the product was purified by column chromatography to yield the desired product 
159 as a white solid in a 56% yield.   
 
The yield of this reaction was only marginally better than our first attempt and one last method was 
tried to improve the Suzuki cross-coupling yields, before settling on the conclusion that the reaction 
does not proceed to completion.  For our last effort we decided to use anhydrous Suzuki conditions 
so that the reaction could occur in only one homogenous solvent phase instead of at the interface 
of the organic and aqueous layers.  Previously synthesised 2-bromo-1,4-dimethoxynaphthalene 
157 and commercially available 2-cyanophenylboronic acid were placed in a 3-neck round bottom 
flask and dissolved in DMF (Scheme 37).  The solution was degassed to exclude all oxygen from 
the system and 0.2 mol% Pd(PPh3)4 and 4 equivalents of K3PO4 were then added to the reaction 
solution under flowing N2 gas.  The reaction mixture was then heated at reflux for 47 hours before 
being quenched with brine.  The organic products were extracted, the solvent removed in vacuo 
and the crude product purified by column chromatography to yield the desired 2-(1,4-
dimethoxynaphthalen-2-yl)benzonitrile 159 as a white solid in a 45% yield. Unfortunately the 
anhydrous Suzuki conditions had little influence in improving the yields, and despite using three 
different reaction conditions the yields remained at about 50% conversion.   
 
In all cases the cross-coupled compound 159 was characterised by NMR spectroscopy and both 
the 1H and 13C NMR spectra verified that the Suzuki-Miyaura reaction had been successful as 
there was the correct number of expected proton and carbon signals.  The presence of four extra 
proton signals in the aromatic region of the 1H NMR spectra corresponded well with the occurrence 
of four extra hydrogen atoms as found on the benzonitrile motif.  Perhaps the key identifying 
feature was a signal at 118.5 ppm in the 13C NMR spectrum which coincided with the carbon of the 
nitrile group.  HRMS failed to give conclusive evidence that the coupling had occurred as a 
molecular ion for C19H15O2N could not be obtained.  However a fragment with molecular formula 
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C12H12O2 and mass 188.0837 was found and this corresponds to the 1,4-dimethoxynaphthalene 
portion of the compound.  IR spectroscopy helped to confirm that the Suzuki reaction had occurred 
as we observe a signal at 2330cm-1 which corresponds to the nitrile functional group. 
 
2.1.5 The Attempted Synthesis of 2-(1,4-Dimethoxynaphthalen-2-yl)phenyl) Methanamine 160 
 
 
 
Scheme 38: Attempted Synthesis of 2-(1,4-Dimethoxynaphthalen-2-yl)phenyl) Methanamine 160 
Reagents and Conditions; i) 5% Pd/C, conc. HCl, H2, CH2Cl2, rt, 16 h; ii) 2.5 eq LiAlH4, THF, 0˚C – 
rt, 1 h; iii) 20.0 eq LiAlH4, THF, 0˚C – rt, 22 h; iv) 2N aq. NaOH, Raney alloy, EtOH, EtOAc, rt, 3 h. 
 
Being confident from the characterisation data that we had in fact synthesised 2-(1,4-
dimethoxynaphthalen-2-yl)benzonitrile 159, although only in moderate yields, we attempted to 
undertake the next step of the synthesis.  This step involved the attempted reduction of the nitrile 
to the benzylic amine to afford the desired product 2-(1,4-dimethoxynaphthalen-2-
yl)phenyl)methanamine 160 (Scheme 38).  Our first attempt at performing this reduction step 
involved the use of hydrogenation with H2 gas and 5% Pd/C catalyst.  Starting material 159 was 
dissolved in CH2Cl2 and placed in the hydrogenation vessel along with 5% Pd/C and 3 drops of 
conc. HCl which activates the hydrogenation catalyst (Scheme 38).  The reactants were then 
stirred at room temperature for 16 h under a 4.5kPa H2 atmosphere, after which time the Pd/C was 
removed by filtering the solution through celite.  The organic filtrate was collected, subjected to a 
work-up procedure and the solvent removed in vacuo to afford a white product which was 
characterised by NMR spectroscopy to be the starting material 159.  The 1H NMR spectrum 
showed no presence of the benzylic protons or of an N-H stretch and we safely concluded that the 
reduction reaction had not been effective. 
 
Having failed in our first attempt at reducing the nitrile to the benzylic amine we thought that by 
varying the hydrogenation conditions we would eventually achieve the desired effect.  It was 
thought that a higher Pd/C catalyst loading, increased pressures and longer reaction times would 
force the reaction forward so as to obtain the required amine.  Unfortunately, all other attempts at 
reducing the nitrile to the amine using the hydrogenation vessel failed and yielded only starting 
material 159 as confirmed by NMR spectroscopy.  The table below (Table 7) highlights the varying 
pressure, time, solvent, catalyst and yields of starting material obtained during the subsequent 
reduction attempts.  
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Table 7:  Conditions for the Attempted Reduction of Compound 159 
 
Pressure/kPa 
 
Time/h 
 
Solvent 
 
Catalyst 
 
Recovery of Starting Material (%) 
 
5 
 
20 
 
CH2Cl2 
 
10% Pd/C and 0.1eq 
 
98 
 
7 
 
20 
 
MeOH 
 
10% Pd/C 
And 0.5eq 
 
99 
 
8 
 
94 
 
MeOH 
 
10% Pd/C and 1.0eq 
 
97 
 
 
It appears that the reduction conditions used may have been too mild as the nitrile is stabilised due 
to conjugation with the aromatic ring. It was considered that perhaps the use of a harsher chemical 
reducing agent may afford the desired reduction.  With this in mind we attempted to reduce the 
nitrile to the amine using LiAlH4 as the reducing agent.  Starting material 159 was dissolved in THF 
and the solution was cooled to 0˚C before the addition of 2.5 equivalent of LiAlH4 (Scheme 38).  
On addition of the reducing agent the reaction mixture effervesced, which was a positive indication 
that a reaction was occurring.  The reaction was stirred for 1 hour at room temperature before 
being quenched with H2O, the organic products extracted and the solvent removed in vacuo to 
afford a white solid.  A crude 1H NMR spectrum showed that the extracted white solid was again 
the starting material 159, which was recovered in a 99% yield.  The same reaction was attempted 
once more, but this time using 20 equivalents of LiAlH4 (Scheme 38) and once again the isolated 
product was none other than starting material 159.  To satisfy ourselves that we were not 
incorrectly interpreting the NMR spectra, an infra red was performed and clearly showed the 
presence of the nitrile at 2225cm-1. 
 
One final attempt at the reduction of compound 159 was performed, this time using a literature 
procedure used in our laboratories and known to give the primary amine from a nitrile.91  As per 
this procedure, compound 159 was dissolved in ethanol and ethyl acetate.  Aqueous NaOH (2N) 
was added to the solution and the reaction mixture was stirred for 10 minutes, before the addition 
of 2.0 mass equivalents of Raney nickel alloy (Scheme 38).  The reaction mixture was stirred for a 
further 3 hours after which time the organic products were extracted and the solvent removed in 
vacuo to afford a white solid, which was once again characterised by NMR spectroscopy to be 
starting material 159.   
 
It is not fully understood why the reduction of this nitrile does not afford the desired primary amine 
160, but perhaps the extra stability conferred due to conjugation with the aromatic system is a 
possibility.46  In any event, it does not seem likely that the hydrogenation reactions will give any 
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worthwhile results, especially if the nitrile is being stabilised by electron donation from the 
aromatic ring.  The use of reducing agent LiAlH4 may still be an option, as even though the 
reactions did not show any positive results we could still attempt these reactions at higher 
temperatures.  The nitrile carbon may not be electrophilic enough as it is once again stabilised by 
conjugation, but if the reaction was to be heated we may be able to overcome this activation 
energy barrier and force the reaction to proceed.  The same reasoning can be applied to the 
attempted Raney nickel reduction and we can once again attempt this reaction at a higher 
temperature to see if we obtain some positive results.   
 
2.2 Attempted Synthesis of 5,6-Dihydrophenanthridine-1,4-dione 161 
 
 
 
 
Scheme 39 Proposed Synthesis of 5,6-Dihydrophenanthridine-1,4-dione 161; i) Oxidation, ii) Intra-
molecular Michael addition 
 
Having been unable to reduce 2-(1,4-dimethoxynaphthalen-2-yl)benzonitrile 159 to the 
corresponding amine 160, we decided to determine if the proposed methodology for the synthesis 
of 5,6-dihydrobenzo[b]phenanthridine-7,12-dione 153 was worthwhile pursuing.  Starting from 
commercially available 1,4-dimethoxybenzene we wished to synthesise 5,6-dihydrophenanthridine-
1,4-dione 161 by employing a similar synthetic strategy to that of the attempted synthesis of 
compound 153 (Scheme 32).  If we could effectively reduce nitrile 164 of this simpler system to the 
corresponding amine 165, we would have a means of testing whether the proposed oxidation 
reaction and intra-molecular Michael addition were a viable way of completing the synthesis of 
these dihydrophenanthridine scaffolds (Scheme 39).    
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2.2.1 Synthesis of 2-Bromo-1,4-dimethoxybenzene 162 
 
 
 
Scheme 40 Synthesis of 2-Bromo-1.4-dimethoxybenzene 162 Reagents and Conditions; NBS, 
CH2Cl2, reflux, 52 h 
 
The first step in the attempted synthesis of 5,6-dihydrophenanthridine-1,4-dione 161 was the 
bromination in the 2-position of commercially available 1,4-dimethoxybenzene.  The starting 
material was dissolved in CH2Cl2 and brominating agent NBS was added to the solution, which 
was set to reflux for 52 hours (Scheme 40).  The crude product was purified by column 
chromatography to give the desired product 162 as a clear oil in an 86% yield.  The product was 
characterised by NMR spectroscopy and the spectroscopic data was in agreement with those 
obtained by Bloomer and Zheng.90   
 
2.2.2 Synthesis of 2,5-Dimethoxyphenylboronic acid 163 
 
 
 
Scheme 41 Synthesis of 2,5-Dimethoxyphenylboronic acid 163 Reagents and Conditions; i) n-
BuLi, THF, -78˚C, 1 h; ii) Trimethyl borate, THF, -78˚C, 1 h  
 
Having successfully synthesised 2-bromo-1,4-dimethoxybenzene 162, we wished to synthesise the 
corresponding boronic acid 163 (Scheme 41), so as to later attempt the Suzuki coupling to build 
the required biaryl axis.  Starting material 162 was dissolved in dry THF, thoroughly degassed and 
cooled to -78˚C, before the addition of 2.0 equivalents of organometallic reagent, n-BuLi.  The 
resultant solution was stirred for a further hour at -78˚C, trimethyl borate was then added and the 
solution was stirred for a further hour at -78˚C.  The solution quenched with 10% aqueous HCl 
solution, the organic products extracted and the solvent removed in vacuo to afford the boronic 
acid 163 as a white solid in a 38% yield.  The product was not characterised due to solubility and 
  
87 
stability problems and was used directly in the following synthetic step.  Although the yield of this 
reaction was extremely poor, we made no subsequent attempts to improve it as this was meant as 
merely a model study.   
 
2.2.3 Synthesis of 2’,5’-Dimethoxybiphenyl-2-carbonitrile 164 
 
 
 
Scheme 42 Synthesis of 2‟,5‟-dimethoxybiphenyl-2-carbonitrile 164 Reagents and Conditions; 
Pd(PPh3)4, 2M aq. Na2CO3, DME, EtOH, reflux, 27 h 
 
Having the required boronic acid 163 in hand, although in poor yield, we now attempted the 
Suzuki-Miyaura cross-coupling using the same aqueous conditions as previously discussed 
(Scheme 36).  Synthesised 2,5-dimethoxyphenyl boronic acid 163 and commercially available 2-
bromobenzonitrile were dissolved in EtOH and DME and added to a reaction vessel containing 
Suzuki catalyst, Pd(PPh3)4 under flowing N2 gas (Scheme 42).  2M Aqueous Na2CO3 was then 
added to the stirring solution and the reaction mixture was set to reflux for 27 hours.  The desired 
product, 2‟,5‟-dimethoxybiphenyl-2-carbonitrile 164, was isolated as a yellow oil in 57% yield after 
purification by column chromatography.  Although the yield of this reaction is quite poor, it would 
probably benefit from the use of a purer boronic acid 163 coupling partner.  Alternatively to improve 
the yield, we could also exchange the Suzuki coupling partners and use 2-bromo-1,4-
dimethoxybenzene 162 and commercially available  2-cyanophenylboronic acid as previously 
shown (Scheme 37).  
 
The Suzuki product 164 was characterised by 1H and 13C NMR spectroscopy and the 
spectroscopic data was in agreement with Al-Fakhri et al.92  A defining characteristic of the 1H 
NMR spectrum was the presence of 4 additional proton signals, which corresponded well to the 
inclusion of the benzonitrile motif.   The 13C NMR spectrum verifies this observation as there are an 
additional 4 ArC-H signals in the spectrum as well as 2 new quaternary signals.  A signal at 118.6 
ppm in the 13C NMR corresponds to the presence of a nitrile functional group in the compound.   
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2.2.4 Attempted Synthesis of (2’,5’-Dimethoxybiphenyl-2-y)Methanamine 165 
 
 
 
 
Scheme 43 Attempted Synthesis of (2‟,5‟-Dimethoxybiphenyl-2-y)Methanamine 165 Reagents and 
Conditions; i) 10% Pd/C, conc. HCl, MeOH, rt, 37 h  ii) LiAlH4, THF, 0˚C – rt, 2 h 
 
Having successfully synthesised 2‟,5‟-dimethoxybiphenyl-2-carbonitrile 164 we could now attempt 
the crucial reduction reaction, in the hopes of obtaining (2‟,5‟-dimethoxybiphenyl-2-y)methanamine 
165.  The success of this reaction was vital if we wanted to pursue the oxidation reaction and intra-
molecular Michael addition to ascertain if this methodology would afford the desired product 161.  
Our first attempt saw starting material 164 dissolved in MeOH and treated with 10% Pd/C and 
conc. HCl in the hydrogenator (Scheme 43).  The reaction was stirred for 37 hours at room 
temperature under a 7kPa atmosphere of H2 gas.   After work-up and purification by column 
chromatography the yellow oil obtained was characterised by NMR spectroscopy and identified as 
starting material 164, which was recovered in a yield of 99%.  The 1H NMR spectrum showed no 
presence of either the benzylic protons or of an N-H and we safely concluded that the isolated 
product was indeed starting material 164.   
 
The hydrogenation attempt once again failed to reduce the nitrile to the primary amine as it had 
done previously when trying to reduce 2-(1,4-dimethoxynaphthalen-2-yl) benzonitrile 159.  This 
failed reduction effort is probably once more attributed to the stability of the nitrile conferred by 
conjugation with the aromatic ring. Since we had no way of trying the hydrogenation reactions at 
higher temperatures, use of the hydrogenator for this transformation was abandoned in favour of 
other methods. 
 
Our second attempt at reducing compound 164 to the desired primary amine 165, made use of 
reducing agent LiAlH4 (Scheme 43).  Starting material 164 was dissolved in THF at 0˚C and 
treated with 20 equivalents of LiAlH4, before being allowed to stir at room temperature for 2 hours.  
Following the work-up procedure, a yellow oil was isolated which was spectroscopically pure, and 
once again was identified as starting material 164.   
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With this crucial reduction step in the synthesis still proving to be elusive it appears that the only 
remaining options for perhaps isolating the desired amines 160 and 165 is to try chemical reducing 
agents at high temperatures.  Without obtaining these amine products we will not be able to 
establish if the oxidation reaction and subsequent intra-molecular Michael addition will be 
successful in forming the 5,6-dihydro benzo[b]phenanthridine-7,12-dione 153 and 5,6-
dihydrophenanthridine-1,4-dione 161 scaffolds.   
  
3. Synthesis of 5-H-dibenzo[c,g]chromene-7,12-dione 154 
 
In a final attempt to determine if the proposed methodology (Scheme 32) would yield the desired 
product 5,6-dihydrobenzo[b]phenanthridine-7,12-dione 153, should we obtain the required amine, 
we turned our focus to the synthesis of the oxygen derivative 5-H-dibenzo[c,g]chromene-7,12-
dione 154.  Feeling certain that we could easily synthesise [2-(1,4-dimethoxynaphthalen-2-
yl)phenyl]methanol 167 by following similar synthetic procedures as already discussed, we could 
then verify if the proposed oxidation reaction and intra-molecular ring closure would give the 
correct product 154 (Scheme 44).  Should this attempt yield the desired product, we could then 
decide if the methodology is worthwhile applying to the phenathridine derivatives 153 and 161. 
 
 
 
Scheme 44 Proposed Methodology for the Synthesis of 5-H-dibenzo[c,g]chromene-7,12-dione 154 
i) oxidation; ii) Michael addition 
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3.1 Synthesis of 2-(1,4-Dimethoxynaphthalen-2-yl)benzaldehyde 166 
 
 
 
Scheme 45 Synthesis of 2-(1,4-Dimethoxynaphthalen-2-yl)benzaldehyde 166 Reagents and 
Conditions; Pd(PPh3)4, 2M aq. Na2CO3, DME, EtOH, reflux, 73 h 
 
The first step in the synthesis of 5-H-dibenzo[c,g]chromene-7,12-dione 154 was to construct a 
biaryl axis from which we could synthesise the rest of the molecule.  Once again aqueous Suzuki-
Miyaura cross-coupling methodology was used. Previously synthesised 2-bromo-1,4-
dimethoxynaphthalene 157 and commercially available 2-formylphenylboronic acid dissolved in 
EtOH and DME were placed with Suzuki catalyst, Pd(PPh3)4, in a round bottom flask under an inert 
atmosphere (Scheme 45).  2 M aqueous Na2CO3 was added to the reaction mixture and the 
solution was heated at reflux for 73 hours.  We isolated a white solid from the reaction which was 
characterised by NMR spectroscopy to be desired product 166, and was obtained in a 63% yield.   
 
The synthesis of product 166 was confirmed from the 1H NMR spectrum, which showed a clear 
aldehyde peak at 9.90 ppm. The corresponding carbon signal was found in the 13C NMR spectrum 
at 192.4 ppm.  Other evidence from the NMR spectral data is the presence of 4 additional aromatic 
proton signals in the 1H spectrum, which coincides with the coupling of the naphthalene motif to the 
benzaldehyde.  These additional signals were also found in the 13C NMR spectrum, along with two 
new quaternary signals.  HRMS shows the exact mass to be 292.1100, for a molecular ion with 
formula C19H16O3, which compares favourably with the calculated mass of 292.1099.  The IR 
spectrum also showed the clear presence of the aldehyde as signals at 2861cm-1, corresponding 
to the aldehyde proton and at 1726cm-1, indicating the carbonyl stretch.   
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3.2 Synthesis of [2-(1,4-Dimethoxynaphthalen-2-yl)phenyl]methanol 167 
 
 
Scheme 46 Synthesis of [2-(1,4-dimethoxynaphthalen-2-yl)phenyl]methanol 167 Reagents and 
Conditions; LiAlH4, THF, 0˚C – rt, 40 min 
 
The next step in the reaction was crucial and involved the reduction of the aldehyde group of 2-
(1,4-dimethoxynapthalen-2-yl)benzaldehyde 166 to the benzylic alcohol of [2-(1,4-
dimethoxynaphthalen-2-yl)phenyl]methanol 167.  Should this reaction be successful we would 
finally be able to test whether oxidation and subsequent intra-molecular Michael addition would 
yield the desired 5-H-dibenzo[c,g]chromene-7,12-dione 154 motif (Scheme 44).  Starting material 
166 was dissolved in dry THF and the solution was cooled to 0˚C before the addition of 3 
equivalents of the reducing agent LiAlH4 (Scheme 46).  After workup and purification by column 
chromatography we isolated the desired compound 167 as a white solid in a yield of 98%.   
 
Compound 167 was characterised by NMR spectroscopy, which showed the clear presence of a 
broad OH signal at 3.56 ppm in the 1H NMR spectrum.  Two distinct doublets at 4.40 ppm were 
also observed which correspond to the two benzylic protons (CH2OH).  It is thought that there may 
be some restricted rotation about the biaryl axis, making the two hydrogens diastereotopic and 
resulting in the observed doublet.  The coupling constant of 13.0Hz is further evidence of non-
equivalent hydrogens and supports germinal coupling.  Further information from the NMR data that 
the reduction had occurred was the disappearance of the characteristic aldehyde signals in both 1H 
and 13C NMR spectra.  Compound 167 has a calculated molecular mass of 294.1256 and HRMS 
showed a clear molecular ion with chemical formula C19H18O3 and a mass of 294.1256.  
Confirmation that the reduction reaction had in fact occured was the replacement of the aldehyde 
signals in the IR spectrum with a broad O-H stretch at 3251cm-1.      
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3.3 Synthesis of 5-H-Dibenzo[c,g]chromene-7,12-dione 154 
 
 
 
Scheme 47 Attempted synthesis of 2-(2-(Hydroxymethyl)phenylnaphthalene-1,4-dione 168 
Reagents and Condtions; CAN, CH3CN, CH3Cl, H2O, rt - 63˚C, 91 h 
 
Having successfully synthesised [2-(1,4-dimethoxynaphthalen-2-yl)phenyl]methanol 164, we now 
wished to determine an appropriate oxidation method to afford 2-(2-
(hydroxymethyl)phenylnaphthalene-1,4-dione 168 (Scheme 44).  Two different strategies were 
employed in an attempt to bring about this transformation.  In our first attempt, starting material 167 
was dissolved in CH3CN and CH3Cl before the addition of 3 equivalents of oxidant CAN dissolved 
in H2O (Scheme 47).  The yellow solution was stirred at room temperature for 68 hours after which 
time a TLC of the reaction mixture revealed only starting material to be present.  An additional 3 
equivalents of CAN were then added to the solution and the reaction was heated at 63˚C for a 
further 23 hours.  A TLC of the reaction mixture showed the formation of two new products and the 
reaction was cooled and the organic products extracted.  Purification of the reaction mixture by 
column chromatography isolated two oily products which were characterised by NMR 
spectroscopy.  The NMR spectra however, revealed the products to be unidentifiable compounds 
which were probably decomposed starting material.    
 
 
 
Scheme 48 Synthesis of 5-H-dibenzo[c,g]chromene-7,12-dione 154 Reagents and Conditions; 
Ag2O, 6M aq. HNO3, THF, rt, 30 min 
 
Having been unable to isolate a discernable product from our first oxidation attempt, we tried a 
different approach.  This time starting material 167 was dissolved in dry THF and 6 equivalents of 
Ag2O were added to the clear solution (Scheme 48).  A 6M aqueous HNO3 solution was then 
added to the stirring reaction at which point the Ag2O was solubilised and the clear solution turned 
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bright orange.  The reaction was stirred for 30 minutes at room temperature after which time the 
organic solvent was removed in vacuo to give a dark red residue.  The crude residue was purified 
by column chromatography to afford a dark red product which was characterised by NMR 
spectroscopy.  From the NMR spectral data it was clear that we had not synthesised desired 
product 168, but we had gone one step further and actually isolated the 5-H-
dibenzo[c,g]chromene-7,12-dione 154 in a 60% yield.   
 
Compound 154 is a known compound and comparison of our spectroscopic data with that of 
Onofrey et al. showed good agreement.80  Perhaps the most obvious evidence that this 
transformation had occurred was the absence of the two OCH3 signals in both the 
1H and 13C NMR 
spectra.  The 13C NMR now also showed two distinct carbonyl signals at 179.17ppm and 
177.19ppm.  Another good indication that the ring closure had occurred was the absence of the 
broad O-H signal in the 1H NMR spectrum.  To be absolutely sure that we had isolated compound 
154, a HRMS was performed and showed the desired molecular ion of C17H10O3 at 262.0625, 
which correlates very well to the calculated mass of 262.0630.   
 
This was an unexpected, but exciting, result as it gave some indication that the ring closing 
methodology we wished to employ for the synthesis of 5,6-dihydro benzo[b]phenanthridine-7,12-
dione 153 and 5,6-dihydrophenanthridine-1,4-dione 161 scaffolds may be effective.  It was clear 
that on oxidation of compound 167 the intra-molecular Michael addition occurred spontaneously to 
afford compound 154.   
 
4. Synthesis and Mechanistic Studies of 12-Methoxy-6H-dibenzo[c,h]chromen-6-one 170 
 
 
 
Scheme 49 Proposed Cu(I)Br Catalysed Ring-Closure for the Synthesis of Compound 154 ; i) 
Cu(I)Br; ii) Oxidation 
 
As a second approach we thought that if we could first close the ring to form the desired 
polyaromatic scaffold, we could then oxidise it to form the 5-H-dibenzo[c,g]chromene-7,12-dione 
154 with less chance of side reactions occurring (Scheme 49).  To perform this transformation we 
first needed to brominate in the remaining ortho-position of compound 167 before removing the 
alcohol proton and replacing it with a Na+ ion.93  We could then attempt a copper(I)halide-catalysed 
ring-closure where the ortho-bromine is replaced with the oxygen atom, forming the polyaromatic 
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scaffold.93  Oxidation of this compound will then hopefully yield the desired product 154 
(Scheme 49). 
 
4.1 Synthesis of 12-Methoxy-6H-dibenzo[c,h]chromen-6-one 170 
 
Before attempting a Cu(I)Br-catalysed ring-closure, we needed to first synthesise the ortho-
brominated starting material 169 (Scheme 50).  To a stirring solution of [2-(1,4-
dimethoxynaphthalen-2-yl)phenyl]methanol 167 in dry CH2Cl2 was added 1 equivalent of NBS.  
The reaction mixture was stirred at room temperature for 21 h during which time the reaction 
changed from clear to dark red in colour.  After the work-up, the crude product was purified by 
column chromatography and the white solid was characterised by NMR spectroscopy.   From the 
NMR data it was clear that we had not isolated desired product 169, but had instead synthesised 
12-methoxy-6H-dibenzo[c,h]chromen-6-one 170 in an 86% yield (Scheme 50).   
 
 
 
 
Scheme 50 Synthesis of 12-Methoxy-6H-dibenzo[c,h]chromen-6-one 170 Reagents and 
Conditions; NBS, CH2Cl2, rt, 21 h 
 
Our spectroscopic data was in agreement with those of Qabaja and Jones and showed clearly that 
we had in fact synthesised compound 170.88  The 1H NMR spectrum showed only one OCH3 peak 
at 4.10 ppm; likewise, in the 13C NMR spectrum which showed this signal at 52.3 ppm.  The 
carbonyl signal of the ester was seen clearly at 161.4 ppm in the 13C NMR spectrum.  Other 
evidence to suggest that this was indeed compound 170 was the presence of a clear singlet at 
7.21 ppm in the 1H NMR spectrum which corresponded to aromatic proton H3.  We could also no 
longer see the benzylic protons or the O-H signal in the 1H spectrum, verifying that this ring closure 
had occurred. 
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Figure 28 Ortep Diagram of Compound 170 
(Showing the 50% probability thermal ellipsoids for all non-hydrogen atoms). 
 
Further evidence that we had indeed synthesised the unexpected compound 12-methoxy-6H-
dibenzo[c,h]chromen-6-one 170 was that an X-ray crystal structure for the compound was obtained 
(Figure 28).  The Ortep diagram of compound 170 clearly shows the benzonaphthopyranone 
scaffold and corroborates our NMR spectroscopy and HRMS data. 
 
Although we never managed to synthesise the desired compound 169, this is a far more interesting 
and novel result and also proved to be highly reproducible.  NBS is known to oxidise aldehydes to 
acid bromides in the presence of a radical initiator, so it not impossible that NBS is firstly oxidising 
the benzylic alcohol to the aldehyde and then converting the aldehyde to an acid bromide, thereby 
facilitating the observed ring closure to occur.94  We will also make an attempt at elucidating the 
mechanism of this novel result in the discussion to follow.  It was this exciting new discovery that 
led to the second major aim of this project as 12-methoxy-6H-dibenzo[c,h]chromen-6-one 170 is a 
scaffold found in a group of natural product antibiotics.67  These benzonaphthopyranone-containing 
antibiotics also show some interesting biological applications and the synthesis of these types of 
compounds is virtually unexplored in the literature.67  Our second major aim was to thus see if we 
could extend this NBS oxidation and ring-closing methodology to a variety of other structurally 
related substrates in the hope of providing a general reaction procedure for the synthesis of a 
range of benzonaphthopyranone molecules.       
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4.2 Mechanistic Studies on the Synthesis of 12-Methoxy-6H-dibenzo[c,h]chromen-6-one 170 
 
4.2.1 Mechanistic Study 1:  Attempted Synthesis of 12-Methoxy-6H-dibenzo[c,h] chromen-6-one 
170 from Aldehyde Intermediate 166 
 
The proposed mechanism for the novel NBS ring-closure, which resulted in the synthesis of 12-
methoxy-6H-dibenzo[c,h]chromen-6-one 170 from 2-(1,4-dimethoxynaphthalen-2-
yl)phenyl)methanol 167, is thought to proceed from the use of NBS as an oxidising agent (Scheme 
51).  It is speculated that NBS oxidises the benzylic alcohol to an aldehyde releasing radicals into 
the solution.  NBS is known to oxidise aldehydes to acid bromides under radical mediation, and it is 
believed that this is what is occurring during our reaction.94  Once the activated acid bromide 
intermediate has been formed, nucleophilic attack of the methoxy group on the carbonyl of the acid 
bromide will result in the ring-closure as the halide is an excellent leaving group.  There is literature 
precedent for this type of substitution reaction and numerous examples show the use of the 
activated acid bromide as an intermediate on route to the synthesis of esters or amides.94, 95 
 
 
 
Scheme 51 Proposed Mechanism for the Synthesis of 170 Using NBS as a Radical Oxidising 
Agent 
 
In order to determine if the proposed mechanism is a viable one we wished to see if treatment of 
the aldehyde intermediate 166 with NBS under radical mediation would afford the final ring-closed 
product 170.  Should this reaction succeed in yielding product 170 we could conclude that the 
benzylic alcohol of compound 167 is indeed being oxidised by NBS to the aldehyde, before being 
converted to the acid bromide and undergoing ring closure.  To test this hypothesis 2-(1,4-
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dimethoxynaphthalen-2-yl)benzaldehyde 166 was dissolved in CH2Cl2 and treated with NBS and 
AIBN (Scheme 52).  After 21 hours a TLC of the reaction solution revealed only starting material 
and an extra equivalent of NBS and AIBN were added to the stirring solution.  The reaction was 
stirred for a further 23 hours before being quenched with saturated aqueous Na2SO3.  The organic 
products were extracted and the solvent removed in vacuo to afford a white solid which was 
purified by column chromatography.  The purified white solid was characterised by NMR 
spectroscopy and was identified, not as desired product 170, but as ortho-brominated product 2-(3-
bromo-1,4-dimethoxynaphthalen-2-yl)benzaldehyde 171 in 88% yield (Scheme 52). 
 
 
 
Scheme 52 Synthesis of 2-(3-Bromo-1,4-dimethoxynaphthalen-2-yl)benzaldehyde 171 Reagents 
and Conditions; NBS, AIBN, CH2Cl2, rt, 44 h 
 
The NMR data confirmed that we had not synthesised the desired compound 170, but rather 
brominated compound 171.  This product was characterised by the disappearance of the singlet 
aromatic hydrogen in the 1H NMR spectrum due to bromination in the position ortho to the methoxy 
group.  No ring-closure had occurred as we could still observe two methoxy signals in the 1H NMR 
spectrum at 4.02 ppm and 3.48 ppm and the corresponding carbon signals were found at 150.8 
ppm and 150.3 ppm in the 13C NMR spectrum.  There was also the presence of the aldehyde 
proton in the 1H NMR spectrum, which was conclusive evidence that the aldehyde had not been 
converted to the acid bromide.  HRMS showed the presence of two molecular ions, each one 
corresponding to a different bromine isotope.  The molecular ions have masses of 370.0201 and 
372.0162 corresponding to the two isotopes C19H15O3
79Br and C19H15O3
81Br respectively.  These 
values compare favourably with the calculated values.  The IR spectrum of compound 171 showed 
the presence of the aldehyde C-H stretch at 2850cm-1 and the C=O stretch at 1727cm-1.  As these 
signal stretches are still visible in the IR spectrum we can conclude that the ring closure from the 
aldehyde to the ester did not occur. 
 
4.2.2 Mechanistic Study 2:  Attempted Synthesis of 12-Methoxy-6H-dibenzo[c,h]chromen-6-one 
170 from Benzylic Bromide  Intermediate 172 
 
Having been unable to show that the mechanism for the NBS ring-closure proceeded from the 
aldehyde intermediate 166 to the desired compound 170, we proposed another mechanism which 
advanced via a benzylic bromide intermediate 172 (Scheme 53).  It was thought that the benzylic 
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alcohol of compound 167 was perhaps being converted to a benzylic bromide intermediate 172 
under radical conditions.  NBS could then perhaps oxidise this intermediate to the required acid 
bromide needed for the ring-closure to occur, affording 12-methoxy-6H-dibenzo[c,h]chromen-6-one 
170.    
 
 
 
Scheme 53 Proposed Mechanism for the Synthesis of 12-methoxy-6H-dibenzo[c,h]chromen-6-one 
170 via a Benzylic Bromide Intermediate 
 
Before we could test if this was a viable reaction mechanism we first needed to synthesise the 
benzyl bromide intermediate 172. Previously synthesised [2-(1,4-dimethoxynaphthalen-2-
yl)phenyl]methanol 167 was dissolved in dry CH2Cl2 in a 2-neck round bottom flask fitted with a 
CaCl2 drying tube.  It was important to exclude all moisture from the reaction as we did not want 
the reverse reaction to occur once we had synthesised 2-[2-(bromomethyl)phenyl]-1,4-dimethoxy 
naphthalene 172.  Next, 5 equivalents of both PPh3 and CBr4 were added to the solution and the 
reaction was left to stir at room temperature for 3 hours (Scheme 54).  After this time the solvent 
was removed in vacuo and the resultant orange residue was purified by column chromatography to 
afford the product 172 as a yellow oil in a 95% yield.   
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Scheme 54 Synthesis of 2-[2-(Bromomethyl)phenyl]-1,4-dimethoxynaphthalene 172 Reagents and 
Conditions; PPh3, CBr4, CH2Cl2, rt, 3 h 
 
Compound 172 was characterised by NMR spectroscopy and strong evidence that the benzylic 
alcohol had indeed been converted to the benzylic bromide was the absence of an O-H signal in 
the 1H NMR spectrum.  Further evidence to support this transformation was an upfield shift of the 
CH2Br signal which was now found at 32.6 ppm in the 
13C NMR spectrum.  As the bromine atom is 
less electronegative than the oxygen atom we expected the benzylic carbon to shift upfield, which 
it did in comparison to the CH2OH signal which was found at 64.1 ppm in the 
13C NMR spectrum.  
Since there was only a small difference between the NMR spectra of compound 167 and 
compound 172, an HRMS was performed to determine if the bromination reaction had occurred.  
Strong evidence for the presence of the bromine atom was that two molecular ions were observed 
in the HRMS spectrum each one corresponding to a different bromine isotope.  HRMS shows the 
exact mass for C19H17O2
79Br to be 356.0391 and for C19H17O2
81Br to be 358.0374, which compared 
very well to the calculated values of 356.0412 and 358.0392.  The IR spectrum for compound 167 
no longer showed an O-H stretch, this confirms the disappearance of the alcohol group.   
 
Having successfully synthesised the required benzylic bromine intermediate 172, we now set out to 
test whether treatment of this intermediate with NBS and a radical initiator would give us the 
desired 12-methoxy-6H-dibenzo[c,h]chromen-6-one 170.  To a stirring solution of 2-[2-
(bromomethyl)phenyl]-1,4-dimethoxy naphthalene 172 in CH2Cl2 was added NBS and AIBN and 
the resulting yellow solution was allowed to stir at room temperature for 64 hours (Scheme 55). 
Following this time the organic products were extracted and the organic solvent was removed in 
vacuo to yield an off-white solid which was spectroscopically pure and needed no further 
purification.  Unfortunately the isolated product was not the desired compound 170, but was again 
identified as having been brominated in the position ortho to the methoxy group, affording 
compound 173 in an 88% yield. 
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Scheme 55 Synthesis of 2-Bromo-3-[2-(bromomethyl)phenyl]-1,4-dimethoxy naphthalene 173 
Reagents and Conditions; NBS, AIBN, CH2Cl2, rt, 64 h 
 
Compound 173 was once again characterised by NMR spectroscopy and perhaps the only 
evidence that bromination ortho to the methoxy on the naphthalene had occurred was the 
disappearance of the singlet proton signal from the 1H NMR spectrum.  It is also clear from the 
NMR spectra that no desired ring-closure had occurred as we could still see the presence of both 
OCH3 groups in the 
1H and 13C NMR spectra.  Also the benzylic protons were still evident in the 1H 
NMR spectrum at 4.44ppm - 4.30ppm and this indicated that oxidation to the acid bromide had not 
occurred.  HRMS further confirmed that additional bromination had occurred as this time the 
spectrum showed the presence of three molecular ions corresponding to the three bromine isotope 
patterns we were likely to see, namely:  79Br79Br, 79Br81Br and 81Br81Br.  These molecular ions were 
found at 433.9511, 435.9491 and 347.9467 and corresponded to compounds of molecular 
formulae C19H16O2
79Br2, C19H16O2
79Br81Br and C19H16O2
81Br2, respectively.  
 
Although we were unable to conclusively prove either one of our proposed reaction mechanisms it 
is still thought that mechanism 1 (Scheme 51), which proceeds via an aldehyde intermediate, is a 
more viable approach.  This is due to the fact that NBS is known to oxidise aldehydes to the 
corresponding acid bromides under radical conditions.94  Perhaps we need to vary the reaction 
conditions in order to test whether the aldehyde intermediate 166 will give the desired ring-closed 
product 12-methoxy-6H-dibenzo[c,h]chromen-6-one 170.  Literature suggests that the use of 
benzoyl peroxide as a radical initiator, as opposed to AIBN, may lead to the conversion of the 
aldehyde to the acid bromide, allowing the ring-closure to occur.95  We could also attempt the 
conversion of the aldehyde to the acid bromide using a much higher boiling solvent, e.g. CHCl3 or 
chlorobenzene, and actually heat the reaction in the hope of isolating compound 170.94  Another 
means of verifying that reaction mechanism 1 is responsible for the synthesis of compound 170 is 
to try to do the NBS ring closure on the ortho-brominated aldehyde intermediate 171.  Seeing that 
the more favourable bromination reaction has already been performed, it may be possible that 
treatment of compound 171 with NBS and a radical initiator would oxidise the aldehyde to the acid 
bromide and ring-closure could then occur.  Unfortunately due to time constraints on the project 
these strategies were never tested and the actual mechanism for the transformation of benzylic 
alcohol 167 to 12-methoxy-6H-dibenzo[c,h]chromen-6-one 170 remains to be elucidated.    
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5.  Expansion of the NBS Radical Oxidation Ring Closing Methodology for the Synthesis 
of Related Naphthopyranone Scaffolds 
 
Having been able to synthesise compound 170 from the benzylic alcohol 167 using NBS, we 
wished to determine if we could extend this methodology to the synthesis of a variety of related 
naphthopyranone scaffolds (Table 8).  As part of this study we wished to ascertain if this 
methodology could be applied in a reproducible fashion to different substrates, in the hope of 
determining an efficient method for the synthesis of napthopyranone scaffolds.  We also wished to 
test which functional groups of the compound 167 were crucial to the synthesis of compound 170.  
Our subsequent starting materials thus focused on determining if the 1,4-dimethoxy aromatic 
system and/or a naphthalene system were crucial to the success of the reaction as illustrated in 
Table 8. 
  
Table 8:  Different Starting Substrate and the Desired Naphthopyranone Motif 
 
Starting Material 
 
Naphthopyranone Product 
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5.1 Attempted Synthesis of 6H-Dibenzo[c,h]chromen-6-one 174 
 
5.1.1 Attempted Synthesis of 2-Bromo-1-methoxynaphthalene 176 
 
 
 
 
Scheme 56 Attempted Synthesis of 2-Bromo-1-methoxynaphthalene 176 Reagents and 
Conditions; i) n-BuLi, THF, 0˚C, 1 h; ii) Br2, THF, 0˚C – rt, 1 h 
 
Before we could begin building the required ring-closing substrate to test whether the presence of 
a single methoxy group on the naphthalene motif would allow for the synthesis of 
naphthopyranone 174 (Table 8) under the radical oxidation conditions, we needed to brominate in 
the ortho-position.  Knowing that the use of a brominating agent such as NBS would only afford the 
para-brominated product, we attempted to use directed-ortho metallation (DOM) to synthesise the 
desired ortho-brominated product 176 (Scheme 56).  To achieve this starting material 1-
methoxynaphthalene 175, dissolved in THF, was placed under an inert N2 atmosphere in a two-
neck round bottom flask.  The solution was cooled to 0˚C before the addition of n-BuLi which saw 
the yellow solution turn dark green, indicating that metallation had occurred.  The solution was then 
stirred at 0˚C for 1 h after which time Br2, which was dissolved in dry THF, was added dropwise to 
the solution by way of a dropping funnel until a dark orange colour was obtained.  The reaction 
was subsequently allowed to heat to room temperature and stirred for a further 1 h before being 
quenched with saturated aqueous Na2SO3.  The organic products were extracted and the solvent 
removed in vacuo to afford a crude brown oil, which was further purified by column 
chromatography to yield a yellow oil which was identified to be starting material 175.   
 
NMR spectroscopy confirmed that no bromination had occurred as all seven protons were still 
visible in the 1H NMR spectrum.  A literature survey revealed that no previous syntheses of ortho-
bromination of this compound had been reported and it was also impossible to obtain compound 
176, or its corresponding boronic acid, as commercially available compound from a fine chemicals 
supplier.  We had to thus abandon this synthesis and could not establish if the NBS radical 
oxidation methodology would work in the case of the synthesis of compound 174. 
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5.2 Attempted Synthesis of 2-Methoxy-6H-benzo[c]chromen-6-one 177 
 
5.2.1 Synthesis of 2’,5’-Dimethoxybiphenyl-2-carbaldehyde 178 
 
 
 
Scheme 57 Synthesis of 2‟,5‟-Dimethoxybiphenyl-2-carbaldehyde 178 Reagents and Conditions; 
Pd(dba)2, PPh3, 2M aq. Na2CO3, DME, EtOH, reflux, 19 h 
 
Before we could test whether the NBS radical oxidation ring-closing procedure would afford the 
desired compound 177 (Table 8) we needed to build the biaryl axis from which we could acquire 
the pre-ring closing substrate.  Suzuki-Miyaura cross coupling was once again employed to afford 
the desired compound 178 (Scheme 57).  Having depleted our available supply of Pd(PPh3)4 we 
decided to attempt the synthesis of Pd(PPh3)4 in situ from Pd(dba)2 and then adding the 
compounds needing to be coupled in Suzuki fashion.  Pd(dba)2 was then dissolved in DME in a 
round bottom flask and the resultant purple solution was degassed with N2 and placed under an 
inert atmosphere. Next PPh3 was dissolved in DME, degassed and added to the reaction mixture 
and the solution was stirred at room temperature for 30 minutes during which time the solution 
changed from purple to yellow in colour, indicating that Pd(PPh3)4 had been synthesised.  
Previously synthesised 2-bromo-1,4-dimethoxybenzene 162 and commercially available 2-
formylphenylboronic acid were then dissolved in DME and EtOH, degassed and added to the 
yellow solution (Scheme 57).  Finally an aqueous 2M Na2CO3 solution was degassed, added to 
the stirring solution and the reaction mixture was set to reflux for 19 hours before being quenched 
with H2O.  The organic products were extracted and the solvent removed in vacuo to afford a crude 
brown oil, which was purified by column chromatography to afford product 178 as a light brown oil 
in a 64% yield.   
 
Compound 178 was characterised by NMR spectroscopy and the spectroscopic data was in 
agreement with Zhao et al.96  The compound was identified by the presence of the aldehyde proton 
at 9.79 ppm in the 1H NMR spectrum and the aldehyde carbonyl carbon at 192.5 ppm in the 13C 
NMR spectrum.  Further evidence to suggest that the Suzuki-coupling had occurred was the 
occurrence of four additional proton signals in the 1H NMR spectrum, which was confirmed by the 
presence of four additional aromatic C-H signals in the 13C NMR spectrum.  
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5.2.2 Synthesis of (2’,5’-Dimethoxybiphenyl-2-yl)methanol 179 
 
 
 
Scheme 58 Synthesis of (2‟,5‟-Dimethoxybiphenyl-2-yl)methanol 179 Reagents and Conditions; 
LiAlH4, THF, rt, 2 h 
 
Having successfully synthesised compound 178, we could now reduce the aldehyde to the 
benzylic alcohol to afford the pre-ring closure product 179 (Scheme 58).  Starting material 2‟,5‟-
dimethoxybiphenyl-2-carbaldehyde 178 was dissolved in dry THF and treated with 3.0 equivalents 
of LiAlH4.  The resulting solution was stirred at room temperature for 2 h before being quenched 
with H2O, the organic products extracted and the organic solvent removed in vacuo to afford an 
oily residue.  Purification of the crude product by flash chromatography afforded the desired 
compound 179 as a clear oil in an 80% yield. 
 
The compound was characterised by NMR spectroscopy and both the 1H and 13C NMR spectra no 
longer showed the presence of the aldehyde moiety in the molecule.  In addition the 1H NMR 
spectrum showed a broad singlet at 2.78 ppm corresponding to the O-H group and a signal at 4.39 
ppm which corresponded to the benzylic protons.  The 13C NMR spectrum verified this observation 
and showed a signal at 63.5 ppm coinciding with the benzylic carbon, CH2OH.  HRMS further 
verified that the reduction had occurred and showed a molecular ion at 244.1031 corresponding to 
a molecular formula of C15H16O3.  IR spectroscopy of compound 179 confirmed that the reduction 
reaction had occurred by the disappearance of the aldehyde signals and the presence of an O-H 
stretch at 3420cm-1. 
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5.2.3 Attempted Synthesis of 2-Methoxy-6H-benzo[c]chromen-6-one 177 
 
 
 
Scheme 59 Synthesis of 3-Bromo-2-methoxy-6H-benzo[c]chromen-6-one 180 Reagents and 
Conditions; NBS, AIBN, CHCl3, rt – reflux, 21 h 
 
Having the pre-ring closure product 179 in hand we now wished to determine whether treatment of 
this compound with NBS would yield the desired 2-methoxy-6H-benzo[c]chromen-6-one 177 
(Table 8).  Starting material (2‟,5‟-dimethoxybiphenyl-2-yl)methanol 179 was dissolved in CHCl3 
and 1.0 equivalent of NBS and 0.2 equivalents of AIBN  were added to the solution (Scheme 59).  
The AIBN was added for this reaction as the same synthesis attempted using only NBS failed to 
afford the desired product.  After stirring at room temperature for 16 hours a TLC revealed only 
starting material to be present and the reaction was thus set to reflux for 3 hours, after which time 
the clear solution had turned orange.  The organic products were then extracted, the solvent 
removed in vacuo and purified by column chromatography to yield a white solid. This white solid 
was characterised by NMR spectroscopy and revealed not to be desired compound 177 (Table 8), 
but rather the desired brominated compound 3-bromo-2-methoxy-6H-benzo[c]chromen-6-one 180 
(Scheme 59) which was isolated in a 32% yield.   
 
Both the 1H and 13C NMR spectra provide strong evidence that compound 180 had been 
synthesised, as we see the presence of only one methoxy peak in both spectra.  A clear carbonyl 
signal was seen at 160.7 ppm in the 13C NMR which corresponded to the ester carbonyl carbon 
and indicated that oxidation had in fact occurred.  We are also certain that bromination in an ortho-
position to a methoxy group did occur as the 1H NMR spectrum does not integrate for the required 
number of protons in compound 177.  The clear singlet at 7.46 ppm in the 1H NMR spectrum was 
another good indication that this ortho-bromination had occurred.  We suspect that bromination 
occurred in the 5-position and not in the 6- or 3-positions as we would not have seen the clear 
singlet, but rather a doublet with a ortho-coupling constant of at least 8.0 Hz or a doublet with a 
meta-coupling constant of about 1.2 Hz respectively.  HRMS confirmed that compound 180 had 
been synthesised as it showed two clear molecular ion peaks each corresponding to one of the 
bromine isotopes, 79Br and 81Br.  These molecular ion peaks were found at 303.9741 and 305.9720 
and coincided with compounds of molecular formulae C14H9O3
79Br and C14H9O3
81Br.  The IR 
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spectrum of compound 180 provided some evidence that the ring closure had occurred, as the 
O-H stretch of compound 179 had disappeared and was replaced by the C=O stretch of an ester at 
1734cm-1. 
 
It was thought that since NBS is known to oxidise aldehydes to acid bromides under radical 
conditions we decided to use a radical initiator for this reaction, as opposed to just treatment with 
NBS.94  A higher boiling solvent than CH2Cl2 was also used should we require added activation 
energy to afford the desired transformation, which was the case during our reaction.  It appears 
that the NBS radical oxidation ring-closure can be applied to different substrates which contain a 
di-methoxy motif, as indicated by the synthesis of compound 180.  Although the yield of this 
reaction was quite poor it is believed that this yield can be improved upon.  Our reaction was 
performed on a 30mg scale with potential for losses during work-up and column chromatography 
procedures, and had this reaction been performed on a larger scale we may have isolated the 
product in a higher yield.  Furthermore it may be impossible to synthesise compound 180 without 
the NBS brominating in the ortho-position to one of the methoxy groups as well.  This due to the 
fact that NBS is a known brominating agent and bromination ortho to a methoxy group is the first 
desired reaction.  This has two important consequences; one it may lead to losses in the yield of 
isolated product 180 and we may need to use two equivalents of NBS for compounds which can 
still undergo bromination reactions; and two, we could use this brominated scaffold as a handle for 
further Suzuki-coupling reactions which may allow us to build larger and more complex 
naphthopyranone products.  One may be asking why bromination did not occur at the 3-position of 
compound 170 (Scheme 50) and it is believed that classic steric hindrance may be a factor.46  The 
5-position in compound 180 provided a sterically unhindered position where bromination could 
occur, and this is another reason why we believe that bromination occurred at this site and not in 
the 3- or 6-postions.  
 
5.3 Attempted Synthesis of 6H-Benzo[c]chromen-6-one 181  
 
5.3.1 Synthesis of 2-Methoxybiphenyl-2-carbaldehyde 182 
 
 
 
Scheme 60 Synthesis of 2-Methoxybiphenyl-2-carbaldehyde 182 Reagents and Conditions; 
Pd(dba)2, PPh3, 2M aq. Na2CO3, DME, EtOH, reflux, 26 h 
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We also wished to determine whether NBS could be used to synthesise 6H-benzo[c]chromen-
6-one 181, if we started with anisole (Table 8).  This synthesis would play an integral part in 
determining whether the NBS ring-closure could only be applied to di-methoxy containing 
substrates, or if this transformation was a completely general reaction.  In order to begin the 
synthesis of compound 181 (Table 8), we once more first needed to build the biaryl axis of the pre-
ring closure compound.  Once again Pd(dba)2 and PPh3 were dissolved in DME, degassed and 
allowed to stir under an inert atmosphere for 30 minutes to produce Pd(PPh3)4 in situ.  After this 
time, commercially available starting materials 2-methoxyphenylboronic acid and 2-
bromobenzaldehyde were dissolved in DME and EtOH, degassed and added to the now yellow 
solution (Scheme 60).  A degassed 2M aqueous Na2CO3 solution was then added to the reaction 
mixture and the reaction was heated at reflux for 26 h.   The organic products were extracted and 
the solvent removed in vacuo to give a crude brown oil, which was further purified by flash 
chromatography to afford the product 182 as a yellow oil in a 99% yield.   
 
The compound 182 was characterised by NMR spectroscopy and the spectroscopic data was in 
agreement with those of Zhao et al.96  A defining characteristic of the synthesised compound was 
the presence of the aldehyde proton in the 1H NMR spectrum at 9.79 ppm and the aldehyde 
carbonyl in the 13C NMR spectrum at 192.6 ppm.  Further evidence that the Suzuki-coupling 
reaction had occurred was that the 1H NMR spectrum integrated for the correct number of aromatic 
protons and also showed the OCH3 signal as a clear singlet at 3.73 ppm.   
 
5.3.2 Synthesis of (2’-Methoxybiphenyl-2-yl)methanol 183 
 
 
 
Scheme 61 Synthesis of (2‟-Methoxybiphenyl-2-yl)methanol 183 Reagents and Conditions; LiAlH4, 
THF, rt, 15 min 
 
Having successfully synthesised compound 182 we could now reduce the aldehyde to the benzylic 
alcohol 183 (Scheme 61), which we required for the NBS radical oxidation reaction.  To a stirring 
solution of 2-methoxybiphenyl-2-carbaldehyde 182 in dry THF was added 3.0 equivalents of LiAlH4 
and the resultant solution was left to stir at room temperature for 15 min.  The extracted organic 
product was purified by flash chromatography to give the desired product 183 as a clear oil in a 
76% yield.   
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Compound 183 was characterised by NMR spectroscopy and both the 1H and 13C NMR 
spectra showed that the aldehyde had indeed been reduced to the benzylic alcohol as there was 
no evidence of the aldehyde proton or carbonyl.  The 1H NMR spectrum showed a broad singlet at 
2.60 ppm which corresponded to the O-H and a signal at 4.36ppm which corresponded to the 
benzylic protons.  The benzylic carbon signal CH2OH is found in the 
13C NMR spectrum at 63.4 
ppm.  HRMS further corroborated that the correct compound had been synthesised as there was a 
molecular ion peak at 214.0986 which corresponded to C14H14O2 molecular formula of compound 
183.  Further evidence that the reduction reaction had occurred was provided by the presence of 
an O-H stretch at 3219cm-1 in the IR spectrum of compound 183.    
 
5.3.3 Attempted Synthesis of 6H-Benzo[c]chromen-6-one 181 
 
 
Scheme 62 Attempted Synthesis of 6H-Benzo[c]chromen-6-one 181 Reagents and Conditions; 
NBS, AIBN, CHCl3, reflux – rt, 53 h 
 
Having successfully synthesised compound 183 we wanted now to determine if treatment with 
NBS and a radical initiator would lead to the synthesis of 6H-benzo[c]chromen-6-one 181 (Table 
8).  To a stirring solution of starting material 183 dissolved in CHCl3 were added 1.0 equivalent of 
NBS and 0.2 equivalents of radical initiator AIBN (Scheme 62).  The solution was heated at reflux 
for 6 hours, cooled and stirred at room temperature for a further 47 hours. After this time the 
solution was quenched with saturated aqueous Na2SO3, the organic products were extracted and 
the solvent removed in vacuo to give a crude residue.  This residue was purified by flash 
chromatography to afford two products, an off-white solid which was characterised to be product 
184a in a 22% yield, and a white solid which was thought to be products 184b or 184c (Scheme 
62).  The compounds were inseparable by chromatography or recrystallisation and made 
characterisation of these compounds very difficult. 
 
Compound 184a was characterised by NMR spectroscopy and both the 1H and 13C NMR spectra 
provided strong evidence that this was not the desired compound 181.  The presence of the 
methoxy group in the 1H NMR at 3.73ppm and in the 13C NMR at 55.76ppm verified that the 
oxidation and ring-closure had not occurred.  The OH group of compound 183 has also been 
replaced by a bromine atom; this is shown by the disappearance of the O-H signal in the 1H NMR 
spectrum and the upfield shift of the benzylic carbon CH2Br to 31.85ppm, as opposed to 63.40ppm 
for the CH2OH.  It was also observed that bromination has occurred as the 
1H NMR spectrum only 
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integrates for 7 aromatic protons as opposed to 8 expected aromatic protons.  HRMS was also 
performed, but provided no valuable information about the compound as a molecular ion or a 
discernable fragment was not obtained.  IR spectroscopy also helped confirm that the benzylic 
alcohol of compound 183 had been replaced by a bromine atom, as the spectrum of 184a did not 
show the presence of the O-H stretch.   
  
We also attempted to characterise the compounds 184b and 184c by NMR spectroscopy, but as 
these compounds were inseparable the NMR spectra were not very helpful in properly identifying 
the molecules.  Certain key characteristics were present in the 1H NMR spectrum and were used to 
give some direction to our assignment of the white solid as compounds 184b and 184c.  The 
presence of an aldehyde proton was seen at 9.77 ppm, which corresponded to the characterisation 
of one of these compounds as an aldehyde.  We could also see what may be an O-H signal at 1.73 
ppm and leads to the characterisation of the other compound as a carboxylic acid.  This O-H signal 
is more probably from a carboxylic acid and not a benzylic alcohol as the 1H NMR spectrum shows 
no presence of these benzylic protons.  IR spectroscopy proved very helpful in this instance as it 
helped to confirm the suspicion that the inseparable compounds 184b and 184c may indeed be 
aldehyde and carboxylic acid respectively.  The IR spectrum showed an O-H stretch at 3071cm-1, 
which likely corresponds to a carboxylic acid.  It also showed two C=O stretches at 1727cm-1 and 
1694cm-1; which correspond to the carbonyl groups of an aldehyde and a carboxylic acid 
respectively.  HRMS was also used as a characterisation tool and it was hoped that we would 
obtain molecular ions for both compound 184b and 184c; however, the spectrum only showed the 
molecular ions of compound 184b.  Two molecular ions were shown for compound 184b 
corresponding to the two bromine isotopes, these were found for C14H11O2
79Br at 289.9941 and for 
C14H11O2
81Br at 291.9928. 
 
It is important to note that many assumptions were made in the assignment of structures 184a-c to 
the compounds isolated as no characterisation evidence was conclusive.  It must also be noted 
that it is not known if these compounds underwent bromination in the position ortho or para to the 
methoxy group as both cases are equally as likely.  However it is clear that the NBS ring-closing 
procedure has not given us the desired compound 181, but it has provided us with some insight 
into the mechanism. From our results it is observed that NBS can convert a benzylic alcohol to a 
benzylic bromide under radical conditions and provides some credit to proposed mechanism 2 
(Scheme 53). However since the second fraction was isolated in a much higher yield it is perhaps 
more likely that mechanism 1 (Scheme 51) is being followed, i.e. the oxidation of the benzylic 
alcohol to an aldehyde.  In this case NBS takes this oxidation one step further and may actually 
oxidise the aldehyde to the carboxylic acid.  It appears unlikely that NBS is able to elicit the ring-
closure on compounds which only contain a single methoxy group.  This may be due to electronic 
enriching factors of an added methoxy group, but the reason is not fully understood.  This may 
seem disappointing at first, but in order to synthesise most of the naphthopyranone-containing 
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natural products we would require the presence of both methoxy groups.  There exists only 
one natural product which does not require the presence of the extra methoxy group, that 
compound is arnottin 1 131 (Figure 25).67 
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Chapter 6:  Conclusions and Future Work 
 
Synthesis of Benzo-fused Hetero-aromatic Naphthoquinone and Naphthopyranone Ring 
Systems 
 
1.  Summaries and Conclusions 
 
The selected overview in Chapter 4 highlighted some of the biological relevance and applications 
of naphthoquinone and naphthopyranone containing antibiotics.  It also exposed the limited 
methodology available for the synthesis of these types of structures; particularly the 
dihydrobenzo[b]phenanthridine motif 153, as found in the jadomycin antibiotics (Figure 24).  There 
have been no reported syntheses of this motif 153 in the literature and it was thus the main 
objective of the project to develop methodology for the synthesis of this 
dihydrobenzo[b]phenanthridine backbone (Scheme 30).   
 
1.1 Synthesis of 5,6-Dihydrobenzo[b]phenanthridine-7,12-dione 153 and 5,6-
Dihydrophenanthridine-1,4-dione 161 
 
In accordance with the first major aim of this project we wished to develop methodology for the 
synthesis of the dihdrobenzo[b]phenanthridine motif 153 (Scheme 30, pg. 75).  Unfortunately we 
were unable to synthesise compound 153 due to the fact that we were unable to reduce the nitrile 
functional group of compound 159 to the benzylic amine of compound 169 (Scheme 39, pg. 85).  
All of the reduction attempts, both hydrogenation and chemical, failed to yield the desired 
compound 2-[(1,4-dimethoxynaphthalene-2-yl)phenyl]methanamine 160.  It is not fully understood 
why the reduction of the nitrile did not afford the desired amine, but it is suspected that the 
conjugated nature of compound 159 confers extra stability to the nitrile.  Having been unable to 
synthesise amine 160 we were unable to determine whether oxidation, followed by intra-molecular 
Michael addition would afford the dihydrobenzo[b]phenanthridine motif 153 (Scheme 63). 
 
 
Scheme 63 Proposed Methodology for the Synthesis of the Dihdrobenzo[b] phenanthridine motif 
153 
 
Having been unable to synthesise the desired dihydrobenzo[b]phenanthridine backbone 153, as 
we could not reduce compound 159 to the corresponding amine 160, we decided to test the 
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proposed methodology on a simpler system.  Following a similar synthetic strategy as that 
used for the synthesis of 2-(1,4-dimethoxynaphthalen-2-yl)benzonitrile 159, we set out to 
synthesise 2‟,5‟-dimethoxybiphenyl-2-carbonitrile 164, from which we could test the planned 
reduction, oxidation and intra-molecular Michael addition synthetic steps.    Unfortunately following 
the synthesis of compound 164, we were once again unable to reduce the nitrile functional group 
of compound 164 to the corresponding amine 165 under the reduction conditions discussed.  This 
meant that we could not determine whether the subsequent oxidation and intra-molecular ring-
closure steps would yield the desired 5,6-dihydrophenanthridine-1,4-dione scaffold 161 (Scheme 
39). 
 
1.2 Synthesis of 5H-Dibenzo[c,g]chromene-7,12-dione 154 
 
For our final attempt at determining whether the methodology shown in Scheme 30 would yield the 
desired product 5,6-dihydrobenzo[b]phenanthridine-7,12-dione 153 should we obtain the required 
amine, we synthesised the oxygen derivative 5H-dibenzo[c,g]chromene-7,12-dione 154.  Having 
successfully reduced the aldehyde functional group of 2-(1,4-dimethoxynapthalene-2-
yl)benzaldehyde 166 to the benzylic alcohol 167 using LiAlH4, we were able to test whether 
oxidation of compound 167 would give the Michael addition precursor 168 (Scheme 47, pg. 92).  
To our surprise, oxidation of compound 167 with Ag2O did not give compound 168, but rather 
yielded the final ring-closed product, 5H-dibenzo[c,g]chromene-7,12-dione 154 (Scheme 48, pg. 
92).   This exciting result gave some indication that the ring-closing strategy we wished to employ 
in the synthesis of phenanthridine scaffolds 153 and 161 may be effective should we yield the 
desired amine precursors 160 and 165. 
 
1.3 Synthesis of 12-Methoxy-6H-dibenzo[c,h]chromen-6-one 170 
 
During an attempt at formulating a different ring closing strategy for the synthesis of 5H-
dibenzo[c,g]chromene-7,12-dione 154, which would result in less side reactions, a novel and 
interesting reaction occurred.  In an effort to brominate the 3‟-position of compound 167 we used a 
standard brominating reagent, NBS.  NBS did not perform the bromination as expected, but 
instead performed a ring-closure on compound 167 which resulted in the synthesis of 12-methoxy-
6H-dibenzo[c,h] chromen-6-one 170 (Scheme 50, pg. 94).  This exciting discovery led to the 
second major aim of this project, the extension of this NBS oxidative ring-closure to a variety of 
structurally related substrates in the hope of forming a general reaction procedure for the synthesis 
of a range of benzonaphthopyranone molecules.   
 
Before we could begin extending this methodology to related substrates it was important that we 
elucidate the mechanism for this novel transformation.  Two different attempts at determining the 
mechanism were undertaken and both failed to conclusively identify the correct mechanism.  The 
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first mechanistic study proposed that NBS was oxidising the benzylic alcohol to an aldehyde 
and releasing radicals into the solution.  Under these radical conditions it was thought that NBS 
was oxidising the aldehyde to an acid bromide facilitating the ring-closure (Scheme 51, pg. 96).  
However, when we tested this hypothesis by starting from what would be the aldehyde 
intermediate none of the expected product 170 was isolated.  Characterisation of the compound 
showed that under the NBS and AIBN reaction conditions, bromination had occurred in the 3‟-
position (Scheme 52, pg. 97).  The second mechanistic study then proposed that the benzylic 
alcohol of compound 167 was being converted to a benzylic bromide intermediate 172, which 
under radical conditions was oxidised to the acid bromide required for the ring-closure (Scheme 
53, pg. 98).  However, when we tested this hypothesis using the benzylic bromide intermediate 
172, it was found once again that bromination had occurred in the 3‟-position of compound 172 
(Scheme 55, pg. 100) and no ring-closure had happened.  Neither of the mechanistic studies 
allowed us to fully elucidate the mechanism for the synthesis of 12-methoxy-6H-
dibenzo[c,h]chromen-6-one 170, however we still believe that mechanism 1 is the correct 
mechanism (Scheme 51, pg. 96) as NBS is known to oxidise aldehydes to the corresponding acid 
bromides.   
 
1.4 Expansion of the NBS Radical Oxidation Ring Closing Methodology 
 
In accordance with the final aim of this project we wished to determine if the novel NBS reaction 
methodology which resulted in compound 170 could be applied to different related starting 
substrates.  We also wished to test which functional groups of compound 167 were crucial in the 
synthesis of the naphthopyranone motif 170 and develop an efficient method for the synthesis of 
naphthopyranone scaffolds. 
 
1.4.1 Synthesis of 6H-Dibenzo[c,h]chromen-6-one 174 
 
This substrate was chosen to determine whether the NBS reaction could be carried out on a 
naphthalene system which contains only one methoxy group.  Unfortunately we could not test this 
as brominating in the ortho-position to the methoxy group of compound 175 was impossible 
(Scheme 56, pg. 102) and thus the subsequent reaction steps could not be carried out. 
 
1.4.2 Synthesis of 2-Methoxy-6H-benzo[c]chromen-6-one 177  
 
This substrate was chosen to test whether the NBS ring-closing methodology could be extended to 
a benzene system.  Under radical conditions NBS completed the desired transformation, but it was 
also noted that bromination had occurred in one of the positions ortho to the methoxy group 
(Scheme 59, pg. 105).  We could conclude that the NBS oxidative ring-closure can be applied to 
different substrates which contain a di-methoxy motif as indicated by the successful synthesis of 
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compound 180.  It may however be impossible to perform this reaction on this type of substrate 
without bromination in addition to the ring-closure.  NBS is a known brominating agent and will 
probably perform the bromination reaction first if there is position available.  However, this may 
also be of interest as we could use the bromine atom as a handle for further Suzuki-coupling 
reactions which may allow us to build larger and more complex naphthopyranone products. 
 
1.4.3 Synthesis of 6H-Benzo[c]chromen-6-one 181 
 
This final substrate was chosen to determine whether a benzene ring with a single methoxy group 
would be able to undergo the NBS transformation.  Our results suggest that this is not the case 
and that a di-methoxy motif is essential for ring closure.  Treatment of the benzylic alcohol 
containing compound 183 with NBS under radical conditions led to the isolation of three different 
compounds (Scheme 62, pg. 108), none of which had undergone ring-closure.  This reaction did 
give us some important information about the mechanism as from the results in can be seen that 
NBS can convert a benzylic alcohol to a benzylic bromide under radical conditions, which gives 
some credit to proposed mechanism 2 (Scheme 53, pg. 98).  However compounds 184b and 184c 
were isolated in a much higher yield which suggests that the NBS is acting as an oxidising agent 
converting the benzylic alcohol to an aldehyde as per mechanism 1 (Scheme 51, pg. 96). 
 
2.  Future Work 
 
Although we were unable to synthesise the desired compound 5,6-dihydrobenzo[b] 
phenanthridine-7,12-dione 153, it is still worthwhile pursuing this methodology as demonstrated by 
the synthesis of 5H-dibenzo[c,g]chromene-7,12-dione 154.  Should we obtain the desired amine 
precursors we may then be able to obtain compound 153 and 161, which are extremely valuable 
synthetic targets.  We could perhaps force the reduction of the nitrile functional group to the amine 
by performing the reduction reactions at higher temperatures.  The reduction reactions using 
LiAlH4 and Raney nickel were done only at low temperatures and it is thought that should we heat 
the reactions sufficiently we may be able to overcome the activation energy barrier conferred to the 
nitrile by conjugation.  Should these attempts still fail to yield the required amine precursors, 
literature suggests that a benzylic alcohol can be converted to a benzylic amine via a one step 
process.97  This means that previously synthesised [2-(1,4-dimethoxynaphthalen-2-
yl)phenyl]methanol 167 can be converted to the required amine 160 by treatment with sodium 
azide and triphenyl phosphine (Scheme 64).97  We could then proceed with the proposed oxidation 
and intra-molecular Michael addition steps, which will hopefully yield 5,6-
dihydrobenzo[b]phenanthridine-7,12-dione 153.  The same strategy can be adopted for the 
synthesis of 5,6-dihydrophenanthridine-1,4-dione 161, as the benzylic alcohol of easily synthesised 
(2‟,5‟-dimethoxybiphenyl-2-yl)methanol 179 can similarly be converted to the benzylic amine by 
treatment with sodium azide and triphenyl phosphine.  Once again we can then test if treatment 
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with an oxidising agent followed by intra-molecular Michael addition will afford the desired 
compound 161. 
 
 
 
Scheme 64:  Proposed Conversion of Compound 167 to Desired Amine Product 160 Reagents 
and Conditions; i) NaN3, PPh3, CH2Cl2, DMF, 90˚C, 4 h 
97 
 
Another important aspect of this project which needs still needs to be addressed in the future is the 
full elucidation of the mechanism for the ring-closure which resulted in the synthesis of 12-
methoxy-6H-dibenzo[c,h]chromen-6-one 170.  It is thought that we may need to vary the reaction 
conditions in order to test whether the aldehyde intermediate 166 will give the desired ring-closed 
product 170, thus showing the reaction to proceed via mechanism 1.  We could do this by perhaps 
using a higher boiling solvent or a different radical initiator, such as benzoyl peroxide.94  Another 
way of verifying that mechanism 1 is the correct mechanism is to attempt the NBS ring-closure on 
the ortho-brominated aldehyde intermediate 171 (Scheme 52, pg. 97).  As the more favourable 
bromination reaction has already occurred it may mean that treatment of 171 with NBS and a 
radical initiator would easily oxidise the aldehyde to the acid bromide allowing ring-closure to 
occur. 
 
Finally having determined that NBS and a radical initiator can be used effectively and reproducibly 
to synthesise the naphthopyranone scaffold we wish to extend this methodology to a variety of 
natural products in the future.  Many of the natural products can be retro-synthesised back to easily 
prepared or commercially available Suzuki-Miyaura cross-coupling precursors from which we can 
build the required biaryl axis.  An example is that of the defucogilvocarcin antibiotics, where 
defucogilvocarcin M 142 (Figure 27) is thought can be easily prepared from boronic acid 185 and 
aryl halide 186 (Scheme 65).  The synthesis of the aromatic bromine precursor of compound 185 
has been described by Jung et al.98 and is a good building block from which other 
naphthopyranone containing natural products can be synthesised.   
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Scheme 65 Retro-synthetic Approach to the Synthesis of defucogilvocarcin M 142 
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Chapter 7:  Experimental Procedures 
 
1.  General Experimental Procedures 
 
1.1 Purification of Solvents and Reagents  
 
All solvents used for chromatographic purposes and work-up procedures were distilled prior to use 
by means of conventional distillation procedures.  Solvents used in reactions were pre-dried in their 
reagent bottles and then distilled over the appropriate drying mediums under a nitrogen 
atmosphere.  Solvents n-butanol, 1,4-dioxane and ethanol (EtOH) were not pre-dried or distilled.  
Tetrahydrofuran (THF) and diethyl ether (Et2O) were distilled from sodium wire using 
benzophenone as an indicator. Acetonitrile (MeCN), dichloromethane (CH2Cl2) and N,N-dimethyl 
formamide (DMF), methanol (MeOH) and triethylamine were distilled from calcium hydride. 
Chloroform (CHCl3) was dried over 4Ǻ molecular sieves. 
 
1.2 General Procedures 
 
Where indicated reactions were performed under an inert atmosphere of nitrogen using a standard 
manifold line and connected to a vacuum pump.  The nitrogen was dehydrated by bubbling the gas 
through sulphuric acid, and then neutralizing by passing the gas over sodium hydroxide pellets. 
 
Concentration or evaporation in vacuo refers to the removal of solvent under reduced pressure 
(approximately 20mmHg, 40-50˚C) on a rotary evaporator and final drying on an oil pump 
(approximately 1-2mmHg) at room temperature.  
 
Hydrogenations were set up in a Bűchiglasuster picoclave “Parr Hydrogenator” with a built in stirrer 
and a maximum pressure of 8 bar. 
 
1.3 Chromatographic Separations 
 
Separation of compounds by column chromatography was performed using Merck or Fluka silica-
gel (particle size 0.200-0.063mm).  The silica was packed into a suitable size column; the product 
was loaded onto the silica surface and then covered in acid washed sand or cotton wool.  The 
elution process was performed using the indicated solvent mixture.  Rf values quoted are for thin 
layer chromatography (TLC) which was performed using Merck silica-gel 60 F254 coated aluminium 
sheets.  Compounds on the TLC plates were viewed under UV light or by staining the plates with 
basic potassium permanganate. 
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1.4 Spectroscopic and Physical Data 
 
1H NMR spectra were recorded either on a Bruker AVANCE 300 spectrometer or on a Bruker 
DRX-400 spectrometer 300.13 and 400.13MHz respectively using standard pulse sequences.  The 
probe temperature for all experiments was 300±1K.  All spectra were recorded in deuterated 
chloroform (CDCl3) in 5mm NMR tubes.  Chemical shifts are reported in parts per million (ppm) 
relative to the tetramethylsilane as the internal standard.  The 1H NMR chemical shifts are reported 
as follows: value (number of hydrogens, multiplicity of signal, coupling constants in hertz (Hz) 
where applicable and assignment).  Abbreviations used: s=singlet, d=doublet, t=triplet, q=quartet 
and m=multiplet.   
 
Decoupled carbon nuclear magnetic resonance (13C NMR) spectra were recorded on either a 
Bruker AVANCE 300 spectrometer or on a Bruker DRX-400 spectrometer at frequencies of 75MHz 
or 101MHz respectively.  Chemical shifts are reported on the δ scale relative to the central signal 
of deuterated chloroform taken as δ 77.00.  The 13C chemical shifts are reported as follows: value 
(assignment).  The 1H and 13C NMR spectroscopic assignments with the *superscript are 
interchangeable.  CH-correlated spectra were routinely run to enable more complete assignment of 
the signals.   
 
Infra-red spectra were recorded on a Bruker Tensor 27 Fourier Transform spectrometer with 
diamond ATR attachment.  The absorptions are reported on the wavenumber (cm-1) scale in the 
600-3500cm-1 range.  Abbreviations used in describing the signals are: s (strong), m (medium), w 
(weak) and br (broad).  Assignments are only indicated for key signals and functional groups. 
 
Melting points were recorded using a JM 626 melting-point apparatus with microscope and digital 
thermometer. 
 
High-resolution mass spectra were recorded either on a VG70 MS (Mass spectrum CC Pyramid 
data system), a VG70 SEQ (VG 11-205J or Mar II data system), or on a DFS High Resolution 
Magnetic Sector mass spectrometer. 
 
Intensity data were collected on a Bruker APEX II CCD area detector diffractometer with graphite 
monochromated Mo K  radiation (50kV, 30mA) using the APEX 299 data collection software. The 
collection method involved -scans of width 0.5  and 512x512 bit data frames. Data reduction was 
carried out using the program SAINT+100 and face indexed absorption corrections were made 
using XPREP 100.  The crystal structure was solved by direct methods using SHELXTL 101. Non-
hydrogen atoms were first refined isotropically followed by anisotropic refinement by full matrix 
least-squares calculations based on F2 using SHELXTL. Hydrogen atoms were first located in the 
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difference map then positioned geometrically and allowed to ride on their respective parent 
atoms.  Diagrams and publication material were generated using SHELXTL, PLATON102 and 
ORTEP-3103. 
 
1.5 Biological Testing 
 
The in vitro HIV reverse transcriptase assays were performed by the CSIR Biosciences 
Pharmacology group.  The assay is based on a sandwich-ELISA protocol employing the ROCHE 
colorimetric reverse transcriptase kit.  Biotin and DIG-labelled nucleotides are incorporated into 
cDNA strands polymerized on an RNA template by the action of HIV-1 reverse transcriptase.  The 
cDNA products are bound to the streptavidin-coated wells of 96-well plate inserts, and their 
associated DIG-moieties detected by incubation with the anti-DIG antibodies conjugated to 
horseradish peroxidase (HRP).  The amount of bound antibody is quantified by incubation with a 
colorimetric HRP substrate, followed by absorbance reading at 405nm using a multiwell 
spectrophotometer.  To assess the inhibitory activity of the test compounds they are incubated with 
HIV-1 reverse transcriptase and substrate and the residual percentage enzyme activity expressed 
relative to a control without inhibitor.   
 
1.6 Nomenclature and Compound Numbering 
 
The compounds prepared during the course of this project are named in the following experimental 
section according to systematic nomenclature.  However, the numbering system used in the 
diagrams of these compounds is one adopted for convenience and is not meant to reflect the 
systematic numbering of these compounds. 
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2.  Experimental Procedures:  Synthesis of Imidazo[1,2-a]pyridines and 3-Amino-1-cyano 
Indolizines 
 
2.1 General Procedure for the Synthesis of Imidazo[1,2-a]pyridines 52-62 
 
2-Aminopyridine (1.0eq, 1.6mmol, 0.15g) or 2-amino-5-bromopyridine (1.0eq, 0.86mmol, 0.15g) 
were dissolved in 1,4-dioxane (8.0cm3) and treated with the aldehyde (1.2eq), isocyanide (1.5eq) 
and montmorillonite clay (1.0eq by mass of 2-aminopyridine or 2-amino-5-bromopyridine) and then 
heated at reflux for 60-90 h.  After this time the reaction mixture was filtered through a celite plug to 
remove the montmorillonite clay and the solvent was removed in vacuo to yield a crude black oil. 
 
2.1.1 Synthesis of N-cyclohexyl-2-(4-methoxypheny)imidazo[1,2-a]pyridine-3-amine 52 
 
 
 
The reagents; p-methoxybenzaldehyde (1.2eq, 1.9mmol, 0.26g), cyclohexyl isocyanide (1.5eq, 
2.4mmol, 0.31cm3) and montmorillonite clay (0.15g) were added together and reacted as per the 
general procedure.  The crude black oil was adsorbed onto silica gel and purified by column 
chromatography (30% – 70% EtOAc-Hexane) to yield an impure yellow oil.  The yellow oil was 
recrystallised from diethyl ether to yield the product 52 as an off white solid (0.45mmol, 0.15g, 28% 
yield).  The spectroscopic data of this known compound was in agreement with that of Rousseau et 
al.48 
 
Rf = 0.53 (70% EtOAc-Hexane); δH (300 MHz, CDCl3) 8.10 (1H, d, J=6.8Hz, Ar-H), 8.04 – 7.93 
(2H, m, 2 Ar-H), 7.55 (1H, d, J=9.0Hz, Ar-H), 7.12 (1H, ddd, J=8.9, 6.7 and 1.2Hz, Ar-H), 7.03 – 
6.95 (2H, m, 2 Ar-H), 6.78 (1H, td, J=6.8 and 1.0Hz, Ar-H), 3.86 (3H, s, OCH3), 3.08 (1H, broad s, 
NHCH(CH2)5), 2.96 (1H, m, NHCH(CH2)5), 1.89 – 1.05 (10H, m, NHCH(CH2)5); δC (75 MHz, CDCl3) 
158.94 (ArCOCH3), 141.48 (ArC), 136.60 (ArC), 128.34 (2 ArC-H), 127.08 (ArC), 124.11 (ArC), 
123.70 (ArC-H), 122.61 (ArC-H), 117.02 (ArC-H), 113.93 (2 ArC-H), 111.40 (ArC-H), 56.78 
(NHCH(CH2)5, 55.22 (OCH3), 34.14 (2 CH2), 25.74 (CH2), 24.80 (2 CH2). 
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2.1.2 Synthesis of 5-Bromo-N-tert-butyl-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine-3-amine 53 
 
 
 
The reagents; p-methoxybenzaldehyde (1.2eq, 1.9mmol, 0.26g), t-butyl isocyanide (1.5eq, 
1.3mmol, 0.15cm3) and montmorillonite clay (0.15g) were added together and reacted as per the 
general procedure. The crude black oil was adsorbed on silica and purified by flash 
chromatography (25% EtOAc-Hexane) to give the pure product 53 as an off-white solid (0.27mmol, 
0.10g, 31% yield). 
  
Rf = 0.54 (50% EtOAc-Hexane); m.p. 189-192˚C; I.R. (v/cm
-1) 3281 (m, CHN-HC(CH3)3), 3047 – 
3010 (m, ArC-H), 2963 – 2834 (m, C(C-H3)3), 1613 (m, C=N-C), 1579 – 1454 (m - s, ArC=C), 1250 
(s, ArC-OCH3); δH (300 MHz, CDCl3) 8.39 – 8.27 (1H, m, Ar-H), 7.89 – 7.70 (2H, m, 2 Ar-H), 7.41 
(1H, dd, J=9.4 and 0.6Hz, Ar-H), 7.17 (1H, dd, J=9.4 and 1.9Hz, Ar-H), 7.05 – 6.90 (2H, m, 2 Ar-
H), 3.86 (3H, s, OCH3), 3.05 (1H, s, NH), 1.05 (9H, s, C(CH3)3); δC (75 MHz, CDCl3) 159.26 
(ArCOCH3), 140.28 (ArC), 129.50 (ArC), 129.39 (2 ArC-H), 127.36 (ArC-H), 127.13 (ArC), 123.61 
(ArC-H), 123.28 (ArC), 117.71 (ArC), 115.55 (ArC-H), 113.83 (2 ArC-H), 56.49 (OCH3), 55.25 
(NHC(CH3)3, 30.32 (C(CH3)3); MS m/z (%) 375 (M
+ 81Br, 61), 373 (M+ 79Br, 78), 320 (25), 316 (100), 
302 (20), 291 (89), 289 (61), 274 (22), 259 (4), 264 (12), 222 (6), 210 (28), 207 (8), 179 (6), 172 
(14), 157 (82); HRMS calculated mass for C18H20ON3
79Br:  373.0787 and for C18H20ON3
81Br: 
375.0769; exact mass for C18H20ON3
79Br:  373.0788 and for C18H20ON3
81Br: 375.0775  
 
2.1.3 Synthesis of 5-Bromo-N-cyclohexyl-2-(4-methoxy-3-methylphenyl)imidazo[1,2-a]pyridine-3-
amine 54 
 
 
 
As per the general procedure 3-methyl-anisaldehyde (1.2eq, 1.0mmol, 0.15cm3), cyclohexyl 
isocyanide (1.5eq, 1.3mmol, 0.17cm3) and montmorillonite (0.15g) were reacted together.  The 
crude black oil was adsorbed on silica and flash chromatography (25% EtOAc-Hexane) gave an 
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impure yellow solid which was recrystallised from diethyl ether to give and the pure product 54 
as an off-white solid (0.29mmol, 0.12g, 33% yield). 
 
Rf = 0.62 (50% EtOAc-Hexane); m.p. 84-86˚C; I.R. (v/cm
-1) 3292 (m, CN-HCH(CH2)5), 2925 - 
2851 (m, NHCH(C-H2)5), 1611 (m, C-C=N), 1500 – 1463 (m-s, ArC=C), 1271 (s, ArC-OCH3); δH 
(300 MHz, CDCl3) 8.12 (1H, d, J=1.1Hz, Ar-H), 7.81 – 7.60 (2H, m, 2 Ar-H), 7.31 (1H, d, J=9.4Hz, 
Ar-H), 7.06 (1H, dd, J=9.4 and 1.9Hz, Ar-H), 6.80 (1H, d, J=8.5Hz, Ar-H), 3.80 (3H, s, OCH3), 2.97 
(1H, s, NHCH(CH2)5), 2.88 (1H, m, NHCH(CH2)5), 2.21 (3H, s, Ar-CCH3), 1.80 –1.13 (10H, m, 
NHCH(CH2)5); δC (75 MHz, CDCl3) 157.41 (ArCOCH3), 139.81 (ArC), 137.83 (ArC), 129.54 (ArC-
H), 126.83 (ArC-H), 126.76 (ArC), 126.10 (ArC), 125.41(ArC-H), 124.36 (ArC-H), 122.75 (ArC-H), 
117.74 (ArC), 109.87 (ArC-H), 106.22 (ArC), 56.81 (NHCH(CH2)5), 55.33 (OCH3), 34.13 (2 CH2), 
25.69 (CH2), 24.76 (2 CH2), 16.34 (Ar-CCH3); MS m/z (%) 415 (M
+ 81Br, 70), 413 (M+ 79Br, 58), 411 
(9), 332 (85), 330 (48), 316 (3), 305 (92), 303 (64), 293 (20), 167 (20), 157 (60), 148 (100), 127 
(23), 103 (11); HRMS  calculated mass for C21H24ON3
79Br:  413.1103 and C21H24ON3
81Br:  
415.1082; exact mass for C21H24ON3
79Br:  413.1094 and C21H24ON3
81Br:  415.1082 
 
2.1.4 Synthesis of N-tert-butyl-2-(4-methoxy-3-methylphenyl)imidazo[1,2-a]pyridine-3-amine 55 
 
 
 
3-Methyl-anisaldehyde (1.2eq, 1.0mmol, 0.15cm3), t-butyl isocyanide (1.5eq, 2.4mmol, 0.27cm3) 
and montmorillonite (0.15g) were reacted together as per the general reaction procedure. The 
crude product was adsorbed onto silica gel and column chromatography (30%-65% EtOAc-
Hexane) gave the pure product 55 as a yellow oil (0.24mmol, 0.08g, 15% yield). 
 
Rf = 0.35 (35% EtOAC-Hexane); I.R. (v/cm
-1) 3273 (broad, CHN-HC(CH3)3), 2963 – 2901 (m, C(C-
H3)3), 1612 (m, C=N-C), 1557 – 1442 (m - s, ArC=C), 1247 (s, ArC-OCH3); δH (300 MHz, CDCl3) 
8.08 (1H, d, J=6.8Hz, Ar-H), 7.72 – 7.55 (2H, m, 2 Ar-H), 7.41 (1H, d, J=9.0Hz, Ar-H), 7.08 – 6.90 
(1H, m, Ar-H), 6.75 (1H, d, J=8.4Hz, Ar-H), 6.61 (1H, t, J=6.6Hz, Ar-H), 3.75 (3H, s, OCH3), 2.99 
(1H, s, NHC(CH3)3), 2.19 (3H, s, Ar-CCH3), 0.94 (9H, s, C(CH3)3); δC (75 MHz, CDCl3) 157.17 
(ArCOCH3), 141.86 (ArC), 139.50 (ArC), 130.49 (ArC-H), 127.29 (ArC), 126.51 (ArC-H), 126.30 
(ArC), 123.65 (ArC-H), 123.31 (ArC-H), 122.82 (ArC), 116.99 (ArC-H), 111.02 (ArC-H) , 109.54 
(ArC-H), 56.24 (OCH3), 55.25 (NHC(CH3)3), 30.37 (NHC(CH3)3), 16.23 (Ar-CCH3); MS m/z (%) 309 
(M+, 9), 252 (25), 225 (28), 149 (100), 147 (8), 135 (37), 133 (7), 119 (15), 107 (54); HRMS 
calculated mass for C19H23ON3:  309.1841; exact mass for C19H23ON3:  309.1836 
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2.1.5 Synthesis of 5-Bromo-2-(4-methoxy-3-methylphenyl)-N-pentylimidazo[1,2-a]pyridine-3-
amine 56 
 
 
As per the general reaction procedure; 3-methyl-anisaldehyde (1.2eq, 1.0mmol, 0.15cm3) and n-
pentyl isocyanide (1.5eq, 1.3mmol, 0.16cm3) were reacted together.  The crude product was 
adsorbed onto silica gel and column chromatography (35% EtOAc-Hexane) gave the desired pure 
product 56 as a green solid (0.79mmol, 0.32g, 79% yield). 
 
Rf = 0.63 (40% EtOAc-Hexane); m.p. 102-104˚C; I.R. (v/cm
-1) 3254 (m, CHN-HC(CH3)3), 2959 – 
2839 (m, NH(C-H2)4C-H3), 1608 (m, C=N-C), 1558 – 1467 (s, ArC=C), 1243 (s, ArC-OCH3); δH 
(300 MHz, CDCl3) 8.08 (1H, d, J=0.9Hz, Ar-H), 7.85 – 7.59 (2H, m, 2 Ar-H), 7.38 (1H, d, J=9.4Hz, 
Ar-H), 7.12 (1H, dd, J=9.4 and 1.7Hz, Ar-H), 6.85 (1H, d, J=8.5Hz, Ar-H), 3.86 (3H, s, OCH3), 3.00 
(3H, m, NHCH2CH2), 2.28 (3H, s, Ar-CCH3), 1.56 – 1.52 (2H, m, NHCH2CH2CH2), 1.45 – 1.21 (4H, 
m, CH2CH2CH2CH3), 0.90 (3H, t, J=6.9Hz, CH2CH3); δC (75 MHz, CDCl3) 157.43 (ArCOCH3), 
139.60 (ArC), 136.88 (ArC), 129.40 (ArC-H), 126.81 (ArC), 126.69 (ArC-H), 125.94 (ArC), 125.77 
(ArC), 125.36 (ArC-H), 122.41 (ArC-H), 117.76 (ArC-H), 109.90 (ArC-H), 106.25 (ArC), 55.31 
(OCH3), 48.12 (NHCH2CH2), 30.34, 29.20 and 22.52 (NHCH2(CH2)3CH3), 16.30 (Ar-CCH3), 14.01 
(CH2CH3); MS m/z (%) 403 (M
+ 81Br, 34), 401 (M+ 79Br, 50), 399 (13), 344 (8), 332 (40), 328 (9), 
305 (100), 303 (80), 252 (21), 239 (8), 225 (24), 157 (30), 149 (58), 135 (30), 114 (36), 110 (43); 
HRMS  calculated mass for C20H24ON3
79Br:  401.103 and C20H24ON3
81Br:  403.1082; exact mass 
for C20H24ON3
79Br:  401.1071 and C20H24ON3
81Br:  403.1095 
 
2.1.6 Synthesis of 5-Bromo-N-(3,5-dimethylphenyl)-2-hexylimidazo[1,2-a]pyridine-3-amine 57 
 
 
 
Reagents; n-heptaldehyde (1.2eq, 1.0mmol, 0.14cm3) and 1-xylyl isocyanide (1.5eq, 1.3mmol, 
0.17g) were reacted together according to the general reaction procedure.  The crude black oil was 
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adsorbed on silica gel and column chromatography (20%-55% EtOAc-Hexane) gave the pure 
product 57 as an orange solid (0.52mmol, 0.21g, 46% yield). 
 
Rf = 0.61 (40% EtOAc-Hexane); m.p. 132-133˚C; I.R. (v/cm
-1) 3185 (m, CHN-HC(CH3)3), 2916 – 
2855 (m, C(C-H2)5C-H3) 1623 (m, C=N-C), 1565 – 1470 (s, ArC=C); δH (300 MHz, CDCl3) 8.04 
(1H, d, J=0.7Hz, Ar-H), 7.23 (1H, d, J=9.4Hz, Ar-H), 7.03 (1H, dd, J=9.4 and 1.6Hz, Ar-H), 6.89 
(2H, d, J=7.4Hz, 2 Ar-H), 6.79 – 6.69 (1H, m, Ar-H), 5.01 (1H, s, NH), 2.28 – 2.18 (2H, m, 
CCH2CH2), 1.89 (6H, s, 2 Ar-CCH3), 1.45 – 1.31 (2H, m, CH2CH2CH3), 1.17 – 0.95 (6H, m, 
CH2(CH2)3CH2), 0.72 (3H, m, CH2CH3); δC (75 MHz, CDCl3) 141.90 (ArC), 141.49 (ArC), 139.54 
(ArC), 129.38 (ArC-H), 126.94 (ArC-H), 126.34 (ArC-H), 122.12 (ArC-H), 121.81 (ArC-H), 121.65 
(ArC), 117.48 (ArC-H), 106.51 (ArC), 31.46, 29.23, 28.59 and 22.48 (CH2(CH2)4CH3), 27.09 
(CCH2(CH2)5), 18.26 (Ar-CCH3), 4.04 (CH2CH3); MS m/z (%) 399 (M
+ 79Br, 17), 397 (2), 370 (2), 
355 (2), 342 (4), 329 (4), 314 (14), 281 (2), 267 (6), 239 (7), 211 (6), 205 (100), 203 (8), 177 (8), 
158 (18); HRMS  calculated mass for C21H26N3
79Br:  399.1310 and C21H26N3
81Br:  401.1290; exact 
mass for C21H26N3
79Br:  399.1280 and C21H26N3
81Br:  401.1273 
 
2.1.7 Synthesis of N-cyclohexyl-2-(4-methoxy-3methylphenyl)imidazo[1,2-a}pyridine-3-amine 58 
 
 
 
In accordance with the general reaction procedure 3-methyl anisaldehyde (1.2eq, 1.9mmol, 
0.23cm3) and cyclohexyl isocyanide (1.5eq, 2.4mmol, 0.31cm3) were reacted.  The crude product 
was adsorbed on silica gel and column chromatography (50% EtOAc-Hexane) gave the desired 
pure product 58 as a yellow oil (0.58mmol, 0.20g, 37% yield). 
 
Rf = 0.47 (50% EtOAc-Hexane); I.R. (v/cm
-1) 3229 (w, CN-HCH(CH2)5), 2978 – 2851 (m, NHCH(C-
H2)5), 1591 (w, C-C=N), 1499 (m, ArC=C), 1247 (s, ArCC-OCH3); δH (300 MHz, CDCl3) 8.09 (1H, 
d, J=6.8Hz, Ar-H), 7.92 – 7.76 (2H, m, 2 Ar-H), 7.53 (1H, d, J=9.0Hz, Ar-H), 7.20 – 6.98 (1H, m, Ar-
H), 6.88 (1H, d, J=8.4Hz, Ar-H), 6.74 (1H, dd, J=6.7 and 5.8Hz, Ar-H), 3.87 (3H, s, OCH3), 3.02 
(1H, s, NHCH(CH2)5), 2.96 (1H, m, NHCH(CH2)5), 2.29 (3H, s, Ar-CCH3), 1.71 - 1.03 (10H, m, 
NHCH(CH2)5); δC (75 MHz, CDCl3) 157.21 (ArCOCH3), 141.24 (ArC), 136.35 (ArC), 129.54 (ArC-
H), 126.61 (ArC-H), 126.27 (ArC), 125.42 (ArC-H), 124.13 (ArC), 123.80 (ArC-H), 122.65 (ArC), 
116.88 (ArC-H), 111.46 (ArC-H), 109.84 (ArC-H), 56.85 (NHCH(CH2)5), 55.31 (OCH3), 34.17, 
25.74 and 24.80 (NHCH(CH2)5, 16.34 (Ar-CCH3); MS m/z (%) 335 (M
+, 88), 334 (70), 252 (74), 238 
(26), 226 (100), 210 (73), 195 (11), 181 (16), 160 (7), 149 (23), 131 (14), 115 (10); HRMS 
calculated mass for C21H23ON3:  335.1998; exact mass for C21H23ON3:  335.1990 
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2.1.8 Synthesis of 5-Bromo-N-cyclohexyl-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine-3-amine 59 
 
 
 
Reagents p-methoxybenzaldehyde (1.2eq, 1.0mmol, 0.12cm3) and cyclohexyl isocyanide (1.5eq, 
1.3mmol, 0.17cm3) were reacted according to the general reaction procedure.  The crude product 
was adsorbed on silica gel and column chromatography (30% EtOAc-Hexane) gave the desired 
pure product 59 as an off-white solid (0.70mmol, 0.28g, 61% yield). 
 
Rf = 0.58 (50% EtOAc-Hexane); m.p. 202-204˚C; I.R. (v/cm
-1) 3247 (m, CN-HCH(CH2)5), 2921 – 
2853 (m, NHCH(C-H2)5), 1610 (s, C-C=N), 1504 – 1455 (m-s, ArC=C), 1248 (s, ArCC-OCH3); δH 
(300 MHz, CDCl3) 8.22 – 8.05 (1H, m, Ar-H), 7.96 – 7.77 (2H, m, 2 Ar-H), 7.32 (1H, d, J=9.4Hz, Ar-
H), 7.08 (1H, dd, J=9.4 and 1.9Hz, Ar-H), 6.91 (2H, d, J=8.9Hz, Ar-H), 3.79 (3H, s, OCH3), 3.03 – 
2.81 (2H, m, NHCH(CH2)5), 1.81 – 1.00 (10H, m, NHCH(CH2)5); δC (75 MHz, CDCl3) 159.11 
(ArCOCH3), 139.82 (ArC), 137.73 (ArC), 128.26 (ArC-H), 126.89 (ArC-H), 126.64 (ArC), 124.33 
(ArC), 122.76 (ArC-H), 117.76 (ArC-H), 113.96 (ArC-H), 106.25 (ArC), 56.71 (NHCH(CH2)5, 55.25 
(OCH3), 34.07, 25.67 and 24.76 (NHCH(CH2)5; MS m/z (%) 399 (M
+ 79Br, 4), 326 (19), 311 (18), 
283 (12), 252 (41), 225 (59), 207 (21), 205 (56), 181 (18), 179 (24), 165 (36), 149 (100), 135 (37), 
123 (43), 109 (74); HRMS  HRMS could not identify a molecular ion for C20H22ON3Br. 
 
2.1.9 Synthesis of N-cyclohexyl-2-(4-(dimethylamino)phenyl)imidazo[1,2-a]pyridine-3-amine 60 
 
 
 
The reagents; 4-dimethylaminobenzaldehyde (1.2eq, 1.9mmol, 0.29g) and cyclohexyl isocyanide 
(1.5eq, 2.4mmol, 0.31cm3) were reacted together as per the general reaction procedure.  The 
resulting crude black oil was adsorbed onto silica gel and column chromatography (30%-70% 
EtOAc-Hexane) gave the desired pure product 60 as a bright yellow solid (0.20mmol, 0.07g, 13% 
yield). 
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Rf = 0.45 (70% EtOAc-Hexane); m.p. 179-181˚C; I.R. (v/cm
-1) 3277 (m, CN-HCH(CH2)5), 2920 
(m – s, N(C-H3)2), 2851 (m, NHCH(C-H2)5), 1612 (s, C-C=N), 1551 – 1439 (s, ArC=C), 1228 (s, 
ArCC-OCH3), 1197 (ArC-N-(CH3)2); δH (300 MHz, CDCl3) 7.97 (1H, d, J=6.7Hz, Ar-H), 7.85 (2H, d, 
J=8.6Hz, 2 Ar-H), 7.40 (1H, d, J=8.9Hz, Ar-H), 7.11 – 6.86 (1H, m, Ar-H), 6.71 (2H, d, J=8.6Hz, 2 
Ar-H), 6.61 (1H, t, J=6.6, Ar-H), 2.98 (1H, s, NHCH(CH2)5), 2.89 (6H, s, N(CH3)2), 2.05 (1H, m, 
NHCH(CH2)5), 1.73 – 0.8 (10H, m, CH(CH2)5); δC (75 MHz, CDCl3) 149.69 (ArC), 141.42 (ArC), 
137.20 (ArC), 127.87 (2 ArC-H), 123.56 (ArC), 123.26 (ArC-H), 122.68 (ArC), 122.51 (ArC-H), 
116.78 (ArC-H), 112.33 (2 ArC-H), 111.08 (ArC-H), 56.78 (NHCH(CH2)5), 40.45 (N(CH3)2), 34.13, 
25.79 and 24.83 (CH(CH2)5); MS m/z (%) 334 (M
+, 82), 332 (20), 227 (10), 251 (96), 237 (12), 224 
(100), 208 (28), 181 (6), 167 (6), 148 (38), 110 (10); HRMS calculated mass for C21H26N4:  
334.2158; exact mass for C21H26N4:  334.2152 
 
2.1.10 Attempted Synthesis of 2-(2-Bromophenyl)-N-(2-morpholinoethyl)imidazo[1,2-a]pyridine-3-
amine 61 and 2-(4-Methoxy-3-methylphenyl)-N-(2-morpholinoethyl) imidazo[1,2-a]pyridine-3-amine 
62 
 
                 
 
For the first reaction 2-bromobenzaldehyde (1.2eq, 1.9mmol, 0.22cm3) and 2-morpholinoethyl 
isocyanide (1.5eq, 2.4mmol, 0.33cm3) were reacted together as per the general reaction 
procedure.  The same procedure was adopted for the attempted synthesis of 62, but this time 3-
methyl anisaldehyde (1.2eq, 1.9mmol, 0.24cm3) was used as the variable aldehyde reagent. The 
crude products were adsorbed onto silica gel and loaded onto a silica gel column (30% EtOAc-
Hexane).  The products decomposed on the column and no discernible compounds were isolated 
from the column chromatography fractions. 
 
2.2 General Procedures for the Synthesis of 3-Amino-1-cyano-indolizines 63-79 
 
2.2.1 Method A:  General Procedure for the Attempted Synthesis of 3-Amino-1-cyano-indolizines 
63-70 
 
2-Pyridylacetonitrile (1.0eq, 1.3mmol, 0.15g, 0.14cm3), an aldehyde (1.2eq) and an isocyanide 
(1.2eq) were dissolved in 1,4-dioxane (8.0cm3) and treated with DBU (0.1eq, 0.13mmol, 0.02g).  
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The reaction mixture was heated at reflux from 60-90 h after which time the solution had turned 
black.  After this time the solvent was removed in vacuo and 10% aqueous HCl (30cm3) was added 
to the crude black oil.  The organic products were extracted with CH2Cl2 (3 x 30cm
3) and dried over 
anhydrous MgSO4.  The solvent was once again removed in vacuo to afford a crude yellow oil.  
Further purification of this crude oil via column chromatography and/or recrystallisation revealed 
that the reaction had not gone to completion and NMR spectral analysis verified the isolated 
products to be aldol condensation products of the 2-pyridylacetonitrile and the various aldehydes.   
 
2.2.1.1 Attempted Synthesis of 2-(4-Methoxyphenyl)-3-(pentylamino)indolizine-1-carbonitrile 63  
 
               
 
For this reaction p-methoxybenzaldehyde (1.2eq, 1.5mmol, 0.19cm3) and n-pentyl isocyanide 
(1.2eq, 1.5mmol, 0.18cm3) were reacted together as per the general reaction procedure. The crude 
yellow oil was adsorbed onto silica gel and purified by flash chromatography (30% EtOAc-Hexane) 
to give starting aldehyde and an impure yellow oil.  Recrystallisation of the impure yellow oil in 96% 
aqueous ethanol, gave a fine yellow powder (0.36mmol, 0.08g, 28%) which is identified by NMR 
spectroscopy to be the aldol product 3-(4-methoxyphenyl)-2-(pyridin-2-yl)acrylonitirile 63a. 
 
Rf = 0.39 (20% EtOAc-Hexane); m.p. 89-92˚C; I.R. (v/cm
-1) 3168 (m, C=C-H), 2221 (w, C-CN), 
1623 (s, C-C=N), 1587 – 1439 (s , ArC=C), 1258 (m, ArC-O-CH3); δH (300 MHz, CDCl3) 8.61 (1H, 
d, J=4.4Hz, Ar-H), 8.39 (1H, s,-C=CH-), 7.99 (2H, d, J=8.8Hz, 2 Ar-H), 7.88 – 7.61 (2H, m, 2 Ar-H), 
7.24 (1H, ddd, J=6.6, 5.2 and 2.8Hz, Ar-H), 6.98 (2H, d, J=8.9Hz, Ar-H), 3.86 (3H, s, OCH3); δC (75 
MHz, CDCl3) 161.97 (ArC), 151.53 (Ar-C), 149.53 (ArC-H), 144.68 (-C=CH-), 137.30 (ArC-H), 
132.08 (2 ArC), 126.13 (ArC), 123.02 (ArC-H), 120.88 (ArC-H), 118.41(C-CN), 114.45 (2 ArC-H), 
106.99 (C-CN), 55.45 (OCH3); MS m/z (%) 235 (M
+, 100), 222 (3), 221 (16), 220 (27), 210 (7), 205 
(6), 193 (16), 192 (97), 191 (7), 177 (2), 166 (10), 151 (5), 139 (8), 123 (4), 111 (6); HRMS 
calculated mass for C15H12ON2:  236.0950 exact mass for C15H12ON2:  236.0924 
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2.2.1.2 Attempted Synthesis of 3-(tert-butylamino)-2-(2-chlorophenyl)indolizine-1-carbonitrile 64 
 
                    
 
As per the general reaction procedure, 2-chlorobenzaldehyde (1.2eq, 1.5mmol, 0.17cm3) and t-
butyl isocyanide (1.2eq, 1.5mmol, 0.17cm3) were reacted together. The crude yellow oil was 
recrystallised from diethyl ether to afford yellow crystals (0.99mmol, 0.24g, 78%) which were 
characterised by NMR spectroscopy to be the aldol product 3-(2-chlorophenyl)-2-(pyridin-2-
yl)acrylonitrile 64a. 
 
Rf = 0.66 (20% EtOAc-Hexane); m.p. 147-149˚C; I.R. (v/cm
-1) 3068 (w, C=C-H), 2219 (w, C-CN), 
1608 (s, C-C=N), 1579 – 1430 (s , ArC=C), 742 (s, ArC-Cl);  δH (300 MHz, CDCl3) 8.80 (1H, s, -
C=CH-), 8.67 (1H, d, J=4.5Hz, Ar-H), 8.17 (1H, dd, J=5.3 and 4.1Hz, Ar-H), 7.92 – 7.65 (2H, m, Ar-
H), 7.58 – 7.21 (4H, m, Ar-H); δC (75 MHz, CDCl3) 150.68 (ArC), 149.92 (ArC-H), 141.79 (-C=CH-), 
137.37 (ArC-H), 135.45 (ArC), 132.00 (ArC), 131.76 (ArC-H), 129.99 (ArC-H), 129.48 (ArC-H), 
127.22 (ArC-H), 123.90 (ArC-H), 121.45 (ArC-H), 117.12 (C-CN), 113.58 (C-CN); MS m/z (%) 242 
(M+ 37Cl, 36), 241 (58) 240 (M+ 35Cl, 96), 239 (80), 235 (16), 214 (26), 207 (64), 206 (74), 205 (100), 
203 (98), 202 (16), 180 (6), 179 (36), 178 (66), 176 (72), 175 (18), 153 (26), 152 (64), 151 (81), 
150 (41), 148 (29), 139 (90, 127 (19), 125 (50), 124 (32), 119 (15); HRMS Could not obtain a 
molecular ion for C14H9N2Cl. 
 
2.2.1.3 Attempted Synthesis of 2-(5-Bromo-2,3-dimethoxyphenyl)-3-(3,5-dimethyl 
phenylamino)indolizine-1-carbonitrile 65 
 
                     
 
In accordance with the general reaction procedure, 5-bromo-2,3-dimethoxybenzaldehyde (1.2eq, 
1.5mmol, 0.37g) and 1-xylyl isocyanide (1.2eq, 1.5mmol, 0.20g) were reacted.  The crude yellow 
oil was adsorbed onto silica gel and purified by column chromatography (35% EtOAc-Hexane) to 
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yield a greenish-yellow solid.  This solid was dissolved in 96% aqueous ethanol and on 
standing a white solid (0.64mmol, 0.22g, 51%) precipitated out of the solution which was collected 
and dried.  Characterisation of the product shows the white solid to be the aldol compound 3-(5-
bromo-2,3-dimethoxyphenyl)-2-(pyridin-2-yl)acrylonitrile 65a. 
 
Rf = 0.31 (10% EtOAc-Hexane); m.p. 165-166˚C; I.R. (v/cm
-1) 3052 (w, C=C-H), 2217 (w - m, C-
CN), 1608 (m, C-C=N), 1584 – 1465 (s , ArC=C), 1266 (m, ArC-O-CH3); δH (300 MHz, CDCl3) 8.67 
(2H, m, -C=CH- and Ar-H), 7.94 (1H, d, J=2.0Hz), 7.88 – 7.70 (2H, m, 2 Ar-H), 7.41 – 7.21 (1H, m, 
Ar-H), 7.14 (1H, d, J=2.1Hz, Ar-H), 3.88 (6H, 2s, 2 OCH3); δC (75 MHz, CDCl3) 153.35 (ArC), 
150.95 (ArC), 149.83 (-C=CH-), 148.06 (ArC), 138.68 (ArC-H), 137.32 (ArC-H), 129.14 (ArC), 
123.76 (ArC-H), 122.62 (ArC-H), 121.37 (ArC-H), 118.17 (ArC-H), 117.15 (C-CN), 116.71 (C-CN), 
112.82 (ArC),  61.75 (OCH3), 56.21 (OCH3); MS m/z (%) 346 (M
+ 81Br, 92) 344 (M+ 79Br, 100), 268 
(1), 267 (6), 266 (32), 241 (1); HRMS calculated mass for C16H13ON2
79Br: 344.0160 and for 
C16H13ON2
81Br: 346.0140, exact mass for C16H13ON2
79Br: 344.0124 and for C16H13ON2
81Br: 
346.0133. 
 
2.2.1.4 Attempted Synthesis of 2-(2-Chlorophenyl)-3-(3,5-dimethylphenylamino)indolizine-1-
carbonitrile 66 
 
 
 
2-Chlorobenzaldehyde (1.2eq, 1.5mmol, 0.17cm3) and 1-xylyl isocyanide (1.2eq, 1.5mmol, 0.20g) 
were reacted in accordance with the general reaction procedure. The crude yellow oil was 
dissolved in hot diethyl ether and upon standing yellow crystals (0.74mmol, 0.18g, 59%) 
precipitated from the solution, which were identified by NMR spectroscopy to be the same aldol 
product as 64a. 
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2.2.1.5 Attempted Synthesis of 3-(Cyclohexylamino)-2-(4-methoxyphenyl)indolizine-1-
carbonitrile 67 
 
 
 
As per the general reaction procedure p-methoxybenzaldehyde (1.2eq, 1.5mmol, 0.18cm3) and 
cyclohexyl isocyanide (1.2eq, 1.5mmol, 0.19cm3) were reacted together.  The crude yellow oil was 
adsorbed onto silica gel and purified by flash chromatography (30% EtOAc-Hexane) to give a 
yellow oil.  Recrystallisation of the impure oil in 96% aqueous ethanol yielded a fine yellow powder 
(0.76mmol, 0.18g 60%) which was characterised by NMR spectroscopy to be the same aldol 
product as 63a. 
 
2.2.1.6 Attempted Synthesis of 2-(2-Chlorophenyl)-3-(cyclohexylamino)indolizine-1-carbonitrile 68 
 
 
 
The reagents; 2-chlorobenzaldehyde (1.2eq, 1.5mmol, 0.17cm3) and cyclohexyl isocyanide (1.2eq, 
1.5mmol, 0.19cm3) were reacted together in accordance with the general reaction procedure. The 
crude oil was purified by column chromatography (20% EtOAc-Hexane) to give a yellow oil, which 
was dissolved in hot diethyl ether and allowed to cool.  Upon cooling yellow crystals (0.86mmol, 
0.21g, 68%) precipitated out of the solution and NMR spectral characterisation of this product 
revealed it to be the same aldol product as 64a. 
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2.2.1.7 Attempted Synthesis of 3-(Cyclohexylamino)-2-(4-methoxy-3-methylphenyl) indolizine-
1-carbonitrile 69 
 
              
 
In accordance with the general reaction procedure; 3-methyl anisaldehyde (1.2eq, 1.5mmol, 
0.22cm3) and cyclohexyl isocyanide (1.2eq, 1.5mmol, 0.19cm3) were reacted together.  The crude 
product was purified by column chromatography (30% EtOAc-Hexane) to give a white solid 
(0.53mmol, 0.13g, 42%) which was identified to be aldol product 3-(4-methoxy-3-methylphenyl)-2-
(pyridin-2-yl)acrylonitirile 69a.  
 
Rf = 0.51 (20% EtOAc-Hexane); m.p. 95-98˚C; I.R. (v/cm
-1) 3012 (w, C=C-H), 2922 – 2842 (w, 
ArCC-H3) 2213 (m, C-CN), 1582 – 1463 (s , ArC=C), 1255 (s, ArC-O-CH3); δH (300 MHz, CDCl3) 
8.62 (1H, d, J=4.7Hz, Ar-H), 8.37 (1H, s, -C=CH-), 8.02 – 7.65 (4H, m, 4 Ar-H), 7.36 – 7.10 (1H, m, 
Ar-H), 6.91 (1H, d, J=8.6Hz, Ar-H), 3.90 (3H, s, OCH3), 2.22 (3H, s, ArC-CH3); δC (75 MHz, CDCl3) 
160.33 (ArCOCH3), 151.71 (ArC) , 149.49 (ArC-H), 144.99 (-C=CH-), 137.25 (ArC-H), 132.59 (ArC-
H), 129.99 (ArC-H), 127.35 (ArC), 125.69 (ArC), 122.88 (ArC-H), 120.80 (ArC-H), 118.50 (C-CN), 
110.05 (ArC-H), 106.54 (C-CN), 55.49 (OCH3), 16.29 (ArC-CH3); MS m/z (%) 249 (M
+, 100), 234 
(16), 208 (2), 207 (8), 205 (14), 192 (12), 179 (6), 165 (6), 149 (10), 135 (6), 128 (5), 114 (10), 109 
(10); HRMS calculated mass for C16H14ON2:  250.1106; exact mass for C16H14ON2:  250.1081 
 
2.2.1.8 Attempted Synthesis of 3-(Cyclohexylamino)-2-(4-(dimethylamino)phenyl) indolizine-1-
carbonitrile 70 
 
                       
 
4-Dimethylaminobenzaldehyde (1.2eq, 1.5mmol, 0.23g) and cyclohexyl isocyanide (1.2eq, 
1.5mmol, 0.19cm3) were reacted together according to the general reaction procedure. The crude 
product was purified by column chromatography (30% EtOAc-Hexane) to give a green solid 
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(0.33mmol, 0.08g, 26%) which was characterised by NMR spectroscopy to be aldol product 3-
(4-(dimethylamino)phenyl)-2-(pyridin-2-yl)acrylonitrile 70a. 
 
Rf = 0.34 (30% EtOAc-Hexane); m.p. 60-63˚C; I.R. (v/cm
-1) 3013 (w, C=C-H), 2904 – 2713 (w, -N-
C-H3) 2203 (m, C-CN), 1659 (s, C-N=C), 1579 – 1464 (s , ArC=C), 1231 (s, N-CH3); δH (300 MHz, 
CDCl3) 8.59 (1H, d, J=4.4Hz, Ar-H), 8.33 (1H, s, -C=CH-), 7.97 (2H, d, J=9.0Hz, 2 Ar-H), 7.71 (2H, 
m, 2 Ar-H), 7.18 (1H, dd, J=8.4 and 3.2Hz, Ar-H), 6.72 (2H, d, J=9.0Hz, 2 Ar-H), 3.02 (6H, s, Ar-
N(CH3)2); δC (75 MHz, CDCl3) 152.47 (ArC), 152.14 (ArC), 149.36 (ArC-H), 145.25 (-C=CH-), 
137.15 (ArC-H), 132.32 (2 ArC-H), 122.17 (ArC-H), 121.17 (ArC), 120.43 (ArC-H), 119.46 (C-CN), 
111.56 (ArC-H), 102.81(C-CN) , 40.02 (N(CH3)2); MS m/z (%) 249 (M
+, 84), 248 (100), 232 (28), 
205 (21), 203 (14), 192 (7), 177 (8), 165 (8), 151 (9), 148 (36), 143 (6), 135 (6), 123 (10), 114 (21); 
HRMS calculated mass for C16H15N3:  249.1266; exact mass for C16H15N3:  249.1257 
 
2.2.2 Method B:  General Procedure for the Synthesis and Attempted Synthesis of 3-Amino-1-
cyano-indolizines 68,72-76  
 
2-pyridylacetonitrile (1.0eq, 1.3mmol, 0.15g, 0.14cm3) or 6-chloro-2-pyridylacetonitrile (1.0eq, 
0.98mmol, 0.15g) a variable aldehyde (1.2eq) and a variable isocyanide (1.2eq) were dissolved in 
n-butanol (5cm3).  DBU (0.1eq, 0.13mmol, 0.02g) was then added to the reaction mixture and the 
solution was heated to 100oC and left to stir for 43 h under an argon atmosphere.  After this time 
the solvent was removed in vacuo to afford a crude black oil which was further purified by flash 
chromatography.   
 
2.2.2.1 Synthesis of 2-(2-Chlorophenyl)-3-(cyclohexylamino)indolizine-1-carbonitrile 68 
 
 
In accordance with the general reaction procedure 2-chlorobenzaldehyde (1.2eq, 1.5mmol, 
0.17cm3) and cyclohexyl isocyanide (1.2eq, 1.5mmol, 0.19cm3) were reacted together.  The crude 
black oil was absorbed onto silica gel and purified via flash chromatography (30% EtOAc-Hexane) 
to give two products; a white solid (0.54mmol, 0.13g, 42%) which was identified from NMR 
spectroscopy to be the aldol product 64a and a yellow oil.  The yellow oil was dissolved in hot 
diethyl ether and placed in the freezer for overnight recrystallisation and the desired product 68 
was isolated as bright yellow crystals (0.30mmol, 0.10g, 23%). 
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Rf = 0.54 (20% EtOAc-Hexane); m.p. 91-94˚C; I.R. (v/cm
-1) 3293 (m, CN-HCH(CH2)5), 2904 – 
2714 (m, NHCH(C-H2)5), 2203 (w, C-CN) 1660 (m, C-C=N), 1580 – 1465 (m-s, ArC=C), 727 (ArC-
Cl); δH and δc*; MS m/z (%) 350 (M
+, 100), 348 (46), 346 (15), 314 (3), 266 (1). HRMS calculated 
mass for C21H20N3
35Cl:  349.1346 and for C21H20N3
37Cl:  351.1316; exact mass for C21H20N3
35Cl:  
349.1339 and for C21H20N3
37Cl:  351.1327 
*The compound is unstable in a variety of deuterated solvents thus no useful NMR spectral data 
was obtained, however we did obtain an x-ray crystal structure for this compound which is 
discussed in Chapter 2 
 
2.2.2.2 Synthesis of 2-(2-Bromophenyl)-5-chloro-3-(cyclohexylamino)indolizine-1-carbonitrile 72 
                     
Commercially available 2-bromobenzaldehyde (1.2eq, 1.2mmol, 0.14cm3) and cyclohexyl 
isocyanide (1.2eq, 1.2mmol, 0.15cm3) were reacted together according to the general reaction 
procedure. On cooling a lightly coloured crystalline substance precipitated from the crude product 
oil.  This was collected and adsorbed onto silica gel and purified further by flash chromatography 
(15% EtOAc-Hexane).  A yellow solid was isolated from the column which was identified as the 
desired product 72 (0.68mmol, 0.29g, 75%) 
 
Rf = 0.33 (15% EtOAc-Hexane); m.p. 191-194˚C; I.R. (v/cm
-1) 3341 (m, CN-HCH(CH2)5), 2923 (m, 
NHCH(C-H2)5), 2206 (w, C-CN) 1660 (m, C-C=N), 1488 (s, ArC=C), 753 (ArC-Cl); δH (300 MHz, 
CDCl3) 7.71 (1H, d, J=8.0Hz, Ar-H), 7.55 (1H, d, J=8.8Hz, Ar-H), 7.40 (2H, m, 2 Ar-H), 7.34 – 7.21 
(1H, m, Ar-H), 6.96 – 6.84 (1H, m, Ar-H), 6.75 (1H, d, J=7.0Hz, Ar-H), 3.36 (1H, s, NHCH(CH2)5), 
2.77 (1H, m, NHCH(CH2)5), 1.76 – 0.93 (10H, m, NHCH(CH2)5); δC (75 MHz, CDCl3) 137.25 (ArC), 
133.52 (ArC), 133.04 (ArC-H), 132.70 (ArC-H), 129.79 (ArC-H), 129.69 (ArC), 127.46 (ArC-H), 
127.19 (ArC), 124.99 (ArC), 124.21 (ArC), 121.38 (ArC-H), 116.82 (ArC-H), 115.92 (C-CN), 115.56 
(ArC-H), 83.13 (ArC), 58.55 (NHCH(CH2)5), 33.08, 32.80, 25.66, 24.67 and 24.47 (NHCH(CH2)5); 
MS m/z (%) 430 (M+ 81Br, 100), 428 (M+ 79Br, 78), 394 (4), 346 (6), 314 (18), 310 (2); HRMS 
calculated mass for C21H19N3Cl
79Br: 427.0451 and for C21H19N3Cl
81Br: 429.0430; exact mass for 
C21H19N3Cl
79Br:  427.0463 and for C21H19N3Cl
81Br:  429.0443 
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2.2.2.3 Synthesis of 5-Chloro-3-(cyclohexylamino)-2-(4-methoxyphenyl)indolizine-1-carbonitrile 
73 
 
 
 
In accordance with the general reaction procedure p-methoxybenzaldehyde (1.2eq, 1.2mmol, 
0.14cm3) and cyclohexyl isocyanide (1.2eq, 1.2mmol, 0.15cm3) were reacted together. The crude 
product was adsorbed onto silica gel and purified by flash chromatography (10% EtOAc-Hexane) 
to yield the product 73 as a yellow solid (0.49mmol, 0.19g, 38%).   
 
Rf = 0.37 (10% EtOAc-Hexane); m.p. 123-124˚C; I.R. (v/cm
-1) 3373 (w, CN-HCH(CH2)5), 2923 – 
2852 (m, NHCH(C-H2)5), 2203 (m, C-CN) 1612 (m, C-C=N), 1577 – 1447 (s, ArC=C), 1249 (s, ArC-
O-CH3), 737 (ArC-Cl);  δH (400 MHz,CDCl3) 7.90 – 7.56 (2H, m, 2 Ar-H), 7.53 (1H, dd, J=8.8 and 
1.2Hz, Ar-H), 7.14 – 6.94 (2H, m, 2 Ar-H), 6.87 (1H, dd, J=8.7 and 7.1Hz, Ar-H), 6.71 (1H, dd, 
J=7.1 and 1.2Hz, Ar-H), 3.87 (3H, s, OCH3), 3.56 (1H, s, NH), 2.90 – 2.52 (1H, m, NHCH(CH2)5), 
1.80 – 0.65 (10H, m, NHCH(CH2)5); δC (101 MHz, CDCl3) 159.06 (ArCOCH3), 137.68 (ArC), 
130.47 (2 ArC-H), 128.50 (ArC), 126.62 (ArC), 125.81 (ArC), 124.77 (ArC), 121.07 (ArC-H), 116.71 
(C-CN), 116.57 (ArC-H), 115.29 (ArC-H), 113.97 (ArC-H), 81.76 (C-CN), 58.76 (NHCH(CH2)), 
55.22 (OCH3), 32.82, 25.64 and 24.69 (NHCH(CH2)5); MS m/z (%) 380 (M
+, 100), 344 (20), 337 
(12), 327 (2), 262 (2); HRMS calculated mass for C22H22N3O
35Cl:  379.1451 and for C22H22N3O
37Cl:  
381.1422; exact mass for C22H22N3O
35Cl: 379.1456 and for C22H22N3O
37Cl: 381.1444 
 
2.2.2.4 Attempted Synthesis of 2-(2-Bromophenyl)-3-(cyclohexylamino)indolizine-1-carbonitrile 74 
 
                  
 
2-Bromobenzaldehyde (1.2eq, 1.5mmol, 0.18cm3) and cyclohexyl isocyanide (1.2eq, 1.5mmol, 
0.19cm3) were reacted according to the general reaction procedure.  Purification of the crude 
product by flash chromatography (10% EtOAc-Hexane) afforded a white solid which was identified 
as aldol product 3-(2-bromophenyl)-2-(pyridin-2-yl)acrylonitrile 74a (0.16mmol, 0.05g, 13%).   
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Rf = 0.50 (10% EtOAc-Hexane); m.p. 143-145˚C; I.R. (v/cm
-1) 3065 (w, C=C-H), 2219 (w, C-CN), 
1644 (s, C-C=N), 1578 – 1464 (s , ArC=C); δH (400 MHz, CDCl3) 8.79 – 8.58 (2H, m, Ar-H and -
C=CH-), 8.25 – 8.01 (1H, m, Ar-H), 7.87 – 7.75 (2H, m, 2 Ar-H), 7.69 (1H, dd, J=8.0 and 1.2Hz, Ar-
H), 7.58 – 7.38 (1H, m, Ar-H), 7.39 – 7.23 (2H, m, 2 Ar-H); δC (75 MHz, CDCl3) 150.65 (ArC), 
149.95 (ArC-H), 144.37 (-C=CH-), 137.37 (ArC-H), 133.84 (ArC), 133.22 (ArC-H), 131.81 (ArC-H), 
129.76 (ArC-H), 127.81 (ArC-H), 125.60 (ArC), 123.89 (ArC-H), 121.44 (ArC-H), 117.00 (C-CN), 
113.77 (C-CN); MS m/z (%) 286 (81Br M+, 66), 285 (100), 284 (79Br M+, 66), 283 (92), 282 (2), 280 
(6), 278 (4), 276 (1); HRMS calculated mass for C14H9N2
79Br: 283.9949 and for C14H9N2
81Br: 
285.9929; exact mass for C14H9N2
79Br: 283.9938 and for C14H9N2
81Br: 285.9918 
 
2.2.2.5 Synthesis of 3-(Cyclohexylamino)-2-(2,6-dichlorophenyl)indolizine-1-carbo-nitrile 75 
 
 
 
In accordance with the general reaction procedure; 2,6-dichlorobenzaldehyde (1.2eq, 1.5mmol, 
0.27g) and cyclohexyl isocyanide (1.2eq, 1.5mmol, 0.19cm3) were reacted together.  On cooling a 
brownish solid precipitated out of the crude product oil, was collected and purified by flash 
chromatography (5% EtOAc-Hexane) to afford the desired product 75 as a yellow solid (0.08mmol, 
0.03g, 7%).  
 
Rf = 0.56 (20% EtOAc-Hexane); m.p. 138-141˚C; I.R. (v/cm
-1) 3351 (w, CN-HCH(CH2)5), 2932 – 
2853 (m, NHCH(C-H2)5), 2195 (m, C-CN) 1633 (m, C-C=N), 1558 – 1470 (s, ArC=C), 745 (ArC-Cl); 
δH (400 MHz, CDCl3) 8.24 – 8.17 (1H, m, Ar-H), 7.59 (1H, dd, J=8.9 and 1.0Hz, Ar-H), 7.48 – 7.42 
(2H, m, 2 Ar-H), 7.31 (1H, dd, J=8.6 and 7.5Hz, Ar-H), 7.04 (1H, ddd, J=8.9, 6.6 and1.0Hz, Ar-H), 
6.78 (1H, td, J=6.9 and 1.1Hz, Ar-H), 2.89 (1H, m, NHCH(CH2)5), 2.76 – 2.58 (1H, broad, NH), 
1.57 - 1.05 (10H, m, NHCH(CH2)5); δC (101 MHz, CDCl3) 136.00 (Ar-CCl), 134.49 (ArC), 130.56 
(ArC), 130.20 (ArC-H), 128.23 (2 ArC-H), 127.16 (ArC), 123.12 (ArC-H), 122.09 (ArC-H), 118.61 
(C-CN), 117.54 (ArC-H), 116.52 (ArC), 112.35 (ArC-H), 80.64 (C-CN), 56.28 (NHCH(CH2)5), 33.64, 
25.52 and 24.51 (NHCH(CH2)5); MS m/z (%) 384 (M
+, 100), 382 (32), 380 (10), 346 (5), 275 (2); 
HRMS calculated mass for C21H19N3
35Cl2: 383.0956 and for C21H19N3
37Cl2: 387.0927; exact mass 
for C21H19N3
35Cl2: 383.0946 and for C21H19N3
37Cl2: 387.0918 
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2.2.2.6 Attempted Synthesis of 2-(2-Chloro-6-fluorophenyl)-3-(cyclohexylamino) indolizine-1-
carbonitrile 76 
                  
 
In accordance with the general reaction procedure reagents 2-chloro-6-flourobenzaldehyde (1.2eq, 
1.5mmol, 0.24g) and cyclohexyl isocyanide (1.2eq, 1.5mmol, 0.19cm3) were reacted together. The 
crude black product was adsorbed onto silica gel and purification by flash chromatography (5% 
EtOAc-Hexane) afforded a white solid which was identified to be the aldol product 3-(2-chloro-6-
fluorophenyl)-2-(pyridin-2-yl)acrylonitrile 76a (0.10mmol, 0.03g, 8%). 
 
Rf = 0.37 (5% EtOAc-Hexane); m.p. 155-157˚C; I.R. (v/cm
-1) 3016 (w, C=C-H), 2226 (w, C-CN), 
1614 (m, C-C=N), 1580 – 1439 (s , ArC=C), 1099 (m, ArC-F), 774 (s, ArC-Cl); δH (400 MHz, 
CDCl3) 8.68 (1H, ddd, J=4.7, 1.7 and 1.0Hz, Ar-H), 8.40 (1H, s, -C=CH-), 7.90 – 7.70 (2H, m, 2 Ar-
H), 7.44 – 7.27 (3H, m, 3 Ar-H), 7.26 – 7.07 (1H, m, Ar-H); δC (75 MHz, CDCl3) 161.69 (ArC), 
158.32 (ArC), 149.95 (ArC-H), 149.84 (ArC), 137.4 (ArC-H), 136.40 (ArC-H), 135.27 (ArC), 131.50 
(ArC-H), 131.38 (ArC-H), 125.52 (ArC-H), 124.24 (ArC-H), 121.66 (ArC-H), 115.13 (C-CN), 114.83 
(C-CN); MS m/z (%) 259 (M+, 100), 225 (5); HRMS calculated mass for C14H8N2ClF: 258.0360; 
exact mass for C14H8N2ClF: 258.0345 
 
2.2.3 Method C: Attempted Synthesis of 3-Amino-1-cyano Indolizines 64, 77-79 
 
2.2.3.1 Attempted Synthesis of 2-(2-Chlorophenyl)-3-(phentylamino)indolizine-1-carbonitrile 77 
 
 
 
3-(2-chlorophenyl)-2-(pyridin-2-yl)acrylonitrile 64a (1.0eq, 0.10mmol, 0.24g) and montmorillonite 
clay (1.0eq, 0.24g) were added to a round bottom flask containing 1,4-dioxane (5cm3) and stirred 
at room temperature. To this solution was added 1-pentyl isocyanide (1.2eq, 1.2mmol, 0.15cm3) 
and the reaction mixture was heated to 100oC and left stirring for 73 h.  After this time the reaction 
mixture was allowed to cool and the solution was filtered through a celite plug to remove the 
Montmorillonite clay.  The filtrate was collected and the solvent was removed in vacuo to afford a 
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yellow oil which was purified by flash chromatography (5% EtOAc-Hexane) to give a solid white 
product (0.84mmol, 0.20g, 84%) which was identified by NMR spectroscopy as starting material 
64a. 
 
2.2.3.2 Attempted Synthesis of 3-(tert-butylamino)-2-(2-chlorophenyl)indolizine-1-carbonitrile 64 
 
 
 
To a stirring solution of 3-(2-chlorophenyl)-2-(pyridin-2-yl)acrylonitrile 64a (1.0eq, 1.5mmol, 0.36g) 
and montmorillonite clay (1.0eq, 0.36g) in 1,4-dioxane (8cm3) was added t-butyl isocyanide (1.2eq, 
1.8mmol, 0.2cm3).  The reaction mixture was then heated to 100oC and stirred for a further 73 h, 
after which time the solution was allowed to cool.  The reaction mixture was then filtered though a 
celite plug to remove the inorganic residues and the filtrate was collected and the solvent removed 
in vacuo to afford a yellow oil.  The crude product was purified by flash chromatography (5% 
EtOAc-Hexane) to give a white solid (1.3mmol, 0.32g, 90%) which was identified as the starting 
material 64a. 
 
2.2.3.3 Attempted Synthesis of 2-(4-Methoxyphenyl)-3-(tosylmethylamino)indolizine-1-carbonitrile 
78 
 
 
 
To a stirring solution of 3-(4-methoxyphenyl)-2-(pyridin-2-yl)acrylonitrile 63a (1.0eq, 0.42mmol, 
0.10g) in 1,4-dioxane (5cm3) was added montmorillonite clay (1.0eq, 0.10g) and p-toluenesulfonyl 
methyl isocyanide (1.2eq, 0.51mmol, 0.10g).  The reaction mixture was then stirred for 73 h at 
100oC, after which time the solution was allowed to cool and then filtered through a celite plug to 
remove the solid inorganic material. The filtrate was collected and the solvent removed in vacuo to 
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afford a crude off-white oil which was purified by flash chromatography (10% EtOAc-Hexane) 
to give an off-white solid (0.33mmol, 0.08g, 78%) which was identified as the starting material 63a. 
 
2.2.3.4 Attempted Synthesis of 2-(5-Bromo-2,3-dimethoxyphenyl)-3-(tosylmethyl-amino)indolizine-
1-carbonitrile 79 
 
 
 
Montmorillonite clay (1.0eq, 0.10g) and p-toluenesulfonyl methyl isocyanide (1.2eq, 0.35mmol, 
0.07g) were added to a stirred solution of 3-(5-bromo-2,3-dimethoxypheny)-2-(pyridin-2-
yl)acrylonitirile 65a (1.0eq, 0.29mmol, 0.10g) in 1,4-dioxane (5cm3).  The reaction mixture was then 
heated to 100oC and stirred for 73 h before being allowed to cool and filtered through celite.  The 
filtrate was collected and the solvent removed in vacuo to afford a crude off-white oil.  The crude 
product was adsorbed onto silica gel and purified by flash chromatography (10% EtOAc-Hexane) 
to yield a white solid (0.17mmol, 0.06g, 60%) which was identified as starting material 65a. 
 
2.3 Synthesis of 2-(6-Chloropyridin-2-yl)acetonitrile 71 
 
 
 
To a stirred solution of n-BuLi (1.4 M/hexane, 1.0eq, 35.4mmol, 25.3cm3) at -78oC under an inert 
atmosphere was rapidly added dry THF (250cm3), followed immediately by the dropwise addition 
of dry MeCN (1.1eq, 39mmol, 2.0cm3) in dry THF (3cm3). The reaction mixture was stirred for 1 h 
at -78oC during which time the clear solution turned to a milky white suspension.  The reaction 
solution was then treated with 2,6-dichloropyridine (1.0eq, 10.83mmol, 1.602g) dissolved in dry 
THF (10cm3) upon which time the solution turned from milky white to pale yellow.  The reaction 
mixture was stirred for a further 1 h at -78oC and then allowed to warm slowly to room temperature 
before being quenched with H2O (50cm
3).  The organic solvent was removed in vacuo to give a 
residual yellow solid, which was then dissolved in CH2Cl2 and washed with saturated aq. NaCl.  
The organic extracts were collected, dried over MgSO4, filtered and the organic solvent removed in 
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vacuo to afford a yellow oil. The crude product was absorbed onto silica gel and purified by 
column chromatography (50% EtOAc-Hexane) to yield the product 71 as a yellow solid (9.09mmol, 
1.39g, 84%).  Spectroscopic data was in agreement with that of Skerlj et al.65 
 
Rf = 0.32 (50% EtOAc-Hexane); δH (400 MHz, CDCl3) 7.73 (1H, t, J=7.8Hz, Ar-H), 7.41-7.39 (1H, 
m, Ar-H), 7.37 – 7.28 (1H, m, Ar-H), 3.94 (2H, s, CCH2CN); δC (101 MHz, CDCl3) 151.06 (ArC-
CH2), 139.96 (ArC-Cl), 123.75 (2 ArC-H), 120.75 (ArC-H), 116.29 (CH2CN), 26.13 (CCH2CN). 
 
3.  Experimental Procedures:  Synthesis of Benzo-fused Heteroaromatic Naphthoquinone 
and Napthopyranone Ring Systems  
 
3.1 Synthesis of 1,4-Dimethoxynaphthalene 156 
 
 
 
Commercially available 1,4-naphthoquinone (1.0eq, 0.588mol, 9.30g), Na2S2O4 (10.0eq, 
0.5881mol, 102.3g), H2O (300cm
3) and Diethyl ether (500cm3) were added together in a separating 
funnel and shaken vigorously for a period of 1 h.  The ethereal layer was then collected, washed 
with brine (2 x 200cm3), dried over Na2SO4, filtered and the organic solvent removed in vacuo to 
yield the naphthalene-1,4-diol as a brown solid.  The intermediate product was not characterised 
as it is sensitive to air and was used directly in the next step.  Dry acetone (250cm3) was added to 
the naphthalene-1,4-diol intermediate followed by K2CO3 (4.0eq, 0.2352mol, 32.51g) and dimethyl 
sulphate (7.0eq, 0.4116mol, 51.92g).  The now orange reaction mixture was heated and left to 
reflux for 22 h, after which time the solution was allowed to cool and filtered to remove the K2CO3.  
The filtrate was collected and the solvent was removed in vacuo to give a brown oil which was 
dissolved in diethyl ether and allowed to stir.  25% Ammonia solution (200cm3) was added slowly 
to the stirring solution until the evolution of gas had stopped and was then transferred to a 
separating funnel where the organic layer was collected.  The organic extracts were then washed 
with H2O (150cm
3), 15% HCl (2 x 150cm3) and brine (150cm3), collected and dried over MgSO4.  
The filtrate was collected and the solvent removed in vacuo to afford a light brown oil which was 
purified by column chromatography (20% EtOAc-Hexane) to yield the product 156 as a off white 
solid (0.046mol, 8.69g, 79%).  Spectroscopic data was in agreement with that of  Wege and co-
workers.89 
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Rf = 0.62 (10% EtOAc-Hexane); δH (300 MHz, CDCl3) 8.21 (2H, dd, J=6.4 and 3.3Hz, 2 Ar-H), 
7.49 (2H, dd, J=6.4 and 3.3Hz, 2 Ar-H), 6.66 (2H, s, H2 and H3), 3.93 (6H, s, 2 OCH3); δC (75 MHz, 
CDCl3) 149.51 (C
1 and C4), 126.36 (C4a and C8a), 125.89 (2 ArC-H), 121.80 (2 ArC-H), 103.18 (2 
ArC-H), 55.73 (OCH3). 
 
3.2 Synthesis of 2-Bromo-1,4-dimethoxynaphthalene 157 
 
 
 
1,4-dimethoxynaphthalene 156 (1.0eq, 0.040mol, 7.58g) and NBS (1.0eq, 0.040mol, 7.17g) were 
dissolved in dry CH2Cl2 (100cm
3) and allowed to stir at room temperature for 21 h.  The reaction 
mixture was then transferred to a separating funnel and washed with a saturated aqueous NaSO3 
solution.  The organic layer was collected, dried over MgSO4, filtered and the solvent removed in 
vacuo to afford a brown oil.  The crude product was purified by column chromatography (10% 
EtOAc-Hexane) to yield the pure product 157 as a white solid (0.026mol, 6.98g, 65%).  
Spectroscopic data was in agreement with that of Bloomer and Zheng.90 
 
Rf = 0.72 (10% EtOAc-Hexane); δH (300 MHz, CDCl3) 8.40 – 7.84 (2H, m, 2 Ar-H), 7.70 – 7.39 
(2H, m, 2 Ar-H), 6.88 (1H, s, H3), 3.96 (3H, s, OCH3
9)*, 3.95 (3H, s, OCH3
10)*; δC (75 MHz, CDCl3) 
152.28 (C1)*, 146.77 (C4)*, 129.00 (ArC), 127.39 (ArC-H), 125.81 (2 ArC-H), 122.60 (ArC-H), 
121.85 (ArC-H), 111.92 (ArC), 107.92 (ArC), 61.44 (C9)*, 55.89 (C10)*. 
 
* Assignments with superscripts can be interchanged 
  
3.3 Synthesis of 1,4-Dimethoxynaphthalen-2-yl boronic acid 158 
 
 
 
The 2-bromo-1,4-dimethoxynaphthalene 157 (1.0eq, 1.488mmol, 0.3528g) was dissolved in dry 
THF (30cm3) in a dry two-necked flask fitted with a septum.  All air was removed from the solution 
by bubbling N2 gas though the reaction mixture for approximately 10 min.  The reaction solution 
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was then cooled to -78oC and n-BuLi (1.6M/hexane, 3.0eq, 4.5mmol, 1.5cm3) was added 
slowly to the reaction via a syringe.  The solution was left to stir at -78oC for 40 min before the 
addition of the trimethyl borate (3.0eq, 4.5mmol, 0.50cm3).  The solution was stirred for a further 1 
h at -78oC and was then allowed to warm to room temperature before being quenched with 10% 
aqueous HCl solution (60cm3) and extracted with diethyl ether (3 x 40cm3).  The organic extracts 
were collected and the solvent removed in vacuo to give a clear oil which yielded a white solid on 
addition of acetone.  The solid was filtered, collected and dried to afford the boronic acid 158 as a 
flaky white solid (1.138mmol, 0.2641g, 76%).  The product was not characterised due to solubility 
and stability problems and was used directly in the following synthetic step. 
 
3.4 Synthesis of 2-(1,4-Dimethoxynaphthalen-2-yl)benzonitrile 159 
 
 
 
3.4.1 Method A: 
 
Pd(PPh3)4 (0.15eq, 0.1144mmol, 0.1322g) was placed in a 3-neck round bottom flask which was 
evacuated of all O2 and placed under an inert N2 atmosphere. Next 1,4-dimethoxynaphthalen-2-yl 
boronic acid 158 (1.5eq, 0.7625mmol, 0.1540g) and commercially available 2-bromobenzonitrile 
(1.0eq, 0.5083mmol, 0.0910g) were dissolved in DME (5cm3) and EtOH (10cm3) in a dropping 
funnel and degassed by bubbling N2 though the solution for 10 min.  This solution was then added 
to the Pd(PPh3)4 in the reaction vessel under a closed system so as to prevent the introduction of 
any O2 to the system.  The yellow solution was stirred for 10 min at room temperature while 2M 
aqueous Na2CO3 (10cm
3) solution was degassed for 10 min in the dropping funnel.  The 2M 
aqueous Na2CO3 solution was then added to the stirring reaction mixture once again careful to 
exclude all O2 from the system.  The resultant solution was then refluxed for 23 h after which time 
the yellow solution turned milky white.  The milky reaction mixture was quenched with H2O (50cm
3) 
and the organic products were extracted into CH2Cl2 (3 x 50cm
3) and dried over MgSO4.  Once the 
extracts were sufficiently dry they were filtered, collected and the solvent removed in vacuo to 
afford a pale residue.  The crude product was purified via column chromatography (20% EtOAc-
Hexane) to afford the product 159 as a white solid (0.2561mmol, 0.0741g, 50%) and debrominated 
starting material, benzonitrile (0.0402g, 8%).   
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3.4.2 Method B:   
 
Once again Pd(PPh3)4 (0.2eq, 0.0748mmol, 0.0864g) was placed in a 3-neck round bottom flask, 
evacuated of all O2 and placed under an N2 atmosphere as in Method A. Previously synthesised 2-
bromo-1,4-dimethoxynaphthalene 157 (1.0eq, 0.3822mmol, 0.1021g) and commercially available 
2-cyanophenylboronic acid (1.0eq, 0.3821mmol, 0.0561g) were dissolved in DME (5cm3) and 
EtOH (5cm3) in a dropping funnel and degassed by bubbling N2 though the solution for 10 min.  
The degassed solution was then added quickly to the Pd(PPh3)4 in the reaction vessel being 
careful to exclude all O2 from the system.  The yellow reaction mixture was then stirred at room 
temperature whilst a 2M aqueous Na2CO3 solution (10cm
3) was degassed for 10 min in the 
dropping funnel.  Finally the 2M aqueous Na2CO3 solution was added to the stirring solution and 
the reaction mixture was refluxed for 19 h upon which time the solution changed form a yellow 
colour to milky white.  The reaction was quenched with H2O (50cm
3) and the organic products were 
extracted with CH2Cl2 (3 x 40cm
3) and dried over MgSO4.  The dried organic extracts were filtered, 
collected and the solvent removed in vacuo to afford a crude oil, which was further purified by 
column chromatography (20% EtOAc-Hexane) to yield the product 159 as a white solid 
(0.2146mmol, 0.0621g, 56%).   
 
3.4.3 Method C:   
 
Synthesised 2-bromo-1,4-dimethoxynaphthalene 157 (1.0eq, 0.3743mmol, 0.1001g) and 
commercially available 2-cyanophenylboronic acid (2.0eq, 0.0.7488mmol, 0.1103g) were placed in 
a 3-neck round bottom flask and dissolved in DMF (4cm3).  The solution was degassed for 10 min 
by bubbling N2 through the reaction mixture and then placed under an inert atmosphere to exclude 
O2 from the system.     Pd(PPh3)4 (0.2eq, 0.1498mmol, 0.1730g) and K3PO4 (4.0eq, 2.9952mmol, 
0.0620g) were then added to the reaction solution under flowing N2 gas to give a yellow reaction 
mixture.  The reaction was then refluxed for 47 h during which time the solution changed from 
yellow to dark brown in colour.  The reaction was quenched with brine (25cm3) and the organic 
products were extracted with Diethyl ether (3 x 25cm3).  The organic extracts were once again 
dried over MgSO4, collected and the solvent removed in vacuo to afford an orange oil.  The crude 
product was purified by column chromatography (20% EtOAc-Hexane) to yield the product 159 as 
a white solid (0.1680mmol, 0.0486g, 45%).   
 
Rf = 0.44 (20% EtOAc-Hexane); m.p. 86-88˚C; I.R. (v/cm
-1) 2959 – 2830 (w, ArCO-C-H3), 2330 (w, 
ArC-CN), 1631 – 1590 (s, ArC=C), 1263 – 1240 (s, ArC-O-CH3); δH (300 MHz, CDCl3) 8.23 (2H, m, 
2 Ar-H), 7.91 – 7.37 (6H, m, 6 Ar-H), 6.73 (1H, s, H3), 4.00 (3H, s, OCH3
9)*, 3.52 (3H, s, OCH3
10)*; 
δC (75 MHz, CDCl3) 151.79 (C
1)*, 147.26 (C4)*, 142.85 (ArC), 133.23 (ArC-H), 132.41 (ArC-H), 
131.38 (ArC-H), 128.77 (ArC), 127.72 (ArC-H), 127.05 (ArC-H), 126.87 (ArC), 126.31 (ArC-H), 
126.21 (ArC), 122.47 (ArC-H), 122.42 (ArC-H), 118.54 (Ar-CN), 112.96 (ArC), 105.42 (ArC-H), 
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61.90 (OCH3
9)*, 55.84 (OCH3
10)*; MS m/z (%) 189 (60), 188 (100), 174 (56). 146 (16), 145 
(86), 143 (20), 129 (72), 127 (18), 118 (12), 116 (28), 115 (86), 114 (52), 113 (14), 105 (2), 103 
(22), 102 (76); HRMS could not obtain a molecular ion for C19H15O2N 
 
3.5 Attempted Synthesis of 2-(1,4-Dimethoxynaphthalene-2-yl)phenyl)methanamine 160 
 
 
 
3.5.1 Method A: Attempted Hydrogenation in the Hydrogenator 
 
2-(1,4-Dimethoxynaphthalen-2-yl)benzonitrile 159 (1.0eq, 0.35mmol, 0.10g) was dissolved in 
CH2Cl2 (5cm
3) in the hydrogenation vessel.  The hydrogenation catalyst 5% Pd/C (0.1eq by mass, 
0.01g) was then added to the reaction vessel followed by conc. HCl (3 drops).  The reactants were 
then stirred at room temperature for 16 h under a 4.5kPa H2 atmosphere.  The resultant solution 
was filtered through celite to remove the Pd/C and the organic filtrate was collected, washed with 
H2O (20cm
3) and the organic products were extracted with CH2Cl2 (3 x 10cm
3).  The organic 
extracts were dried over MgSO4, collected and the solvent removed in vacuo to afford a white 
product (0.342mmol, 0.990g, 99%) which was characterised by NMR spectroscopy to be starting 
material 159.   
 
All other attempts at reducing the nitrile to the amine using varying pressures, solvents and catalyst 
loadings in the hydrogenator yielded only starting material 159 and are discussed in Chapter 5.  
 
3.5.2 Method B:  Attempted Hydrogenation using LiAlH4 as a Reducing Agent 
   
3.5.2.1 Method B1 
 
2-(1,4-Dimethoxynaphthalen-2-yl)benzonitrile 159 (1.0eq, 0.55mmol, 0.16g) was dissolved in THF 
(20cm3) and cooled to 0oC whilst stirring. LiAlH4 (2.5eq, 1.38mmol, 0.053g) was added slowly to 
the solution to avoid a vigorous reaction and once the addition was completed the reaction was 
allowed to warm to room temperature and stir for 1 h.  After this time the reaction was quenched 
with H2O (20cm
3) and 10% aqueous HCl (20cm3) and the organic solvent was removed in vacuo.  
The organic products were then extracted with diethyl ether (3 x 30cm3), dried over MgSO4, 
collected and the solvent was once again removed in vacuo to yield a white solid.  A crude NMR 
showed the white solid to be starting material 159 (0.5480mmol, 0.1586g, 99%).  
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3.5.2.2 Method B2 
 
Once again 2-(1,4-dimethoxynaphthalen-2-yl)benzonitrile 159 (1.0eq, 1.2mmol, 0.29g) was 
dissolved in THF (30cm3) and cooled to 0oC whilst stirring.  LiAlH4 (20.0eq, 0.02mol, 0.92g) was 
then added slowly to the stirring solution.  After the addition of LiAlH4 was complete the reaction 
was allowed to warm to room temperature and was stirred for 22 h after which time it was 
quenched with H2O (50cm
3) and 10% aqueous HCl (20cm3).  The organic solvent was removed in 
vacuo and the organic products were then extracted with diethyl ether (3 x 50cm3), dried over 
MgSO4 and collected.  The organic solvent was removed in vacuo to afford a white solid which was 
characterised by NMR spectroscopy to be starting material 159 (1.204mmol, 0.2881g, 99%).   
 
3.5.3 Method C:  Attempted Hydrogenation using Raney-Nickel  
 
2-(1,4-Dimethoxynaphthalen-2-yl)benzonitrile 159 (1.0eq, 0.1728mmol, 0.0502g) was dissolved in 
EtOH (5cm3) and EtOAc (5cm3) and to this clear solution was added 2N NaOH (10cm3).  The 
solution was stirred at room temperature for 10 min before the Raney alloy (2.0eq by mass, 0.10g) 
was added in one portion causing the clear solution to become black.  The reaction mixture was 
stirred for a further 3 h after which time the organic solvent was removed in vacuo and the organic 
products were extracted with CH2Cl2 and dried over MgSO4.  The organic extracts were collected 
and the solvent removed in vacuo to afford a white solid which was characterised by NMR 
spectroscopy to be starting material 159 ( 0.1701mmol, 0.0491g, 98%).   
 
3.6 Synthesis of 2-Bromo-1,4-dimethoxybenzene 162 
 
 
 
Commercially available 1,4-dimethoxybenzene (1.0eq, 0.022mol, 3.02g) and NBS (1.0eq, 
0.022mol, 3.89g) were dissolved in CH2Cl2 (30cm
3) and refluxed for 52 h.  After which time the 
reaction was transferred to a separating funnel and quenched with saturated aqueous NaSO3 -
solution.  The organic layer was collected and dried over MgSO4 to afford a clear solution.  The 
solvent was removed in vacuo to give a crude oil which was purified by column chromatography 
(20% EtOAc-Hexane) to yield the product 162 as a clear oil (0.019mol, 4.08g, 86%).  
Spectroscopic data was in agreement with Bloomer and Zheng.90 
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Rf = 0.66 (20% EtOAc-Hexane); δH (300 MHz, CDCl3) 7.13 (1H, d, J=1.7Hz, H
3), 6.83 (2H, m, 2 
Ar-H), 3.84 (3H, s, OCH3
7)*, 3.76 (3H, s, OCH3
8)*; δC (75 MHz, CDCl3) 154.02 (C
1)*, 150.28 (C4)*, 
119.01 (ArC-H), 118.92 (ArC), 113.39 (ArC-H), 112.89 (ArC-H), 56.98 (OCH3
7)*, 55.88 (OCH3
8)*. 
 
3.7 Synthesis of 2,5-Dimethoxyphenylboronic acid 163 
 
 
 
2-Bromo-1,4-dimethoxybenzene 162 (1.0eq, 9.26mmol, 2.01g) was dissolved in dry THF (50cm3) 
in a two-necked flask fitted with a septum.  The solution was degassed for 10 min and placed 
under an inert N2 atmosphere to exclude moisture.     The reaction solution was then cooled to -
78oC using an acetone and liquid N2 bath and n-BuLi (1.2M/hexane, 2.0eq, 0.019mol, 15.5cm
3) 
was added slowly to the reaction via a syringe.  The solution was left to stir at -78oC for 1 h before 
trimethyl borate (3.0eq, 0.03mol, 3.1cm3) was added to the reaction.  The solution was stirred for a 
further 1 h at -78oC and was then allowed to warm to room temperature over night before being 
quenched with 10% aqueous HCl solution (100cm3) and extracted with diethyl ether (3 x 100cm3).  
The organic extracts were collected, dried over MgSO4, filtered and the solvent removed in vacuo 
to give a clear oil which yielded a white solid on addition of acetone.  The solid was collected and 
dried to afford the boronic acid 163 as a flaky white solid (3.561mmol, 0.6480g, 38%).  The product 
was not characterised due to solubility and stability problems and was used directly in the following 
synthetic step. 
 
3.8 Synthesis of 2’,5’-Dimethoxybiphenyl-2-carbonitrile 164 
 
 
 
Pd(PPh3)4 (0.1eq, 0.1923mmol, 0.2219g) was placed in a 3-neck round bottom flask which was 
evacuated of all oxygen and placed under an inert N2 atmosphere.  Commercially available 2-
bromobenzonitrile (1.0eq, 1.923mmol, 0.3506g) and previously synthesised 2,5-
dimethoxyphenylboronic acid 163 (1.0eq, 1.9mmol, 0.35g) were dissolved in EtOH (7cm3) and 
DME (7cm3) in dropping funnel.  The solution was degassed by bubbling N2 through the solution 
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for 10 min and then added to the Pd(PPh3)4 in the round bottom flask being careful to maintain 
the inert atmosphere.  The resulting yellow solution was allowed to stir at room temperature for 10 
min whilst a 2M aqueous Na2CO3 solution was being degassed in the dropping funnel.  The 
degassed aqueous Na2CO3 was then added to the stirring yellow solution and the reaction mixture 
was set to reflux for 27 h.  After this time the reaction was quenched with H2O (30cm
3) and the 
organic products were extracted with CH2Cl2 (3 x 30cm
3), dried over MgSO4 and the solvent was 
removed in vacuo to afford a yellow oil. The yellow oil was further purified by column 
chromatography (10% EtOAc-Hexane) to yield the product 164 as a yellow oil (1.103mmol, 
0.2640g, 57%). Spectroscopic data was in agreement with Al-Fakhri et al.92 
 
Rf = 0.61 (20% EtOAc-Hexane); δH (300 MHz, CDCl3) 7.28 – 7.03 (4H, m, 4 Ar-H), 6.80 (2H, m, 2 
Ar-H), 6.72 – 6.61 (1H, d, J=1.71Hz, H3), 3.71 (3H, s, OCH3
7)*, 3.62 (3H, s, OCH3
8)*; δC (75 MHz, 
CDCl3) 153.54 (C
1)*, 150.65 (C4)*, 142.33 (ArC), 132.79 (ArC-H), 132.51 (ArC-H), 130.86 (ArC-H), 
127.98 (ArC), 127.54 (ArC-H), 118.66 (Ar-CN), 116.74 (ArC-H), 114.98 (ArC-H), 113.34 (ArC), 
112.48 (ArC-H), 55.97 (OCH3
7)*, 55.78 (OCH3
8)*. 
 
3.9 Attempted Synthesis of (2’,5’-Dimethoxybiphenyl-2-yl)methanamine 165 
 
 
 
 
 
3.9.1 Method A: 
 
2‟,5‟-Dimethoxybiphenyl-2-carbonitrile 164 (1.0eq, 0.3762mmol, 0.0903g) was dissolved in MeOH 
(7cm3) in the hydrogenation vessel and 10% Pd/C (0.1eq, 0.0090g) and conc. HCl (3 drops) were 
then added to this solution.  The reaction mixture was then set up to stir at room temperature for 37 
h at 7 kPa in the hydrogenator.  After which time the pressure was released and the reaction 
mixture was filtered through celite to remove the solid Pd/C.  The organic products were collected, 
washed with H2O, dried over MgSO4 and the solvent was removed in vacuo to afford a crude oil.  
The crude product was purified by column chromatography (10% EtOAc-Hexane) to yield a yellow 
oil, which was identified by NMR spectroscopy to be starting material 164 (0.3744mmol, 0.0891g, 
99%).   
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3.9.2 Method B:  
 
2‟,5‟-Dimethoxybiphenyl-2-carbonitrile 164 (1.0eq, 1.046mmol, 0.2503g) was dissolved in THF 
(10cm3) and cooled to 0oC in an ice bath.  LiAlH4 (20.0eq, 0.0209mol, 0.7940g) was then added 
slowly to the stirring solution after which time the reaction was allowed to warm to room 
temperature.  The reaction was stirred at room temperature for 2 h before it was quenched with 
H2O (30cm
3) and 10% aqueous HCl solution (20cm3).  The organic solvent was removed in vacuo 
and the organic products were then extracted with diethyl ether (3 x 40cm3), dried over MgSO4 and 
collected.  The organic solvent was removed in vacuo to afford a yellow oil which was pure enough 
to be characterised by NMR spectroscopy as starting material 164 (1.034mmol, 0.2474g, 99%).   
 
3.10 Synthesis of 2-(1,4-Dimethoxynaphthalen-2-yl)benzaldehyde 166 
 
 
 
Pd(PPh3)4 (0.2eq, 2.05mmol, 2.37g) was placed under an inert N2 atmosphere in a 3-necked round 
bottom flask.  2-bromo-1,4-dimethoxynaphthalene 157 (1.0eq, 0.010mol, 2.74g) and 2-
formylphenylboronic acid (2.0eq, 0.021mol, 3.07g) were dissolved in EtOH (20cm3) and DME 
(20cm3) and the solution was degassed using N2 for 10 min.  The degassed solution was then 
added to the round bottom flask and the mixture was stirred at room temperature for 10 min whilst 
a 2M aqueous Na2CO3 solution (20cm
3) was degassed in the same way.  Once the aqueous 
Na2CO3 solution had been added to the mixture the reaction was set to reflux for 73 h, after which 
time the reaction was quenched with H2O (100cm
3).  The organic products were extracted with 
CH2Cl2 (3 x 100cm
3), dried over MgSO4 and the organic solvent removed in vacuo to afford a 
yellow oil.  The crude product was further purified by column chromatography (5%-25% EtOAc-
Hexane) to yield the product 166 as a white solid (6.43mmol, 1.88g, 63%).   
 
Rf = 0.63 (20% EtOAc-Hexane); m.p. 190-192˚C; I.R. (v/cm
-1) 2935 (w, ArCO-C-H3), 2861 (w, -
CHO), 1726 (m, -HC=O), 1625 – 1469 (s, ArC=C), 1263 – 1224 (s, ArC-O-CH3); δH (300 MHz, 
CDCl3) 9.90 (1H, s, CHO), 8.42 – 8.20 (1H, m, Ar-H), 8.25 – 7.97 (2H, m, 2 ArH), 7.83 – 7.45 (5H, 
m, 5 Ar-H), 6.74 (1H, s, H3), 4.01 (3H, s, OCH3
9)*, 3.40 (3H, s, OCH3
10)*; δC (75 MHz, CDCl3) 
192.48 (CHO), 152.06 (C1)*, 146.98 (C4)*, 141.93 (ArC), 133.74 (ArC), 133.60 (ArC-H), 131.02 
(ArC-H), 128.39 (ArC), 127.97 (ArC), 127.26 (ArC-H), 127.09 (ArC-H), 126.63 (ArC), 126.27 (ArC-
H), 125.39 (ArC), 122.39 (ArC-H), 122.36 (ArC-H), 105.84 (ArC-H), 60.96 (OCH3
9)*, 55.81 
(OCH3
10)*; MS m/z (%)  292 (M+, 67), 279 (2), 277 (67), 276 (6), 263 (18), 262 (76), 261 (99), 249 
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(60), 246 (52), 249 (52), 234 (100), 221 (22), 219 (48), 218 (80), 205 (56), 202 (32), 190 (40), 
189 (78), 178 (65), 163 (10), 152 (16), 151 (22), 148 (37), 138 (14), 130 (21), 128 (11), 117 (7), 
114 (34); HRMS calculated mass for C19H16O3:  292.1099; exact mass for C19H16O3:  292.1100  
 
3.11 Synthesis of (2-(1,4-Dimethoxynaphthalen-2-yl)phenyl)methanol 167 
 
 
 
To a solution of synthesised 2-(1,4-dimethoxynaphthalen-2-yl)benzaldehyde 166 (1.0eq, 
0.27mmol, 0.08g) in dry THF (5cm3)  was slowly added LiAlH4 (3.0eq, 0.8210mmol, 0.0312g).  The 
resulting reaction mixture was stirred for 40 min at room temperature before being quenched with 
H2O (10cm
3). The organic products were extracted into diethyl ether (3 x 30cm3), dried over 
MgSO4 and the solvent removed in vacuo to afford a crude oil.  The crude product was further 
purified by column chromatography (30% EtOAc-Hexane) to yield the product 167 as a white solid 
(0.2684mmol, 0.0790g, 98%). 
 
Rf = 0.31 (20% EtOAc-Hexane); m.p. 114-115˚C; I.R. (v/cm
-1) 3251 (m broad, CH2O-H), 2838 (m, 
ArC-C-H2OH), 1625 – 1454 (s, ArC=C), 1273 – 1229 (s, ArC-O-CH3); δH (300 MHz, CDCl3) 8.29 
(1H, d, J=7.8Hz, Ar-H), 8.10 (1H, d, J=7.7Hz, Ar-H), 7.74 – 7.30 (6H, m, 6 Ar-H), 6.62 (1H, s, H3), 
4.40 (2H, d, J=13.0Hz, CH2OH), 3.95 (3H, s, OCH3
9)*, 3.56 (1H, broad s, CH2OH), 3.48 (3H, s, 
OCH3
10)*; δC (75 MHz, CDCl3) 152.00 (C
1)*, 146.16 (C4)*, 139.49 (ArC), 137.96 (ArC), 130.09 
(ArC-H), 129.96 (ArC), 129.14 (ArC), 128.33 (ArC-H), 128.31 (ArC-H), 127.88 (ArC-H), 127.12 
(ArC), 126.15 (ArC-H), 125.85 (ArC-H), 122.36 (ArC-H), 122.10 (ArC-H), 106.32 (ArC-H), 64.13 
(CH2OH), 61.66 (OCH3
9)*, 55.75 (OCH3
10)*; MS m/z (%) 294 (M+, 86), 292 (28), 279 (7), 278 (12), 
276 (6), 263 (17), 262 (58), 261 (78), 250 (20), 249 (100), 247 (45), 235 (24), 234 (92), 221 (36), 
218 (71), 206 (12), 205 (46), 202 (46), 191 (44), 189 (90), 178 (40), 165 (40), 152 (26), 149 (30), 
131 (18), 123 (19), 115 (43); HRMS calculated mass for C19H18O3:  294.1256; exact mass for 
C19H18O3:  294.1256 
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3.12 Synthesis of 5-H-dibenzo[c,g]chromene-7,12-dione 154 
 
 
 
3.12.1 Method A: 
 
To a solution of (2-(1,4-dimethoxynaphthalen-2-yl)phenyl)methanol 167 (1.eq, 0.17mmol, 0.05g) in 
CH3CN (2cm
3) and CH3Cl (2cm
3) was added CAN (3.0eq, 0.5096mmol, 0.2790g) dissolved in H2O 
(8cm3).  The milky yellow solution was stirred at room temperature for 68 h after which time a TLC 
revealed only starting material to be present.  Additional CAN (3.0eq, 0.5096mmol, 0.2786g) was 
added to the reaction mixture and the solution was heated to 63oC and stirred for a further 23 h.  
The reaction mixture was then allowed to cool and the organic products were extracted with 
EtOAc, dried over MgSO4 and the solvent removed in vacuo to afford a brown oil.  The crude 
product was purified by column chromatography (10%-50% EtOAc-Hexane) to afford two oily 
products which when characterised by NMR spectroscopy appeared to be nothing more than 
decomposition of the starting material.   
 
3.12.2 Method B: 
 
To a stirred clear solution of (2-(1,4-dimethoxynaphthalen-2-yl)phenyl)methanol 167 (1.eq, 
0.14mmol, 0.04g) in dry THF (3cm3) was added Ag2O (6.0eq, 0.82mmol, 0.10g).  Addition of 6M 
HNO3 (1.5cm
3) solubilised the Ag2O the clear solution became orange.  The reaction was stirred 
for 30 min at room temperature after which time the organic solvent was removed in vacuo to give 
a dark red residue which was dissolved in CH2Cl2 (20cm
3) and H2O (20cm
3).  The organic products 
were extracted with CH2Cl2 (3 x 30cm
3), dried over MgSO4 and the solvent removed in vacuo to 
afford a crude red oil.  The crude product was purified by column chromatography (25%-80% 
EtOAc-Hexane) to afford the product 154 as a dark red amorphous solid (0.0774mmol, 0.0203g, 
60%). Spectroscopic data was in agreement with that of Onofrey et al.80 
 
Rf = 0.47 (50% EtOAc-Hexane); δH (300 MHz, CDCl3) 8.47 (1H, d, J=7.9Hz, Ar-H), 8.12 (1H, d, 
J=7.5Hz, Ar-H), 7.94 (1H, d, J=7.8Hz, Ar-H), 7.70 (1H, t, J=7.6Hz, Ar-H), 7.58 (1H, t, J =7.6Hz, Ar-
H), 7.37 (2H, m, 2 Ar-H), 7.14 (1H, d, J=7.3Hz, Ar-H), 5.42 (2H, s, O-CH2-C); δC (75 MHz, CDCl3) 
179.17 (C1=O)*, 177.19 (C4=O)*, 164.15 (ArC), 135.18 (ArC-H), 131.67 (ArC), 131.60 (ArC-H), 
130.29 (ArC), 129.07 (ArC-H), 128.92 (ArC-H), 128.42 (ArC-H), 126.84 (ArC), 126.65 (ArC), 
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125.94 (ArC-H), 124.84 (ArC-H), 123.85 (ArC-H) 113.84 (ArC), 70.20 (O-CH2-C); MS m/z (%) 
263 (M+, 100); HRMS calculated mass for C17H10O3:  262.0630; exact mass for C17H10O3:  
262.0625 
 
3.13 Synthesis of 12-Methoxy-6H-dibenzo[c,h]chromen-6-one 170 
 
 
 
To a stirring solution of (2-(1,4-dimethoxynaphthalen-2-yl)phenyl)methanol 167 (1.0eq, 
0.1698mmol, 0.0503g) in dry CH2Cl2 (5cm
3) was added NBS (1.0eq, 0.1698mmol, 0.0302g).  The 
reaction mixture was stirred at room temperature for 21 h during which time the reaction had 
changed from clear to dark red in colour.  The reaction was quenched with saturated aqueous 
Na2SO3 solution (15cm
3) and the organic products were extracted with CH2Cl2 (3 x 20cm
3), dried 
and the solvent removed in vacuo to yield a brown solid.  The crude product was purified by 
column chromatography (20% EtOAc-Hexane) to afford a brown solid.  This solid was dissolved in 
hot diethyl ether and placed in the freezer overnight to yield the product 170 as a pure white 
crystalline substance (0.1466mmol, 0.0405g, 86%).  Spectroscopic data was in agreement with the 
of Jones and Qabaja.88 
 
Rf = 0.24 (20% EtOAc-Hexane); δH (300 MHz, CDCl3) 8.52-8.46 (2H, m, 2 Ar-H), 8.26 (1H, d, 
J=7.5Hz, Ar-H), 8.11 (1H, d, J=7.8Hz, Ar-H), 7.84 (1H, dt, J=7.6 and 1.2Hz, Ar-H), 7.62 (3H, m, 3 
Ar-H), 7.21 (1H, s, H3), 4.10 (3H, s, OCH3); δC (75 MHz, CDCl3) 161.40 (C=O), 152.36 (C
4), 141.78 
(C1), 135.44 (ArC), 134.76 (ArC-H), 130.68 (ArC-H), 128.45 (ArC-H), 127.64 (ArC-H), 127.35 (ArC-
H), 126.73 (ArC), 124.72 (ArC), 122.12 (ArC-H), 122.05 (ArC-H), 121.85 (ArC-H), 121.36 (ArC), 
112.64 (ArC), 95.71 (ArC-H), 55.77 (OCH3). 
 
3.14 Synthesis of 2-[2-(Bromomethyl)phenyl]-1,4-dimethoxynaphthalene 172 
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The previously synthesised (2-(1,4-dimethoxynaphthalen-2-yl)phenyl)methanol 167 (1.0eq, 
0.6795mmol, 0.2004g) was dissolved in dry CH2Cl2 (15cm
3) in a 2-neck round bottom flask fitted 
with a CaCl2 drying tube. PPh3 (5.0eq, 3.397mmol, 0.8913g) and CBr4 (5.0eq, 3.397mmol, 1.133g) 
were then added to the clear solution which turned dark orange and was then left to stir at room 
temperature for 3 h.  After this time the solvent was removed in vacuo and the orange residue was 
purified by column chromatography (5% EtOAc-Hexane) to afford the product 172 as a yellow oil 
(0.6438mmol, 0.2310g, 95%). 
 
Rf = 0.31 (5% EtOAc-Hexane); I.R. (v/cm
-1) 2931.73 (w, -CH2Br), 1625.34 – 1458.12 (m - s, 
ArC=C), 1271.46 – 1225.43 (s, ArC-O-CH3); δH (300 MHz, CDCl3) 8.12 (2H, m, 2 Ar-H), 7.71 – 
7.21 (6H, m, 6 Ar-H), 6.68 (1H, s, H3), 4.43 (2H, q, J=10.1, CH2Br), 3.92 (3H, s, OCH3
9)*, 3.41 (3H, 
s, OCH3
10)*; δC (75 MHz, CDCl3) 151.48 (C
1)*, 146.51 (C4)*, 138.62 (ArC), 136.21 (ArC), 130.91 
(ArC-H), 130.80 (ArC-H), 128.74 (ArC), 128.36 (ArC-H), 128.24 (ArC-H), 127.88 (ArC), 126.91 
(ArC-H), 126.31 (ArC), 125.85 (ArC-H), 122.43 (ArC-H), 122.29 (ArC-H), 106.34 (ArC-H), 61.63 
(OCH3
9)*, 55.91 (OCH3
10)* , 32.61 (CH2Br); MS m/z (%) 314 (1), 308 (2), 294 (1), 200 (2), 279 (1), 
278 (6), 277 (21), 276 (100), 274 (15), 262 (2), 261 (8), 260 (27), 245 (7), 236 (), 230 (1); HRMS 
calculated mass for C19H17O2
79Br:  356.0412 and C19H17O2
81Br:  358.0392; exact mass for 
C19H17O2
79Br:  356.0391 and C19H17O2
81Br:  358.0374 
 
3.15 Attempted Synthesis of 12-Methoxy-6H-dibenzo[c,h]chromen-6-one 170 
 
3.15.1 Attempted Synthesis from 2-[2-(Bromomethyl)phenyl]-1,4-dimethoxy naphthalene 172 
 
 
 
To a stirring solution of 2-(2-(bromomethyl)phenyl)-1,4-dimethoxy naphthalene 172 (1.0eq, 
0.5598mmol, 0.2012g) in dry CH2Cl2 (25cm
3) was added NBS (1.0eq, 0.5598mmol, 0.1004g) and 
AIBN (0.1eq, 0.06mmol, 0.01g) and the resulting yellow solution was allowed to stir at room 
temperature for 64 h. Following this time the reaction was quenched with saturated aqueous 
Na2SO3 solution (30cm
3). The organic products were extracted with CH2Cl2 (3 x 40cm
3), dried over 
MgSO4 and the organic solvent was removed in vacuo to yield an off-white solid which was 
identified as product 173 (0.4907mmol, 0.2140g, 88%). 
 
Rf = 0.46 (10% EtOAc-Hexane); m.p. 103-104˚C; I.R. (v/cm
-1) 2994 – 2843  (w, -CH2r and O-C-
H3), 1664 – 1451 (m - s, ArC=C), 1266 – 1220 (s, ArC-O-CH3); δH (300 MHz, CDCl3) 8.22 – 8.10 
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(2H, m, 2 Ar-H), 7.65 – 7.57 (3H, m, 3 Ar-H), 7.44 (2H, m, 2 Ar-H), 7.27 (1H, dd, J=7.8 and 
2.2Hz, Ar-H), 4.44 (1 H, d, J=10.5Hz, CHHBr), 4.30 (1 H, d, J=10.5Hz, CHHBr), 4.02 (3H, s, 
OCH3
9)*, 3.56 (3H, s, OCH3
10)*; δC (75 MHz, CDCl3) 150.46 (C
1)*, 150.29 (C4)*, 136.84 (ArC), 
136.37 (ArC), 131.25 (ArC-H), 130.50 (ArC-H), 129.96 (ArC), 129.02 (ArC), 128.78 (ArC-H), 
128.17 (ArC), 127.41 (ArC-H), 126.90 (ArC-H), 123.15 (ArC-H), 122.77 (ArC-H), 122.58 (ArC-H), 
115.50 (ArC), 61.98 (OCH3
9)*, 61.46 (OCH3
10)*, 31.77 (CH2Br); MS m/z (%) 435 (M
+, 16), 420 (7), 
395 (2), 356 (6), 345 (60), 330 (100), 326 (7), 276 (10), 261 (25), 246 (30), 234 (68), 206 (70), 180 
(42), 171 (28), 155 (10), 130 (28), 113 (29), 100 (41), 74 (32), 69 (50); HRMS calculated mass for 
C19H16O2
79Br2:  433.9517 and C19H16O2
79Br81Br: 435.9497; exact mass for C19H16O2
79Br2:  
433.9511; for C19H16O2
79Br81Br:  435.9491 and for C19H16O2
81Br2:  437.9467 
 
3.15.2 Attempted Synthesis from 2-(1,4-Dimethoxynaphthalen-2-yl)benzaldehyde 166 
 
 
 
2-(1,4-dimethoxynaphthalen-2-yl)benzaldehyde 166 (1.0eq, 0.41mmol, 0.12g) was dissolved in 
CH2Cl2 (20cm
3) to afford a clear solution.  NBS (2.0eq, 0.8210mmol, 0.1460g) and AIBN (0.2eq, 
0.0821mmol, 0.0143g) were added to the reaction mixture and the resulting solution was allowed 
to stir at room temperature for 44 h after which time the reaction was quenched with saturated 
aqueous Na2SO3 solution (15cm
3).  The organic products extracted with CH2Cl2, dried over MgSO4 
and the solvent removed in vacuo to afford a white solid.  The white solid was purified by column 
chromatography (20% EtOAc-Hexane) to yield a white product which was identified by NMR 
spectroscopy to be product 171 (0.3610mmol, 0.1340g, 88%). 
 
Rf = 0.68 (20% EtOAc-Hexane); m.p. 95-98˚C; I.R. (v/cm
-1) 2997 – 2932  (w, -O-C-H3), 2850 – 
2758 (w, CHO), 1727 (s, HC=O), 1595 – 1456 (m - s, ArC=C), 1261 – 1229 (s, ArC-O-CH3); δH 
(300 MHz, CDCl3) 9.82 (1H, s, CHO), 8.30 – 8.04 (3H, m, 3 Ar-H), 7.66 (4H, m, 4 Ar-H), 7.42 (1H, 
d, J=7.3Hz, Ar-H), 4.02 (3H, s, OCH3
9)*, 3.48 (3H, s, OCH3
10)*; δC (75 MHz, CDCl3) 191.54 (CHO), 
150.83 (C1)*, 150.38 (C4)*, 140.33 (ArC), 134.10 (ArC), 133.53 (ArC-H), 132.06 (ArC-H), 129.21 
(ArC), 128.68 (ArC-H), 128.23 (ArC), 127.95 (ArC), 127.63 (ArC-H), 127.20 (ArC-H), 123.10 (ArC-
H), 122.62 (ArC-H), 119.11 (ArC-H), 114.73 (ArC), 61.55 (OCH3
9)*, 61.48 (OCH3
10)*; MS m/z (%) 
372 (M+, 4), 291 (100), 276 (24), 261 (81), 233 (22), 231 (3), 205 (11), 202 (5), 189 (12), 176 (24), 
163 (3), 151 (6), 138 (6), 114 (3); HRMS calculated mass for C19H15O3
79Br:  370.0205 and for 
C19H15O3
81Br: 372.0184; exact for C19H15O3
79Br: 370.0201 and for C19H15O3
81Br:  372.0162  
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3.16 Synthesis of 2’,5’-Dimethoxybiphenyl-2-carbaldehyde 178 
 
 
 
Pd(dba)2 (0.15eq, 0.8295mmol, 0.4770g) was dissolved in DME (8cm
3) in a 3-neck round bottom 
flask and the resultant purple solution was degassed with N2 and placed under an inert 
atmosphere. PPh3 (0.8eq, 4.42mmol, 1.15g) was dissolved in DME (8cm
3), degassed with N2 for 
10min and added to the stirring reaction mixture via a dropping funnel.  The solution was allowed 
to stir at room temperature for 30 min during which time the solution changed from purple to yellow 
in colour.  Previously synthesised 2-bromo-1,4-dimethoxybenzene 162 (1.0eq, 5.52mmol, 1.20g) 
and commercially available 2-formylphenylboronic acid (1.2eq, 6.63, 1.77g) were dissolved in DME 
(10cm3) and EtOH (10cm3) in the dropping funnel and degassed for 10 min before being added to 
the stirring yellow solution.  A 2M aqueous Na2CO3 solution (20cm
3) was degassed in the same 
way for 10 min and then added to the stirring solution.  The reaction mixture was set to reflux for 19 
h before being quenched with H2O.  The organic solvent was removed in vacuo and the organic 
products were extracted from the residue with CH2Cl2 (3 x 50cm
3), dried over MgSO4 and once 
again the solvent was removed in vacuo to afford a crude brown oil.  The crude product was 
purified by column chromatography (10% EtOAc-Hexane) to yield the product 178 as a light brown 
oil (3.537mmol, 0.8570g, 64%).  Spectroscopic data was in agreement with Zhao and co-
workers.96 
 
Rf = 0.40 (20% EtOAc-Hexane); δH (300 MHz, CDCl3) 9.79 (1H, s, CHO), 7.98 (1H, dd, J=7.8 and 
1.1Hz, Ar-H), 7.62 (1H, m, Ar-H), 7.52 – 7.30 (2H, m, 2 Ar-H), 6.98 – 6.83 (3H, m, 3 Ar-H), 3.79 
(3H, s, OCH3
7)*, 3.66 (3H, s, OCH3
8)*; δC (75 MHz, CDCl3) 192.53 (CHO), 153.80 (C
1)*, 150.74 
(C4)*, 141.60 (ArC), 134.02 (ArC), 133.68 (ArC-H), 131.04 (ArC-H), 127.85 (ArC-H), 127.67 (ArC), 
126.58 (ArC-H), 117.30 (ArC-H), 114.41 (ArC-H), 111.81 (ArC-H), 55.90 (OCH3
7)*, 55.78 (OCH3
8)*. 
 
3.17 Synthesis of (2’,5’-Dimethoxybiphenyl-2-yl)methanol 179 
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To a stirring solution of 2‟,5‟-dimethoxybiphenyl-2-carbaldehyde 178 (1.0eq, 0.74mmol, 0.18g) 
in dry THF (10cm3) was added LiAlH4 (3.0eq, 2.229mmol, 0.0851g).  The resulting solution was 
stirred at room temperature for 2 h before being quenched with H2O (20cm
3) and 10% aqueous 
HCl (30cm3).  The organic products were extracted with diethyl ether (3 x 30cm3), dried over 
MgSO4 and the solvent removed in vacuo to afford an oily residue.  Flash chromatography (20% 
EtOAc-Hexane) afforded the product 179 as a clear oil (0.5936mmol, 0.1450g, 80%). 
 
Rf = 0.30 (20% EtOAc-Hexane); I.R. (v/cm
-1) 3420 (broad, CH2O-H) 2999 – 2835 (w, -C-H2-OH 
and -O-C-H3), 1600 – 1461 (m - s, ArC=C), 1261 – 1211 (s, ArC-O-CH3);  δH (300 MHz, CDCl3) 
7.51 (1H, dd, J=7.3 and 1.5Hz, Ar-H), 7.41 – 7.26 (2H, m, 2 Ar-H), 7.19 (1H, dd, J=7.3 and 1.6Hz, 
Ar-H), 6.87 (2H, m, 2 Ar-H), 6.73 (1H, dd, J=2.5 and 0.8Hz, Ar-H), 4.39 (2H, 2s, CHHOH), 3.73 
(3H, s, OCH3
7)*, 3.62 (3H, s, OCH3
8)*, 2.78 (1H, broad s, CH2OH); δC (75 MHz, CDCl3) 153.89 
(C1)*, 150.63 (C4)*, 139.38 (ArC), 137.34 (ArC), 131.05 (ArC), 130.12 (ArC-H), 128.54 (ArC-H), 
128.07 (ArC-H), 127.62 (ArC-H), 117.07 (ArC-H), 113.63 (ArC-H), 112.79 (ArC-H), 63.54 (CH2OH), 
56.61 (OCH3
7)*, 55.72 (OCH3
8)*; MS m/z (%) 240 (10), 226 (21) 224 (100); HRMS calculated for 
C15H16O3:  244.1099; exact for C15H16O3:  244.1093. 
 
3.18 Synthesis of 3-Bromo-2-methoxy-6H-benzo[c]chromen-6-one 180 
 
 
 
Previously synthesised compound (2‟,5‟-dimethoxybiphenyl-2-yl)methanol 179 (1.0eq, 
0.1244mmol, 0.0304g) was dissolved in CHCl3 (7cm
3).  To this stirred solution was added NBS 
(1.0eq, 0.1244mmol, 0.0222g) and radical initiator AIBN (0.2eq, 0.0249mmol, 0.0048g) and the 
clear solution was left to stir at room temperature for 16 h.  Marking no distinct change in the 
starting material the reaction was set to reflux for 3 h upon which time the solution turned orange in 
colour.  The reaction solution was quenched with saturated aqueous Na2SO3 solution (20cm
3) and 
the organic products extracted with CH2Cl2 (3 x 30cm
3).  The organic extracts were dried over 
MgSO4, the solvent removed in vacuo and purified by column chromatography (10% EtOAc-
Hexane) to yield the product 180 as a white solid (0.0393mmol, 0.0120g, 32%). 
 
Rf = 0.32 (10% EtOAc-Hexane); m.p. 233-235˚C; I.R. (v/cm
-1) 2921 – 2851  (w, -O-C-H3), 1734 ( s, 
C-O-C=O), 1605 – 1449 (m - s, ArC=C); δH (300 MHz, CDCl3) 8.42 (1H, d, J=7.9Hz, Ar-H), 8.08 
(1H, d, J=8.1Hz, Ar-H), 7.85 (1H, t, J=7.8Hz, Ar-H), 7.72 – 7.53 (2H, m, 2 Ar-H), 7.46 (1H, s, Ar-H), 
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4.03 (3H, s, OCH3); δC (75 MHz, CDCl3) 160.72 (C=O), 153.02 (C
1)*, 145.45 (C4)*, 134.90 
(ArC-H), 134.15 (ArC), 130.91 (ArC-H), 129.26 (ArC-H), 122.64 (ArC-H), 121.56 (ArC-H), 121.27 
(ArC), 117.72 (ArC), 114.34 (ArC), 104.32 (ArC-H), 56.85 (OCH3); MS m/z (%) 307 (M
+ 81Br, 56), 
305 (M+ 79Br, 58), 285 (4), 279 (6), 261 (4), 259 (8), 241 (4), 229 (4), 228 (30), 227 (100); HRMS 
calculated for C14H9O3
79Br:  303.9735 and for C14H9O3
81Br: 305.9715; exact for C14H9O3
79Br:  
303.9741 and exact for C14H9O3
81Br: 305.9720 
   
3.19 Synthesis of 2’-Methoxybiphenyl-2-carbaldehyde 182 
 
 
 
Pd(DBA)2 (0.15eq, 0.4935mmol, 0.2841g) was dissolved in DME (5cm
3) and degassed by bubbling 
N2 through the solution for 10 min.  The solution was placed under an inert atmosphere to exclude 
all oxygen from the system.  The PPh3 (0.8eq, 2.6mmol, 0.69g) was dissolved in DME (5cm
3) in a 
dropping funnel and degassed by passing N2 through the solution for 10 min.  The PPh3 solution 
was then added to the stirring purple solution in the flask and allowed to stir at room temperature 
for 30 min.  After this time commercially available starting materials 2-methoxyphenylboronic acid 
(1.0eq, 3.3mmol, 0.50g) and 2-bromo benzaldehyde (1.0eq, 3.3mmol, 0.60g) were dissolved in 
DME (10cm3) and EtOH (10cm3), degassed with N2 for 10 min and added to the now yellow 
solution.  A 2M aqueous Na2CO3 solution (15cm
3) was degassed for 10 min in a dropping funnel 
and added to the reaction mixture.  The reaction was refluxed for 26 h after which time H2O 
(30cm3) was added to quench the reaction and the organic solvent was removed in vacuo to afford 
a dark brown residue.  The organic products were extracted from the residue with CH2Cl2 (3 x 
40cm3), dried over MgSO4 and the solvent removed in vacuo to give a crude brown oil.  The crude 
product was further purified by flash chromatography (5% EtOAc-Hexane) to yield the product 182 
as a yellow oil (3.251mmol, 0.6902g, 99%).  Spectroscopic data was in agreement with Zhao et 
al.96 
 
Rf = 0.39 (5% EtOAc-Hexane); δH (300 MHz, CDCl3) 9.79 (1H, s, CHO), 7.99 (1H, dd, J=7.7 and 
1.2Hz, Ar-H), 7.64 (1H, td, J=7.5 and 1.5Hz, Ar-H), 7.53 – 7.23 (4H, m, 4 Ar-H), 7.05 (2H, m, 2 Ar-
H), 3.73 (3H, s, OCH3); δC (75 MHz, CDCl3) 192.60 (CHO), 156.54 (ArC-OCH3), 141.83 (ArC), 
134.06 (ArC), 133.63 (ArC-H), 131.41 (ArC-H), 131.19 (ArC-H), 129.97 (ArC-H), 127.72 (ArC-H), 
126.87 (ArC), 126.60 (ArC-H), 121.00 (ArC-H), 110.68 (ArC-H), 55.38 (OCH3). 
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3.20 Synthesis of (2’-Methoxybiphenyl-2-yl)methanol 183 
 
 
 
LiAlH4 (3.0eq, 4.240mmol, 0.1611g) was added slowly to a stirring solution of 2‟-methoxybiphenyl-
2-carbaldehyde 182 (1.0eq, 1.413mmol, 0.3012g) in dry THF (15cm3) and stirred at room 
temperature for 15 min.  The reaction was then quenched with H2O (20cm
3) and the organic 
solvent removed in vacuo to afford a white residue.  This residue was dissolved in 5% aqueous 
HCl solution (30cm3) and the organic products were extracted with diethyl ether (3 x 30cm3).  The 
organic extracts were collected, dried over MgSO4 and the solvent was removed in vacuo to give 
crude residue.  The crude product was purified by flash chromatography (5% EtOAc-Hexane) to 
yield the desired product 183 as a clear oil (1.1mmol, 0.23g, 76%). 
 
Rf = 0.16 (5% EtOAc-Hexane); I.R. (v/cm
-1) 3219 (broad, CH2O-H) 2949 – 2836  (w, CH2OH), 
1594 – 1455 (m - s, ArC=C), 1230 (s, Ar-C-O-CH3); δH (300 MHz, CDCl3) 7.54 – 7.45 (1H, m, Ar-
H), 7.30 (3H, m, 3 Ar-H), 7.13 (2H, m, 2 Ar-H), 6.96 (2H, m, 2 Ar-H), 4.36 (2H, 2 s, CHHOH), 3.64 
(3H, s, OCH3), 2.60 (1H, broad s, CH2OH); δC (75 MHz, CDCl3) 156.48 (ArC-OCH3), 139.56 (ArC), 
137.44 (ArC), 131.31 (ArC-H), 130.30 (ArC-H), 129.95 (ArC), 129.11 (ArC-H), 127.93 (ArC-H), 
127.50 (ArC-H), 126.54 (ArC-H), 121.07 (ArC-H), 111.20 (ArC-H), 63.40 (CH2OH), 55.70 (OCH3). 
MS m/z (%) 215 (M+, 2), 214 (12), 205 (2), 195 (22), 180 (100), 168 (10), 164 (32), 151 (72), 138 
(16), 127 (10), 114 (20), 107 (12); HRMS calculated for C14H14O2: 214.0994; exact for C14H14O2: 
214.0986. 
 
3.21 Attempted Synthesis of 6H-Benzo[c]chromen-6-one 181 
 
 
 
To a stirring solution of starting material (2‟-methoxybiphenyl-2-yl)methanol 183 (1.0eq, 
0.9335mmol, 0.2006g) dissolved in CHCl3 (15cm
3) was added NBS (1.0eq, 0.9335mmol, 0.1660g) 
and AIBN (0.2eq, 0.1867mmol, 0.0315g).  The solution was refluxed for 6 h and then cooled and 
stirred at room temperature for a further 47 h. After this time the solution was quenched with 
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saturated aqueous Na2SO3 solution (20cm
3) and the organic products were extracted with 
CH2Cl2 (3 x 30cm
3) and dried over MgSO4.  The solvent was removed in vacuo to give a crude 
residue which was purified by flash chromatography (15% EtOAc-Hexane) to afford three products; 
an off-white solid which was characterised to be product 184a (0.2091mmol, 0.0740g, 22%) and a 
white solid which are thought to be products 184b and 184c, were inseparable by chromatography 
methods or recrystallisation and a clear NMR spectrum could not be obtained (0.1620g). 
 
184a:  Rf = 0.59 (15% EtOAc-Hexane); m.p. 125-127˚C; I.R. (v/cm
-1) 2913 – 2837  (w, CH2Br), 
1590 – 1464 (m - s, ArC=C), 1237 (s, Ar-C-O-CH3); δH (300 MHz, CDCl3) 7.57 – 7.43 (2H, m, 2 Ar-
H), 7.42 – 7.28 (3H, m, 3 Ar-H), 7.21 – 7.11 (1H, m, Ar-H), 6.85 (1H, d, J=8.8Hz, Ar-H), 4.34 (2H, 
2d, J=10.1Hz, CH2OH), 3.73 (3H, s, OCH3); δC (75 MHz, CDCl3) 155.63 (ArC-OCH3), 136.98 
(ArC), 136.16 (ArC), 133.71 (ArC-H), 131.87 (ArC-H), 130.90 (ArC), 130.60 (ArC-H), 130.35 (ArC-
H), 128.44 (ArC-H), 128.38 (ArC-H), 112.75 (ArC), 112.48 (ArC-H), 55.76 (OCH3), 31.85 (CH2Br) ; 
MS m/z (%) 315 (1); 306 (8), 291 (48), 276 (64), 261 (76), 248 (10), 212 (100), 180 (94), 151 (80), 
138 (26), 114 (10; HRMS could not obtain a molecular ion for C14H13OBr2 
 
184b and 184c:  Rf = 0.54 (15% EtOAc-Hexane); m.p. 108-117˚C; I.R. (v/cm
-1) 3071 (broad w, -
COO-H), 2860 (w, -CHO), 1727 (s, -HC=O), 1694 (s, (OH)C=O), 1596 – 1459 (m - s, ArC=C); MS 
m/z (%) 309 (M+ C14H11O3
81Br, 18), 307 (M+ C14H11O3
79Br, 100), 293 (M+ C14H11O2
81Br, 21), 291 (M+ 
C14H11O3
79Br, 24), 279 (14), 274 (10), 261 (5), 258 (10), 242 (4), 241 (20), 227 (16), 198 (6), 197 
(32), 195 (6), 178 (22); HRMS calculated for C14H11O2
79Br:  289.9942 and for  C14H11O2
81Br: 
291.9922; exact mass for C14H11O2
79Br:  289.9941 and for  C14H11O2
81Br: 291.9928; could not 
obtain a molecular ion for C14H11O3Br.   
 
3.22 Synthesis of 1-Methoxynaphthalene 175 
 
 
 
Commercially available starting material 1-naphthol (1.0eq, 0.022mol, 3.15g) was dissolved in dry 
acetone (100cm3) and placed under an inert N2 atmosphere.  Dimethyl sulfate (3.0eq, 0.07mol, 
6.2cm3) and K2CO3 (2.0eq, 0.044mol, 6.04g) were added to the stirring dark brown solution.  The 
solution was then refluxed for 67 h after which time the solution was allowed to cool and then 
filtered to remove the solid K2CO3.  The filtrate was collected and the solvent removed in vacuo to 
afford a brown oil which was dissolved in diethyl ether and allowed to stir.  25% Ammonia solution 
(100cm3) was added slowly to the stirring solution until the evolution of gas has stopped and was 
then transferred to a separating funnel where the ammonia solution was run off and collected.  The 
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remaining organic layer was then washed with H2O (50cm
3), 10% aqueous HCl (50cm3) and 
brine (50cm3), collected and dried over Na2SO4.  The solvent was removed in vacuo to afford the 
product 175 as a yellow oil (0.021mol, 3.27g, 95%), which was spectroscopically pure and required 
no further purification.  The spectroscopic data was in agreement with that of Adkin and Musser.97  
 
Rf = 0.67 (20% EtOAc-Hexane); δH (300 MHz, CDCl3) 8.36 – 8.16 (1H, m, Ar-H), 7.90 – 7.62 (1H, 
m, Ar-H), 7.57 – 7.25 (4H, m, 4 Ar-H), 6.76 (1H, d, J=7.3Hz, Ar-H), 3.90 (3H, s, OCH3); δC (75 
MHz, CDCl3) 156.05 (ArC-OCH3), 135.11 (ArC), 128.07 (ArC-H), 127.00 (ArC-H), 126.48 (ArC-H), 
126.24 (ArC), 125.78 (ArC-H), 122.60 (ArC-H), 120.83 (ArC-H), 104.38 (ArC-H), 56.03 (OCH3). 
 
3.23 Attempted Synthesis of 2-Bromo-1-methoxynaphthalene 176 
 
 
 
1-Methoxynaphthalene 175 (1.0eq, 6.76mmol, 1.07g) was placed under an inert N2 atmosphere in 
a two-neck round bottom flask fitted with a septum and dissolved in dry THF (50cm3).  The stirring 
solution was then cooled to 0oC using and ice bath before the addition of n-BuLi (1.3M/hexane, 
1.5eq, 0.01mol, 8.0cm3) to the reaction via a syringe.  The yellow solution turned dark green on 
addition of the n-BuLi and was stirred at 0oC for 1 h.  After this time Br2 (1.5eq, 0.01mol, 1.0cm
3) 
was dissolved in dry THF (5cm3) in a dropping funnel and added dropwise to the solution until a 
dark orange colour was obtained.  The reaction was allowed to heat to room temperature and 
stirred for a further 1 h before being quenched with saturated aqueous Na2SO3 (50cm
3).  The 
organic solvent was removed in vacuo to afford a dark orange residue and the organic products 
were extracted with diethyl ether (3 x 50cm3).  The organic extracts were dried and the solvent 
removed in vacuo to afford a crude brown oil which was purified by column chromatography to 
yield a yellow oil which was identified to be starting material 175 (6.46mmol, 1.02g, 95%). 
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Appendix A:  Selected NMR Spectra 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2 
5-bromo-N-cyclohexyl-2-(4-methoxy-3-methylphenyl)imidazo[1,2-a]pyridine-3-amine 54       
                                                                                                 
 
 
 
 
 
 
  
3 
N-tert-butyl-2-(4-methoxy-3-methyl-phenyl)imidazo[1,2-a]pyridine-3-amine 55 
 
 
 
 
 
 
 
 
 
  
4 
5-bromo-2-(4-methoxy-3-methylphenyl)-N-pentylimidazo[1,2-a]pyridine-3-amine 56 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
5 
5-bromo-N-(3,5-dimethylphenyl)-2-hexylimidazo[1,2-a]pyridine-3-amine 57 
 
 
 
 
 
 
 
 
 
 
 
  
6 
N-cyclohexyl-2-(4-(dimethylamino)phenyl)imidazo[1,2-a]pyridine-3-amine 60 
 
 
 
 
 
 
 
 
 
 
  
7 
3-(4-methoxyphenyl)-2-(pyridin-2-yl)acrylonitirile 63a 
 
 
 
 
 
 
 
 
 
 
  
8 
 
3-(2-chlorophenyl)-2-(pyridin-2-yl)acrylonitrile 64a 
 
 
 
 
 
 
 
 
 
  
9 
 
3-(4-methoxy-3-methylphenyl)-2-(pyridin-2-yl)acrylonitirile 69a 
 
 
 
 
 
 
 
  
10 
5-chloro-3-(cyclohexylamino)-2-(4-methoxyphenyl)indolizine-1-carbonitrile 73 
 
 
 
 
 
  
11 
3-(cyclohexylamino)-2-(2,6-dichlorophenyl)indolizine-1-carbo-nitirle 75 
 
 
 
 
 
 
  
12 
3-(2-chloro-6-fluorophenyl)-2-(pyridin-2-yl)acrylonitrile 76a 
 
 
 
 
 
 
  
13 
2-(6-chloropyridin-2-yl)acetonitrile 71 
 
 
 
 
 
 
  
14 
 
1,4-dimethoxynaphthalene 156 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
15 
2-bromo-1,4-dimethoxynaphthalene 157 
 
 
 
 
 
 
  
16 
 
2-(1,4-dimethoxynaphthalen-2-yl)benzonitirle 159 
 
 
 
 
 
 
  
17 
2-bromo-1,4-dimethoxybenzene 162 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
18 
2-(1,4-dimethoxynaphthalen-2-yl)benzaldehyde 166 
 
 
 
 
 
 
 
  
19 
(2-(1,4-dimethoxynaphthalen-2-yl)phenyl)methanol 167 
 
 
 
 
 
 
  
20 
 
2-bromo-3-(2-(bromomethyl)phenyl)-1,4-dimethoxynaphthalene 173 
 
 
 
 
 
  
21 
 
2-(3-bromo-1,4-dimethoxynaphthalen-2-yl)benzaldehyde 171 
 
 
 
 
 
  
22 
 
2’,5’-dimethoxybiphenyl-2-carbaldehyde 178 
 
 
 
 
 
  
23 
3-bromo-2-methoxy-6H-benzo[c]chromen-6-one 180 
 
 
 
 
 
 
 
  
24 
(2’-methoxybiphenyl-2-yl)methanol 183 
 
 
 
 
 
 
  
25 
 
3-bromo-2’-(bromomethyl)-2-methoxybiphenyl 184a 
 
 
 
 
  
1 
Appendix B:  Single-Crystal X-ray Diffraction Data 
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1.1 Crystal Structure Data for 3-(2-chlorophenyl)-2-(pyridin-2-yl)acrylonitrile 64a 
 
 
Table 1:  Crystal Data and Structure Refinement for Compound 64a 
 
Empirical formula  C14 H9 Cl N2 
Formula weight  240.68 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 3.80440(10) Å α= 98.634(2)°. 
 b = 12.2280(4) Å β= 90.676(2)°. 
 c = 12.2766(4) Å γ =93.692(2)°. 
Volume 563.33(3) Å3 
Z 2 
Density (calculated) 1.419 Mg/m3 
Absorption coefficient 0.314 mm-1 
F(000) 248 
Crystal size 0.48 x 0.18 x 0.10 mm3 
Theta range for data collection 1.68 to 28.00°. 
Index ranges -4≤h≤5, -14≤k≤16, -16≤l≤16 
Reflections collected 8849 
Independent reflections 2693 [R(int) = 0.0522] 
Completeness to theta = 28.00° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9693 and 0.8640 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2693 / 0 / 154 
Goodness-of-fit on F2 1.064 
Final R indices [I>2sigma(I)] R1 = 0.0410, wR2 = 0.0873 
R indices (all data) R1 = 0.0560, wR2 = 0.0944 
Largest diff. peak and hole 0.289 and -0.259 e.Å-3 
 
 
 
  
3 
1.2 Crystal Structure Data for 2-(2-chlorophenyl)-3-(cyclohexylamino)indolizine-1-carbonitrile 68 
 
 
 
Table 2:  Crystal Data and Structure Refinement for Compound 68 
. 
Empirical formula  C25 H30 Cl N3 O  
Formula weight  423.97  
Temperature  293(2) K  
Wavelength  0.71073 Å  
Crystal system  Monoclinic  
Space group  P2(1)/c  
Unit cell dimensions a = 9.1055(2) Å α= 90°. 
 b = 18.7282(4) Å β= 108.48°. 
 c = 14.3646(3) Å γ= 90°. 
Volume 2323.30(9) Å3  
Z 4  
Density (calculated) 1.212 Mg/m3  
Absorption coefficient 0.185 mm-1  
F(000) 904  
Crystal size 0.46 x 0.45 x 0.29 mm3  
Theta range for data collection 1.85 to 28.00°.  
Index ranges -12≤h≤12, -24≤k≤17, 
 -18≤l≤18 
 
Reflections collected 29802  
Independent reflections 5596 [R(int) = 0.0448]  
Completeness to theta = 28.00° 100.0 %   
Absorption correction None  
Max. and min. transmission 0.9483 and 0.9197  
Refinement method Full-matrix least-squares on F2  
Data / restraints / parameters 5596 / 0 / 277  
Goodness-of-fit on F2 1.055  
Final R indices [I>2sigma(I)] R1 = 0.0464, wR2 = 0.1240  
R indices (all data) R1 = 0.0576, wR2 = 0.1307  
Largest diff. peak and hole 0.435 and -0.416 e.Å-3  
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1.3 Crystal Structure Data for 12-methoxy-6H-dibenzo[c,h]chromen-6-one 170 
 
 
 
Table 3:  Crystal data and structure refinement for Compound 170 
 
Empirical formula  C18 H12 O3 
Formula weight  276.28 
Temperature  173(2) K 
Wavelength  0.71069 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.1970(7) Å       α=103.237(3)°. 
 b = 9.0700(9) Å       β=105.722(3)°. 
 c = 10.8400(11) Å   γ=104.026(3)°. 
Volume 627.07(11) Å3 
Z 2 
Density (calculated) 1.463 Mg/m3 
Absorption coefficient 0.100 mm-1 
F(000) 288 
Crystal size 0.62 x 0.14 x 0.04 mm3 
Theta range for data collection 2.06 to 27.00°. 
Index ranges -9≤h≤9, -11≤k≤10, -13≤l≤13 
Reflections collected 6387 
Independent reflections 2743 [R(int) = 0.0758] 
Completeness to theta = 27.00° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9960 and 0.9409 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2743 / 0 / 191 
Goodness-of-fit on F2 0.874 
Final R indices [I>2sigma(I)] R1 = 0.0479, wR2 = 0.1016 
R indices (all data) R1 = 0.0902, wR2 = 0.1190 
Largest diff. peak and hole 0.229 and -0.271 e.Å-3 
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